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ABSTRACT
Maternal Diabetes, Related Biomarkers and Genes, and Risk of Orofacial Clefts
by
Tiwaporn Maneerattanasuporn, Doctor of Philosophy
Utah State University, 2017

Major Professor: Dr. Ronald G. Munger
Department: Nutrition, Dietetics, and Food Sciences
Orofacial clefts (OFCs) are among the most common congenital birth defects and
are characterized by incomplete development of the lip or the palate or both. The lip and
palate develop separately at different times during the first trimester of pregnancy. The
etiology of OFCs is multifactorial and includes a combination of genetic and
environmental factors. This project aims to examine the role of maternal diabetes mellitus
in orofacial clefts through studies of medical histories, biomarkers, and genes.
Firstly, the association between maternal pre-pregnancy weight and maternal
diabetes mellitus and the risk of orofacial clefts (OFCs) in a population-based casecontrol study of birth certificate data in Utah was examined. The study found that
maternal obesity increased the risk of OFCs with or without birth defects (non-isolated
and isolated). Underweight mothers had a reduced risk of cleft lip only (CLO), and an
increased risk of cleft palate only (CPO). Pre-existing diabetes and gestational diabetes
mellitus (GDM) increased the risk of non-isolated OFCs. Mediation analysis indicated
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that obesity had a direct effect of increasing the risk of OFCs without the mediating effect
of known maternal diabetes.
Secondly, the association between maternal medical history and maternal
biomarkers of metabolic syndrome and OFCs was examined using case-control interview
and clinical examination data from the Utah population. This study was limited to
isolated OFCs. Mothers having GDM in any pregnancy had an increased risk of OFCs.
Mothers of children with cleft palate with or without cleft lip (CP/L), compared to
controls, had higher mean levels of plasma glucose, insulin, triglycerides, waist
circumference and systolic blood pressure, and lower HDL; these associations were not
seen for mothers of children with CLO. Plasma IL-8 and leptin levels were associated
with CP/L but not with CLO. Metabolic syndrome indices were associated with CP/L;
these scores were not associated with CLO.
Finally, the association between genes related to GDM and the risk of OFCs was
examined using data from a large scale genome-wide association study of European and
Asian populations. Many genes previously known to be related to GDM were associated
with OFCs through genetic effects alone and gene-environment interaction effects with
periconceptional maternal multivitamin use, maternal smoking, and environmental
tobacco smoke. These results support the hypothesis that GDM may be causally related to
OFCs via multiple GDM susceptibility genes and interactions with environmental factors.
Individuals with OFCs face both physical and mental health problems, which
require multi-specialty team care. OFC prevention and prediction are important to public
health. This dissertation reported that maternal diabetes mellitus, maternal pre-pregnancy
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weight and genes related to GDM had an association with the risk of OFCs. Mothers
having an OFC child had an increased risk of developing metabolic abnormalities later in
life. Potential risk factors that are reported in this dissertation may be useful for OFC
prevention. This dissertation also reported potential biomarkers for predicting OFCs.
Moreover, mothers having an OFC child require regular monitoring for maternal
metabolic abnormalities later in life.
(442 Pages)
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PUBLIC ABSTRACT

Maternal Diabetes, Related Biomarkers and Genes, and Risk of Orofacial Clefts
Tiwaporn Maneerattanasuporn
Orofacial clefts (OFCs) are among the most common congenital birth defects and
are characterized by incomplete development of the lip or the palate or both. The lip and
palate develop separately at different times during the first trimester of pregnancy. The
etiology of OFCs is multifactorial and includes a combination of genetic and
environmental factors. This project aims to examine role of maternal diabetes mellitus in
orofacial clefts through studies of medical histories, biomarkers, and genes.
In a study of Utah birth certificates, mothers with pre-existing diabetes and
gestational diabetes mellitus (GDM) had an increased risk of OFCs, and obese mothers
also had an increased risk. Mothers of children with OFCs were more likely than mothers
of unaffected children to develop obesity, metabolic syndrome and gestational diabetes
mellitus later in life. These result were more strongly related to cleft palate than cleft lip.
Many genes related to GDM were associated with OFCs through genetic effects alone
and gene-environment interaction effects with periconceptional maternal multivitamin
use, maternal smoking, and environmental tobacco smoke. These results support the
hypothesis that GDM may be causally related to OFCs via multiple GDM susceptibility
genes and interactions with environmental factors.
Individuals with OFCs face both physical and mental health problem, which
require multi-specialty team care. OFC prevention and prediction are important to public
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health. This dissertation reported that maternal diabetes mellitus, maternal pre-pregnancy
weight and genes related to GDM had an association with the risk of OFCs. Mothers
having an OFC child had an increased risk of developing metabolic abnormalities later in
life. Potential risk factors were reported in this dissertation that may be useful for OFC
prevention. This dissertation also reported potential biomarkers for predicting OFCs.
Moreover, mothers having an OFC child may require regular monitoring of metabolic
abnormalities later in life.
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CHAPTER 1
INTRODUCTION
1.1 Background
Orofacial clefts (OFCs) are among the most common congenital birth defects and
are characterized by incomplete development of the lip or the palate or both. The lip and
palate develop separately at different times during the first trimester of pregnancy.
Globally, approximately 1 in 700 newborns suffer from OFCs (1). The prevalence of
OFCs is different among varying ethnic and racial groups; the highest rate was found in
Asians and Native Americas (2 per 1000 births) (2). In the United States, Utah has a high
rate of clefts (2.25 per 1000 births) (3).
Even though OFCs are not a major cause of death, they have an adverse effect on
affected children and their families. Children with OFCs have difficulty in feeding,
speaking, hearing, and socializing. The difficulties faced by children with OFCs include
the need of multidisciplinary team clinical care (plastic surgery, speech therapy,
audiology, otolaryngology, dentistry, orthodontics, and psychology) over their lifetime
(4). Moreover, the parents of affected children have a greater risk of financial and mental
health problems (5, 6).
The etiology of OFCs is multifactorial and includes a combination of genetic and
environmental factors. The environmental factors that may increase the risk of OFCs
include smoking, alcohol consumption, and certain medications during pregnancy and
prior to pregnancy. Other environmental factors including maternal nutritional status,
supplement intake, and eating behavior have also been associated with the incidence of
OFCs (4). Moreover, some dietary patterns may have a protective effect on the rate of
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OFCs such as the DASH (Dietary Approach to Stop Hypertension diet) and
Mediterranean diet patterns (7, 8).
Insulin resistance and obesity are considered as risk factors of metabolic diseases
and may be related to the risk of OFCs. Some studies have reported that mothers with
high body mass index (BMI) have a higher rate of OFCs when compared with mothers
with normal BMI (9). Moreover, an association between pre-gestational diabetes mellitus
and OFCs has been reported, but has not been studied in detail (10).
The genetic factors of OFCs have been studied by many methods such as linkage
studies and genome-wide association studies (GWAS). The gene-disease associations
appear different among different ethnic groups (1, 11). The linkage study aims to identify
genetic markers related to the disease in a family. These studies found have associations
between non-syndromic orofacial clefts and genes related to growth factors, transcription
factors, xenobiotic metabolism, immune response and one-carbon metabolism (12).
GWAS have provided some similar and some different genetic markers associated with
non-syndromic orofacial clefts but the data are limited. However, no study has reported
the correlation between genes related to diabetes and metabolic syndrome and the risk of
OFCs.
Due to the adverse effect of orofacial clefts on children and their family, studies
of the complex etiology of OFCs are needed in order to reduce the incidence of OFCs.
Moreover, studies of the health problems of mothers near the time of conception are
needed to reduce the incidence of OFCs which occur in the first trimester of pregnancy.
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1.2

Objectives
The overall objective is to examine role of maternal diabetes mellitus in orofacial

clefts through studies of medical histories, biomarkers, and genes. The specific objectives
and hypothesis are:
Aim 1: To determine the association between maternal diabetes mellitus and
gestational diabetes mellitus and the risk of orofacial clefts using data from Utah birth
certificates, Intermountain Healthcare (IHC) and University of Utah medical records,
and the Utah Clefts 2 case-control study.
Hypothesis: Diabetes is more common among mothers of children with orofacial
clefts compared to controls before, during, and after the index pregnancy.
Aim 2: To determine the association between the occurrence of maternal diabetes
and maternal biomarkers of metabolic syndrome and isolated orofacial clefts (OFCs)
using data from the Utah Cleft 2 case-control study.
Hypothesis: Mothers of children with orofacial clefts have a higher prevalence of
maternal diabetes and abnormal biomarkers associated with metabolic syndrome
compared to controls.
Aim 3: To determine the association between genes related to diabetes and
obesity and risk of orofacial clefts
Hypothesis: Genes associated with diabetes mellitus and obesity are associated
with the risk of orofacial clefts
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1.3

Structure of the Dissertation
This dissertation consists of six chapters. The first chapter introduces the recent
problems related to OFCs and the way of the dissertation can contribute to solve these
problems. The second chapter provided and overview of epidemiology, etiology, and
risk factors of OFCs, diabetes mellitus, and metabolic syndrome. This chapter also
presented biomarkers and genes related to diabetes and metabolic syndrome. The
third chapter presented the finding of first aim, which is to determine the association
between maternal diabetes mellitus and gestational diabetes mellitus and the risk of
orofacial clefts. The fourth chapter presented the finding of second aim, which is to
determine the association between maternal biomarkers of metabolic syndrome and
orofacial. The fifth chapter showed the finding of third aim, which is to determine the
association between genes related to diabetes and obesity and risk of orofacial clefts.
The sixth chapter concludes the results from three aims, provides the public health
significance, and gives suggestion for further research. The references for each
chapter were listed at the end of each.

1.4

Study Design
The study in this dissertation used the data from Utah Birth Defect Network

(UBDN), the Utah Cleft 2 case-control study, and the International Genetic
Epidemiology study of Oral Clefts.
The UBDN, operated by the Utah Department of Health (UDOH) is a statewide
population-based surveillance system, identifies all prenatal or postnatal major structural
birth defects in fetuses and neonates. The OFC classifications used in the data analyses
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were based on the final UBDN diagnoses, which were reviewed by a medical geneticist.
OFC cases were divided into cleft lip alone, cleft palate alone, cleft lip without cleft
palate, and cleft lip with cleft palate and classified as isolated, syndromic, or multiple
birth defect cases. The case mothers of a child with an OFC during 1995-2011 were
linked to the Utah Population database (UPDB). The UPDB provides information for
research on genetics, epidemiology, demography, and public health, which receives
annual updates from birth and death certificates, hospitalization and ambulatory surgery
records, and driver licenses. Controls were randomly selected from Utah birth certificates
at a ratio of 4:1 to live-born cases matched by birth month and year. The anonymized
identification numbers of cases and controls from UPDB were linked to the Utah Birth
Certificate database. In addition, the UPDB provided information on OFC cases noted in
fetal and neonatal death records. In total, 1,611 OFC live-born cases and 6,444 controls
linked to the birth certificate records, in which 1,451 cases and 5,804 controls provided
complete data, were used for analysis.
The Utah Cleft 2 study, a collaboration of Utah State University (USU), the
University of Utah Health Sciences Center and the Utah Department of Health (UDOH),
is a study of orofacial clefts in Utah. Cases and controls were selected from the
participants in the Utah Cleft 1 case-control study (13) and the National Birth Defects
Prevention Study (NBDPS) in Utah (14). In the Utah Cleft 1 study, case‐mothers having
a child with OFCs between January 1995 and June 2005 were recruited from UDOH, and
control mothers were randomly selected, frequency matched by birth month and year, and
gender of case child at ratio 1:1 by using Utah birth certificate files. The NBDPS in Utah,
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also a state-wide population-based case-control study, recruited case mothers having a
child with OFCs between 2005-2011 from UDOH database, and randomly selected
control mothers from birth certificates. The OFC cases were limited to isolated OFCs;
cases with multiple birth defects were excluded.
The International Genetic Epidemiology study of Oral Clefts, a part of the GeneEnvironment Association Studies Initiative (GENEVA) of the National Institutes of
Health (NIH). This study is a multi-center, international study of trios from Europe, the
U.S., including Utah, China, Taiwan, Singapore, Korea, and the Philippines, which aims
to investigate genes associated with oral clefts. Families were recruited from treatment
centers or population-based registries. OFC cases were examined by either a clinical
geneticist or an experienced clinician to minimize misclassification of the OFCs. All
cases with cleft palate with or without cleft lip (CP) were analyzed together based on
evidence that maternal obesity and diabetes have a specific effect on palate development.
Trios having CL/P and CP (cleft palate with or without cleft lip) were analyzed in this
study separately. For Asians, 892 CL/P and 910 CP trios, and for Europeans, 665 CL/P
and 644 CP trios were analyzed in this dissertation.
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CHAPTER 2
LITERATURE REVIEW

2.1 Orofacial Clefts
Orofacial clefts (OFCs) are craniofacial birth defects which can be divided into
cleft lip only (CLO), cleft lip with cleft palate (CLP), cleft lip with or without cleft palate
(CL/P), cleft palate only (CPO), and cleft palate with or without cleft lip (CP/L). The
other terminology is used to describe OFCs: syndromic and non-syndromic (isolated).
Isolated or non-syndromic OFCs refers to OFCs without other congenital malformations
or anomalies. Syndromic OFCs means the OFCs with other known patterns of anomalies.
OFCs with other deformations, which cannot classify to existing syndromes, are multiple
birth defect OFCs. About 70% CL/P are isolated. Isolated OFCs are not typically a cause
of mortality, but individuals with OFCs face difficulty with feeding, speaking, hearing,
and socializing.
2.1.1

Classification

Orofacial clefts have many classification systems depending on the purpose. The
systems are divided into an anatomic system for surgeons and an embryology-based
system for genetic counselling and research.
a) Anatomic system
The common form of CLP involves disruption of tissue planes above the
lip extending into the nares and/or the hard and/or soft palate. For example,
the Iowa system (1) classified OFCs into 5 groups
group 1: cleft of the lip only (either unilateral or bilateral cleft lip)
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group 2: secondary palate cleft only
group 3: clefts of the lip, alveolus, and secondary palate (complete cleft
lip and palate)
group 4: cleft of lip and alveolus (primary palate cleft and cleft lip)
group 5: miscellaneous
Additionally, Millard (2) suggested the ICPR system classifying OFCs
into 3 groups
group 1: clefts of the primary palate (lip and/or alveolus)
group 2: clefts of the primary and secondary palate (lip and/or alveolus
and palate)
group 3: clefts of the secondary palate (hard palate and/or soft palate)
b) Syndromic clefts and multiple birth defects
This system divides orofacial clefts into syndromic and non-syndromic clefts.
Syndromic clefts are the orofacial clefts occurring with other birth defects related
to known genetic syndromes such as Van der Woude syndrome, Treacher Collins
Syndrome, and Apert Syndrome. Cases with multiple birth defect OFCs have
OFCs with other congenital deformations, which cannot classify to existing
syndromes. Non-syndromic clefts have no other structural or functional
anomalies.
2.1.2

Embryological development of OFCs

OFCs results from non-closure of facial structures associated with lip and palate
formation during the fourth through the twelfth week of pregnancy. The development of
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face and jaws involves cell migration from the cranial neural crest, proliferation,
differentiation and apoptosis (3).
The lip develops between the fourth and eighth week of pregnancy, which
correlates with the formation of the frontonasal prominence, the paired maxillary
processes, and the paired mandibular process. By the end of the fourth week of gestation,
migrating neural crest cells of the first pharyngeal arch form the frontonasal prominence.
The lower portion of the frontonasal prominence is divided into paired medial and lateral
nasal processes. By the end of the sixth week of embryogenesis, the medial nasal
processes merge with each other and with the bilateral maxillary processes to form the
upper lip and the primary palate, giving rise to the premaxilla (central upper lip,
maxillary alveolar arch and four teeth, and hard palate anterior to the incisive foramen).
A cleft lip results from a failure to maintain an epithelial bridge due to lack of
mesodermal penetration and proliferation from the maxillary and nasal processes.
The development of the secondary (soft) palate occurs after the primary palate
(alveolar ridge and a triangular area of the anterior hard palate) during weeks 6-12.
During the sixth week of development, the maxillary processes of paired palatal shelves
initially rise vertically down the sides of the developing tongue, and grow to a horizontal
position above the tongue and come into contact and fuse to form a midline epithelial
seam during the seventh week. The palatal shelves also fuse in the midline with the
primary palate anteriorly and with the nasal septum dorsally. These fusion processes are
complete by the tenth week of pregnancy, separating the oral and nasal cavities,
permitting simultaneous respiration and mastication. Clefts of the secondary palate are
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due to lack of fusion of the palatal shelves. Normal development occurs sequentially;
thus a cleft lip may or may not be associated with a cleft palate.
2.1.3 Epidemiology of OFCs
Orofacial clefts (OFCs) remains a health issue in both developed and developing
countries. OFCs occur in every 0.4 to 2 per 1000 births depending on geographic
location, racial and ethnic groups, maternal age, environmental exposures, and
socioeconomic status (4, 5). The global average prevalence of OFCs is 1.43 in 1000 live
births (6, 7). The Centers for Disease Control and Prevention (CDC) reported the
incidence during 2004-2006 of CL/P was 1.06 in 1000 live births and 0.64 in 1000 live
births for CP (8). National Birth Defects Prevention Network reported the prevalence of
OFCs during 2002-2006 of CL/P was 1.33 per 1000 live births, and 0.73 per 1000 live
births for CP, which is higher than The US prevalence during 1999-2001 (1.05 and 0.64
per 1000 live births for CL/P and CP respectively) (9). International data from 57
registries for 1993–98 suggest a variation in prevalence at birth of cleft lip with or
without cleft palate of 0.34-2.29 per 1000 births, and an even more pronounced variation
for isolated cleft palate, with prevalence of 0.13-2.53 in 1000 births (10). Asians and
Native Americas present the highest rate (2 in 1000 births), Europeans present at a rate
around 1 in 1000, and Africans have the lowest rate (0.4 in 1000 births) (11). The
National Center on Birth Defects and Developmental Disabilities updated the prevalence
of CL/P and CP in the United States during 2006-2010 showing that Alaska (2.01 and
1.77 per 1000 births respectively), North Dakota (1.58 and 1.51 per 1000 births
respectively), Oklahoma (0.80 and 1.33 per 1000 births respectively), Utah (1.37 and 0.
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65 per 1000 births respectively), Washington (1.14 and 0.88 per 1000 births
respectively), and Colorado (1.17 and 0.82 per 1000 births respectively) are the five
states with the highest prevalence of CL/P and CP (1.14 and 1.10 per 1000 births
respectively for overall prevalence in the United States) (12). Butali and Mossey
reported that prevalence of OFCs differed among African populations (13), including;
Uganda (0.75 per 1000 births in 1968), Kenya (1.65 per 1000 births during 1963-1964),
South Africa (0.33 per 1000 births during 1983-1984), Nigeria (0.3 per 1000 births
during 1976-1980), Tunisia (1.5 per 1000 births during 1983-1984), Zaire (0.46 per 1000
births during 1977-1979), Malawi (0.67 per 1000 births during 1998-1999), and Sudan
(0.9 per 1000 births during 1997-2000). Recent studies also reported the different
prevalence among regions of Africa, including; 0.313 per 1000 births for South Africa
during 2002-2006 (14), 0.5 per 1000 births for Nigeria during 2006-2010 (15), 0.63 per
1000 births for Ghana in 2006 (16), 0.77 per 1000 births for Uganda during 2005-2010
(17). These studies showed that the prevalence of OFCs in South Africa, Nigeria and
Uganda increased from the past.
The rate of CL/P differs by sex. The ratio of CL/P in males to females is 2:1; a
ratio of 1:2 of males to females was found in populations of isolated cleft palate. In white
populations, the male to female ratio for cleft lip with or without cleft palate is about 2:1
(18). In Japanese populations, CL/P shows a significant excess for males, but this excess
is not seen for cleft lip alone (19). These findings are similar to studies done in China and
Nigeria (15, 20). Moreover, among unilateral cleft lip cases, the left: right ratio is 2:1
(18).
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2.1.4 Risk factors of OFCs
The etiology of orofacial clefts is not fully understood. The updated evidence
suggests that there are the multiple factors for this defect including both genetic and
environmental factors.
a) Environmental factors
i)

Maternal smoking
Maternal smoking has consistently been reported to increase the

risk of both cleft lip with or without cleft palate and isolated cleft palate.
An international population-based study, including Norway and the United
States, reported that mothers with active smoking increased risk of all
types of isolated clefts (odds ratio (OR): 1.38, 95% confidence interval
(95% CI): 1.24-1.53 for all OFCs; OR: 1.42, 95% CI: 1.26-1.61 for CL/P,
OR: 1.27, 95% CI: 1.08-1.51 for CP) (21). A case-cohort study from
Denmark by Bille et al. (22) collecting first trimester maternal life style
data found that maternal smoking increased the risk of orofacial clefts
with statistical significance (OR: 1.50; 95% CI: 1.05-2.14). The metaanalysis study, analyzing 22 case-control studies, also reported that
maternal tobacco smoking increased the risk of both CL/P and CP
(relative risk (RR):1.34, 95% CI: 1.25-1.44 for CL/P and RR: 1.22, 95%
CI: 1.10-1.35) (23). Another study from Brazil by Leite et al. (24),
however, did not present a statistically significant association between
maternal smoking during the first trimester of gestation and orofacial
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clefts (OR: 1.13, 95% CI: 0.81-1.57). The inconsistent association
between maternal smoking and OFCs from the Brazil study may result
from the small sample size and quality of data (recall bias from
retrospective study).
The effect of environmental tobacco smoke from passive exposure
on the risk of OFCs still appears to be inconsistent. The study from Brazil
(24) reported that maternal passive smoking during pregnancy associated
with CL/P with statistical significance (OR: 1.39, 95% CI: 1.01-1.98),
except for CP (OR: 1.67, 95% CI: 0.9-3.11). Case-control studies in
different cities (Shenyang and Heilongjiang) in China stated that passive
smoke exposure of mothers increased the risk of OFCs (Shenyang: OR:
2.05, 95% CI: 1.47-2.87 for OFCs and Heilongjiang: OR: 2.52, 95% CI:
1.90-3.33 for CL/P, OR: 1.87, 95% CI: 1.28-2.75 for CP) (20, 25). The
slight association between maternal passive smoke and isolated OFCs and
CL/P except CP was reported in the international population-based study
(OR: 1.14, 95% CI: 1.03-1.25 for OFCs; OR: 1.14, 95% CI: 1.02-1.28 for
CL/P, OR: 1.12, 95% CI: 0.95-1.31 for CP) (21). However, Honein et al.
reported that environmental tobacco smoke exposure was not associated
with CL/P and CP (26).
ii)

Alcohol consumption
Maternal alcohol consumption has been advanced as a risk factor,

although the evidence is still inconsistent. The study in Brazil by Leite et
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al. (24) reported maternal alcohol consumption during first trimester was
associated with CL/P and CP with statistical significance (OR: 2.08, 95%
CI: 1.27, 3.41 and OR: 2.89, 95% CI: 1.25-8.30, respectively). A recent
study in Brazil by Bezerra et al. (27) also found that alcohol drinking
during pregnancy increased risk of non-syndromic OFCs (OR: 3.64, 95%
CI: 1.6-8.3). The Danish National Birth Cohort (22) presented a slight
positive association between alcohol consumption during the first
trimester of gestation without statistical significance (OR: 1.11; 95% CI:
0.79-1.55). A case-control study in Norway (28) which collected the data
from 1996 to 2001 showed that mother consuming greater than or equal to
5 drinks per setting (binge drinking pattern: high dose of alcohol
consumption in short periods) had increased the risk of CL/P (OR: 2.2,
95% CI: 1.1-4.2) and the risk of CP (OR: 2.6, 95% CI: 1.2-5.6). The Iowa
case-control study reported that increased alcohol consumption increased
risk of isolated CL/P except isolated CP (OR: 1.5, 95% CI: 0.9-2.4 for 1-3
drinks/month; OR: 3.5, 95% CI: 0.8-15.4 for 4-10 drinks/month; OR: 4.0,
95% CI: 1.1-15.1 for >10 drinks/month; p-trend 0.007) (29). Additionally,
a meta-analysis evaluating data from 33 studies (23 case-control and 10
cohort studies) reported that maternal alcohol consumption during
pregnancy was not associated with the occurrence of OFCs (30).
iii)

Coffee and caffeine-containing beverages consumption
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A Norwegian case-control study by Johansen et al. (31) reported a
statistically significant correlation between coffee consumption and the
risk of CL/P (OR: 1.39, 95% CI: 1.01-2.39) for 1-2 cups per day and (OR:
1.59, 95% CI: 1.05-2.39) for 3 cups or more per day. There was no
statistically significant association between coffee consumption and CP.
Moreover, the study in Norway (31) presented a negative correlation
between daily tea consumption of 3 or more cups and both CL/P and CP
(OR: 0.55, 95% CI 0.32-0.95 and OR: 0.58, 95% CI: 0.31-1.07) when
compared with no tea intake. However, the evidence for an association
between coffee intake and orofacial clefts is still inconsistent. Kurppa et
al. (32) reported that coffee intake of more than 4 cups a day was not
associated with the risk of orofacial clefts (OR 1.0, 95% CI: 0.6-1.6). On
the contrary, the cohort study in Denmark showed that daily coffee
consumption of more than 5 cups reduced the risk of orofacial clefts by 37
% (95% CI: 0.32-1.44) when compared with no coffee consumption,
though the confidence intervals in this study are biased and included 1.0
(22).
iv)

Maternal age
A meta-analysis (23 published case-control studies) showed that a

maternal age of 40 years or more increased the risk of CLP by 56%
compared to a maternal age between 20 and 29 years (33). A populationbased case-control study in China supported the hypothesis of maternal
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age being associated with OFCs (34). The study reported that mothers
older than 35 years old experienced an increased risk of CL/P (OR: 2.12,
95% CI: 1.26-3.57).
v)

Medication
Therapy with anticonvulsant drugs, notably diazepam, phenytoin,

and phenobarbital in maternal epilepsy increased the risk of both CL/P
(OR: 7.77, 95% CI: 2.02-26.0) and CP (OR: 3.61, 95% CI: 0.08-26.5) (35,
36). Use of valproic acid monotherapy in the first trimester of pregnancy
increased the risk of cleft palate (OR: 5.2, 95% CI: 2.8-9.9) (37).
Maternal amoxicillin use in the third month of gestation increased
the risk of both CL/P and CP with OR: 4.3, 95% CI: 1.4-13.0 and OR: 7.1,
95% CI: 1.4-36, respectively, and increased the risk of CL/P with OR 2.0,
95% CI: 1.4-4.1 for the first trimester use of amoxicillin (38).
The association between maternal corticosteroid use and risk of
OFCs is still inconsistent. Maternal corticosteroid use had positive
associations with OFCs (OR: 3.35, 95% CI: 1.97-5.69) (39). The data
from MADRE project, an international women’s human right
organization, showed the association between corticosteroid use in the first
trimester and the occurrence of CL/P (OR: 2.59, 95% CI: 1.18-5.67)(40).
The case-control study in Norway presented the positive association of
dermatologic corticosteroids with both CL/P (OR: 2.3, 95% CI: 0.71-7.7)
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and CP (OR: 3.4, 95% CI: 0.87-13) (41), which is similar to the result
from study in Denmark (42).
The population-based case-control study in China reported
analgesics or antipyretics (aspirin, aminopyrine, and phenacetin) increased
the risk of OFCs (OR: 7.85, 95% CI: 3.15-19.58) (20).
The association between OFCs and medication used for depression
and anxiety has been reported in many studies. A case-control study found
maternal benzodiazepine use increased the risk of CLP (43). Shiono et al.
reported that maternal diazepam use during the first trimester had no
significant association with orofacial clefts (RR: 1.22, 95% CI: 0.17-8.95)
(44). The National Birth Defect Prevention Study found the association
between OFCs and venlafaxine use one month before conception and
during early pregnancy (OR:1.5, 95% CI: 0.5-4.3 for CL/P and OR:3.3,
95% CI: 1.1-8.8 for CP) (45).
vi)

Folate nutritional status
Folate is a cofactor in the metabolism of one-carbon (the transfer

and utilization of one-carbon-groups), the synthesis of DNA (donation of
one-carbon units in the process of DNA -biosynthesis), and the
remethylation of homocysteine to methionine (46). Maternal folate status
has been suggested to influence the risk of OFCs (5). The case-control
study in the Netherlands (47) found that the mothers of children with CL/P
consumed dietary folate in quantities less than the mothers in the control
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group. In addition, increasing quartiles of dietary folate intake was
associated with decreased the risk of CL/P (quartile 1 is reference, quartile
2 (OR: 0.74; 95% CI: 0.40-1.37), quartile 3 (OR: 0.73; 95% CI: 0.391.35), quartile 4 (OR: 0.63; 95% CI: 0.32-1.23) quartile 5 (OR: 0.54; 95%
CI: 0.27-1.05); p-trend 0.06). A recent case-control study in Brazil
reported that low folate levels (< 7 ng/ml) increased risk of non-syndromic
OFCs (OR: 2.18; 95% CI: 1.12-5.67) (27).
The data from a Utah case-control study reported that plasma
folate and erythrocyte folate levels in mothers of children with isolated
clefts (CL/P and CP) were lower than the controls group with statistical
significance (48). A report in the Philippines by Munger et al. also
presented a similar association, and noted that the folate association
depended on the background of vitamin B6 level (49). However, Bille et
al. studied the effect of IgG and IgM autoantibodies on folate receptor
alpha (FRalpha) in pregnant women and found that the levels of folate
receptor antibody were not associated with increased risk of oral clefts
(50).
vii) Vitamin B6 nutritional status
Vitamin B6, pyridoxine, is a co-factor required for amino acid,
glucose, and lipid metabolism including the metabolism of folate and
homocysteine (51). Mouse studies reported the protective effect of
vitamin B6 supplementation on incidence of corticosteroid-induced OFCs
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(52-55) and dexamethasone-induced cleft palate (56). Davis et al.
presented that mice with vitamin B6 deficiency resulted in birth defects
including cleft palate (57). Another mouse study found that dietary
vitamin B6 deprivation leaded to isolated cleft palate in 20% of the
offspring (58). Moreover, animal studies reported that vitamin B6
prevented the induction of OFCs by vitamin A excess (59),
cyclophosphamide (60), and β-aminoproprionitrile (61).
The association between vitamin B6 nutritional status and OFCs in
human study is limited. A case-control study in Netherland by Krapels et
al. showed no association between dietary vitamin B6 consumption and
risk of OFCs after adjustment for dietary folate intake (62). This study
also reported increased dietary consumption of vitamin B6 significantly
reduced risk of OFCs in periconceptional supplement group (quintile 1:
1.07-1.51 mg/day is reference, quintile 2: 1.52-1.61 mg /day (OR: 0.69;
95% CI: 0.24-1.99), quintile 3: 1.62-1.72 mg /day (OR: 0.49; 95% CI:
0.16-1.54), quintile 4: 1.72-1.84 mg /day (OR: 0.20; 95% CI: 0.07-0.61),
quintile 5: 1.84-2.42 mg /day (OR: 0.22; 95% CI: 0.08-0.64), p-trend =
0.0006), but the association was not found in non-supplementary group . A
human study in Philippines (49) reported the positive association between
OFCs and maternal vitamin B6 activation coefficient (increased levels
indicate poorer vitamin B6 status) in both sites (Negros Occidental: tertile
1 is reference, tertile 2 (OR: 4.01; 95% CI: 1.09-14.75), tertile 3 (OR:
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6.54; 95% CI: 1.93-22.24), p-trend = 0.002 and Davao: tertile 1 is
reference, tertile 2 (OR: 2.65; 95% CI: 1.16-6.09), tertile 3 (OR: 6.01;
95% CI: 2.53-14.30), p-trend < 0.001. A case-control study in Netherland
(63) showed that mothers having pyridoxal-5’- phosphate (PLP) level ≤ 44
nmol/L increased risk of OFCs (OR: 2.9; 95% CI: 1.2-7.1), and the risk
increased in mothers without periconceptional supplement (OR: 16.4; 95%
CI: 1.8-152.2). However, the association between vitamin B6 status and
OFCs was not found in a case-control study in Utah, the United States
(48).
viii) Vitamin B12 nutritional status
Vitamin B12 (cobalamin) functions as a coenzyme in the synthesis
of methionine by methylation of homocysteine to methionine and
demethylation of N5-methyl-tetrahydrofolate to tetrahydrofolate. In
addition, vitamin B12 is a coenzyme of methylmalonyl-CoA mutase.
Vitamin B12 is involved in the metabolism of fatty acids and amino acids,
and affecting DNA synthesis and regulation(46). Lu et al. conducting a
mouse study reported that vitamin B12 prevented the dexamethasoneinduced cleft palate (64). However, Zho et al. found no association
between vitamin B12 and cleft palate induced by 2,3,7,8tetrachlorodibenzo-p-dioxin and dexamethasone (65).
A case-control study in Netherland by Krapels et al. (62) found
that increased dietary intake of vitamin B12 increased risk of OFCs with
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marginally statistical significance (quintile 1: 2.20-4.13 μg/day is
reference, quintile 2: 4.14-4.92 μg/day (OR: 0.88; 95% CI: 0.44-1.76),
quintile 3: 4.92-5.53 μg/day (OR: 1.30; 95% CI: 0.66-2.54), quintile 4:
5.53-6.24 μg/day (OR: 1.18; 95% CI: 0.60-2.35), quintile 5: 6.27-42.92
μg/day (OR: 1.79; 95% CI: 0.90-3.56), p-trend = 0.06). Another casecontrol study in Netherland by Van Aooil et al. (63) reported that that
mothers having low serum vitamin B12 levels (≤ 185 pmol/L) increased
risk of OFCs (OR: 3.1; 95% CI: 1.3-7.4 for total group and OR: 4.4; 95%
CI: 1.1-18.2 for none periconceptional supplement.
ix)

Zinc nutritional status
Zinc plays role in the absorption of folate by polyglutamate

hydrolase, a zinc‐dependent enzyme, and is involved in the conversion of
5‐methyltetrahydrofolate into tetrahydrofolate by the zinc‐ dependent
methionine synthase enzyme. Maternal zinc deficiency can disrupt the
normal function of trophoblasts, the production and secretion of
hormones, establishment of the maternal-fetal barrier, and the mediation
of metabolic exchanges across the maternal-fetal barrier (66). A Dutch
study (67) used a food frequency questionnaire to assess nutrient intake
and compare it between mothers of OFCs children and the control group
mothers. This study reported that zinc intake in mothers in the control
group was statistically significantly higher than mothers of the OFCs
group.
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A case-control study in Philippines (68) showed the correlation
between poor maternal zinc nutritional status and increased risk of OFCs.
The mean level of plasma zinc concentration in the control group was
higher (10.11.6 μmol/l) than in the group of mothers with CL/P children
(9.61.2 μmol/l) with statistical significance and the group of mothers
with CP children (9.41.1 μmol/l) without statistical significance. In
addition, after adjusting for potential confounding factors, increasing
quartile of plasma zinc was associated with a decreased the risk of both
CL/P (quartile 1: ≤8.9 μmol/l is reference, quartile 2: 9.0-9.8 μmol/l (OR:
0.95; 95% CI: 0.38-2.35), quartile 3: 9.9-10.9 μmol/l (OR: 0.81; 95% CI:
0.33-1.97), quartile 4: ≥ 11.0 μmol/l (OR: 0.32; 95% CI: 0.11-0.92); ptrend 0.037) and CP (quartile 1: ≤8.9 μmol/l is reference, quartile 2: 9.09.8 μmol/l (OR: 0.65; 95% CI: 0.16-2.68), quartile 3: 9.9-10.9 μmol/l
(OR: 0.27; 95% CI: 0.05-1.45), quartile 4: ≥ 11.0 μmol/l (OR: 0.07; 95%
CI: 0.01-0.73); p-trend 0.007). The case-control study in Poland and the
Netherlands presented a similar correlation between concentrations of zinc
and risk of OFCs (69, 70). However, the study in Utah with a much higher
level of zinc status did not present the association between maternal
plasma zinc concentration and OFCs (71).
x)

Maternal supplement use
Maternal use of multivitamin supplements in early pregnancy has

been linked to decreased risk of OFCs; in a meta-analysis on overall 25%
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reduction in birth prevalence of OFCs with multivitamin use was reported
(72). Johnson and Little reported the negative association between
maternal multivitamin use and both CL/P (OR: 0.75, 95% CI: 0.65-0.88)
and CP (OR: 0.88, 95% CI: 0.76-1.01) (73).
Folic acid supplementation has been recommended to reduce the
risk of OCFs although the evidence is still controversial. A case-control
study in the Netherlands reported that higher folate supplementation
lowered risk of CL/P (quartile 1: 152 µg/day is reference, quartile 2: 178
µg/day (OR: 0.74; 95% CI: 0.40-1.37), quartile 3: 196 µg/day (OR: 1.73;
95% CI: 0.39-1.35), quartile 4: 213 µg/day (OR: 0.63; 95% CI: 0.32-1.23),
quartile 5: 242 µg/day (OR: 0.54; 95% CI: 0.27-1.05); p-trend 0.06) with
marginal statistical significance (47). Data from the Hungarian Congenital
Anomaly Registry showed that the high dose of folic acid (6 mg) in the
first month of gestation reduced only the risk of CP (OR: 0.50, 95% CI:
0.68-0.96 for CP and OR: 0.89, 95% CI: 0.67-1.20 for CL/P) (74). Studies
in China from different cities (Heilongjiang and Xuzhou) reported the
protective effect of folic acid (Heilongjiang Province: OR: 0.43, 95% CI:
0.21-0.88 for CL/P and OR: 0.69, 95% CI: 0.28-1.69 for CP and Xuzhou
city: OR: 0.23, 95% CI: 0.10-0.55 for OFCs) and multivitamin
(Heilongjiang Province: OR: 0.0.4, 95% CI: 0.01-0.11 for CL/P and OR:
0.08, 95% CI: 0.02-0.25 for CP and Xuzhou city: OR: 0.16, 95% CI: 0.040.58 for OFCs) supplement during preconception period on OFCs (25,
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75). These studies found a weaker association between high dose of folic
acid containing multivitamin in the second month and risk of OFCs (OR:
0.82, 95% CI: 0.64-1.03 for CL/P and OR: 0.70, 95% CI: 0.48-1.02 for
CP). The protective effect of folic acid containing multivitamin on risk of
OFCs was supported by a case-control study in Norway (76) and the
United States (77). However, later data from the National Birth Defects
Prevention Study (NBDPS) found no association between maternal use of
supplement containing folic acid and risk of CL/P (OR: 1.01; 95% CI:
0.82-1.24) and CP (OR: 1.02; 95% CI: 0.77-1.34) (78).
Moreover, a study in the United States presented that food
fortification programs with folic acid decreased the prevalence of orofacial
clefts (prevalence ratio 0.94, 95% CI: 0.92-0.96) (79). A retrospective
population-based study in Canada reported food fortification program,
cereal grain products fortified with folic acid, did not decrease the
prevalence of orofacial clefts (prevalence ratio 1.06, 95% CI: 0.86-1.30)
(80).
xi)

Maternal obesity
A cohort study in Sweden presented a positive association between

maternal obesity and the occurrence of OFCs. Maternal BMI greater than
29 increased the risk of OFCs 31 % after adjusting the potential variables
(81). Blomberg and Kallen provided a similar correlation between
maternal overweight (BMI 25-29.9) and obesity (BMI ≥ 30) and orofacial
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clefts (adjusted OR: 1.15, 95% CI: 1.04-1.28 and adjusted OR: 1.26, 95%
CI: 1.09-1.95; respectively) (82). The international consortium of casecontrol studies, Utah, Iowa, Norway, and the U.S. National Birth Defects
Prevention Study, found that maternal obesity (pre-pregnancy BMI >35)
increased the risk of isolated CLP and CP except CL (OR: 1.30, 95% CI:
1.05-1.60 for CLP, OR: 1.29, 95% CI: 1.02-1.64 for CP, and OR: 1.03,
95% CI: 0.78-1.37 for CL) when compared to mothers with normal weight
(83). These studies found increased BMI increased risk of all cleft palate
(p-trend = 0.004) but not isolated cleft lip. A study in Washington State
also reported the same BMI result as the former studies (adjusted OR:
1.26, 95% CI: 1.03-1.55) (84). Moreover, the meta-analysis from 18
articles showed that maternal obesity increased risk of both cleft palate
(OR: 1.23, 95% CI: 1.03-1.47) and cleft lip and palate (OR: 1.20, 95% CI:
1.03-1.40) (85).
xii) Diabetes mellitus (pre-gestational and gestational)
Many studies have reported the association between maternal
diabetes and the risk of orofacial cleft in offspring. Spilson et al.
investigated the 1996 National Center for Health Statistics States Natality
database and reported that diabetic mothers increased the risk of CL/P,
(adjusted OR 1.35, 95% CI: 1.00-1.82; P<0.05) (86). Carinci et al.
reported the positive association between familial diabetes and isolated
cleft palate (P=0.0014) (87). Data from a large international consortium
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from the U.S., Denmark, and Norway confirmed that maternal diabetes
increased the incidence of OFCs (OR 1.33, 95% CI: 1.14-1.55) after
adjusting for maternal age, education levels, multivitamin use, maternal
BMI categories, and history of smoking (88). A few studies reported that
maternal diabetes increased birth defects including orofacial clefts. The
Atlanta Birth Defects Case-Control Study (89) evaluated the risk of
malformations from diabetic pregnancy. The study showed that being an
insulin-dependent diabetic mother increased the risk of cleft palate (RR:
23.7, 95% CI: 3.1-183.1). Correa et al. analyzed the data from the National
Birth Defect Prevention Study (NBDPS) and reported an association
between maternal diabetes mellitus and both isolated defects and multiple
defects of CL/P and CP (90). Both pre-gestational (type 1 or 2) and
gestational diabetes mellitus increased the risk of isolated CL/P (OR: 2.93,
95% CI: 1.45-5.87 and OR: 1.45, 95% CI: 1.03-2.04, respectively) and CP
(OR: 1.80, 95% CI: 0.67-4.87 and OR: 1.54, 95% CI: 1.01-2.37,
respectively).
Data from the a case-control study of Utah births during 19952005 (83) showed that GDM increased the risk of both isolated (OR: 2.63,
95% CI: 1.30-5.34) and non-isolated clefts (OR: 2.66, 95% CI: 1.02-6.97).
b) Established Genetic factors
Jugessur et al. reported that the majority of OFCs are isolated OFCs
(around 70% of all CLP cases and around 50% of all CPO) (91). Syndromic and
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multiple birth defects make up the minority of OFCs. Around 75% of syndromic
orofacial clefts can be described by known genetic conditions including: Van der
Woude syndrome, Bamforth–Lazarus syndrome, Kabuki syndrome, Pierre Robin
syndrome, and Treacher Collins syndrome (7).
Genetic studies have reported genes related to syndromic OFCs and
provided clear associations between cleft phenotypes and the mutations of genes.
However, some published genes for isolated OFCs often remain with questions of
genetic etiology and there is need for more research to confirm and explain these
associations (91).
i)

IRF6 (Interferon regulatory factor 6)
Nine interferon regulatory factors have been identified in humans.

Interferon regulatory factor family relates to innate immunity and
interferon signaling, while IRF6 is essential for normal epidermal
differentiation and development. In both vitro and vivo studies found that
IRF6 suppressed growth and promoted differentiation of keratinocytes,
cell type in the epidermis, and mammary carcinoma cells (92).
IRF6 has been reported the association with both syndromic and
isolated OFCs. IRF6 was found to be the cause of Van der Woude
syndrome and Popliteal Pterygium syndrome (93). Zucchero et al. (94)
confirmed the association between IRF6 and non-syndromic CL/P in a
large study of 10 populations with ancestry in Asia, Europe, and South
America. Subsequent candidate gene studies confirmed the correlation of
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IRF6 with non-syndromic CL/P in Belgian (95), Taiwanese (96), and
Norwegian populations (97). The results from genome-wide linkage
studies (98) and genome-wide association studies (99-101) also reported
similar result with candidate gene studies.
Mouse models have also demonstrated the role of IRF6 showing
that Irf6 mutant mice presented a hyper-proliferative epidermis causing
failure to undergo terminal differentiation. The hyper-proliferative
epidermis causes multiple epithelial adhesions which can occlude the oral
cavity and lead to a cleft palate (102, 103).
ii)

MAFB (v-maf musculoaponeurotic fibrosarcoma oncogene
homolog B)
MAFB gene encodes a basic leucine zipper transcription factor

which regulates lineage-specific hematopoiesis. MAFB is expressed in the
palate shelves and the medial edge epithelia during palate formation (101).
Moreover, MAFB regulates the functions of establishing, differentiating,
and developing the function of cells, tissues and organs, including
pancreatic alpha and beta islets (104), which may be related to diabetes.
Genome-wide association studies in Chinese Han (105), Hispanic
(106), European and Asian (101) populations reported an association
between MAFB and non-syndromic orofacial clefts. However, no
association was found in a Brazilian population (107).
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iii)

ABCA4 (ATP-binding cassette, sub-family A (ABC1), member 4)
ABCA4 gene is a member of ATP-binding cassette (ABC) family.

The ABCA4 gene plays an obvious role in retina photoreceptor cells.
ABCA4 accelerates the clearance of all-trans-retinal to all-trans-retinol by
translocating all-trans-retinal from the luminal to the cytoplasmic side of
the disk membrane. ABCA4 mutation had strong association with vision
disease such as Stargardt disease, cone-rod dystrophy, and autosomal
recessive retinitis pigmentosa (108). The function of ABCA4 in other
organs is unknown.
The genome-wide association study in the GENEVA Cleft
Consortium provided the statistical evidence of linkage and association
between ABCA4 and non-syndromic CL/P (101). This evidence was
supported with other genome-wide association studies in other populations
such as Hispanic (106) and Brazilian (107) populations. However, the
genome-wide association study in a Chinese Han population was not
associated with the risk of non-syndromic orofacial clefts (105).
iv)

8q24
8q24 is a 640-kb region on chromosome 8 with no well-annotated

genes in this interval. 8q24has been associated with non-syndromic CL/P
and many types of cancer such as breast (109, 110), prostate (111-113),
bladder (114), colon (115-117), lung (118), ovarian (119), pancreatics
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(120), and brain (121) cancer. The 8q24 gene was strongly associated with
non-syndromic CL/P in GWAS (99, 100).
v)

FOXE1 (Forkhead box E1)
FOXE1, a member of the forkhead family, is a thyroid-specific

transcription factor. FOXE1 is essential for the development and
differentiation of thyroid, and the maintenance of thyroid differentiated
state in adults (122). FOXE1 expression was observed in the rostral
epithelium of the oral pharynx, the caudal epithelium of the nasal and
maxillary processes, and epithelium involved in the fusion between the
medial nasal and maxillary processes, which represents the role of FOXE1
in lip development (123). FOXE1 mutation is also associated with thyroid
agenesis, cleft palate, and choanal atresia (124). Moreno et al. reported
that FOXE1 had a significant association with non-syndromic orofacial
clefts (123). This association was confirmed by the subsequent candidate
gene study in European (125, 126), Thai (127), Arab (128) populations.
The GWAS in the Hispanic population also reported the association (106).
vi)

VAX1 (Ventral anterior homeobox 1)
VAX1 is a transcription factor containing a DNA-binding

homeobox domain in developing anterior ventral forebrain (129). Mouse
studies found that VAX1 related to forebrain development and neuronal
differentiation (129), and VAX1 mutations affected the development of
basal forebrain and the formation of visual system (130).
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With GWAS, Mangold et al. and the GENEVA Cleft Consortium
reported the association between VAX1 and risk of non-syndromic CL/P
(101, 131). Figueiredo et al. reported VAX1 was associated with the risk
of orofacial clefts in the Southeast Asian population, but not in the African
population (132). An animal study found that the mouse knockout for
Vax1 developed cleft palate and VAX1 was expressed in developing
craniofacial structures (130)
vii) Other genes
The associations between the risk of orofacial clefts and the gene
related to folate metabolism (MTHFR: Methylenetetrahydrofolate gene,
MTHFD: Methylenetetrahydrofolate dehydrogenase gene, MTR: 5Methytetrahydrofolate-homocysteine methyltransferase, MTRR:
Methionine synthase reductase, RFC1: Reduced folate carrier 1, FOLR:
Folate receptor, BHMT: Betaine-homocysteine methyltransferase, and
CBS: Cystathionine beta-synthase) is still controversial (133). In addition,
no GWAS has reported the association between OFCs and diabetes-related
genes. Published genes associated with OFCs have various function, only
MAFB gene has function on pancreatic alpha and beta cells, which may
related to diabetes.
c) Gene-environment interaction
Many studies have suggested that the development of CL/P and CP
results from interaction of genetic and maternal environmental exposures.
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Indeed, interaction between maternal exposures and specific allelic variants
may have more significant relevance for the occurrence of CL/P and CP than
studies in maternal exposures or genes alone.
Maternal smoking has been associated with the increased risk of CL/P due
to interference of genes in the metabolic pathways related to CLP. GSTT1
(glutathione S-transferase theta), NOS3 (nitric oxide synthase 3), MSX1 (Msh
homeobox homolog1), TGFA (transforming growth factor alpha) and TGFB3
(transforming growth factor beta 3) genes influence the risk of orofacial clefts in
infants of mothers who smoked during the peri-conceptual period (134-138).
Beaty et at. (139) reported GRID2 (glutamate receptor, ionotropic, delta 2) and
ELAVL2 (ELAV like neuron-specific RNA binding protein 2) provided the
strong evidence for a gene-smoking interaction among European maternal smoker
but those did not show significant evidence of genotypic effects alone. Infants
with allelic variants at the MSX1 (Msh homeobox homolog1) site had
significantly elevated risk of CL/P with maternal alcohol consumption (> or = 4
drinks/month) and CP with maternal smoking (> or = 10 cigarettes/day) (140).
Offspring polymorphism of BMP4T538C (bone morphogenetic protein 4) was
associated with an increased risk of non-syndromic CL/P for maternal passive
smoking, and a decreased the risk of CL/P for maternal multivitamin use (141).
Jia et al. (142) stated that IRF6 (Interferon regulatory factor 6) provided a similar
result to BMP4T538C. The presence of ADH1C (alcohol dehydrogenase 1C) is
associated with risk of orofacial clefts that mothers consume alcohol (143).
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Moreover, CBS and MTHFD2L in Asian population and DHFR, MMAA, MTR,
and TCN2 in European population show association between orofacial clefts and
maternal multivitamin use (144).
2.2 Diabetes Mellitus
2.2.1

Overview

Diabetes Mellitus is a disorder of the regulation of blood glucose. Hyperglycemia
is a characteristic of diabetes mellitus resulting from a defect in insulin secretion or
insulin action or both. Diabetes mellitus can be divided into four groups as follows
(145):
a) Type 1 diabetes mellitus
Type 1 diabetes mellitus, accounts for around 5% of all diabetes cases, and
results from a cellular-mediated autoimmune destruction of β-cells of the pancreas.
Patients with type 1 diabetes mellitus are typically diagnosed as children or young
adults.
b) Type 2 diabetes mellitus
Type 2 diabetes mellitus is the most common type of diabetes (90-95%). This
type of diabetes results from insulin resistance or insulin deficiency or both, which is
caused by genetic and lifestyle factors. The most significant factors leading to type 2
diabetes mellitus are overweight, abdominal obesity, and physical inactivity. Many
patients with type 2 diabetes mellitus are undiagnosed for many years because of no
significant signs and symptoms during the early stages of the disease.
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c) Gestational diabetes mellitus (GDM)
GDM is defined as glucose intolerance that begins or is first recognized during
pregnancy. The cause of GDM is not clear, but it has been suggested that it is from
the effect of placental and adipose tissue hormones. Placental hormones such as
human placental lactogen, progesterone, cortisol, placental growth hormone and
prolactin decreases phosphorylation of insulin receptor substrate 1, which leads to
insulin resistance. Decreased adiponectin and increased tumor necrosis factor-α
(TNF-α) and leptin during pregnancy are also associated with insulin resistance
during pregnancy.
d) Other specific types
In addition to the causes of type 1 and type 2 diabetes mellitus and gestational
diabetes mellitus, there are many causes that can lead to diabetes mellitus.
i)

Genetic defects of β -cells function result in impaired insulin secretion
because β-cells lose the function to convert pro-insulin to insulin. (e.g.
maturity-onset diabetes of the young (MODY), mitochondrial disorders,
et al.).

ii)

Genetic defects in insulin action result from the mutation of insulin
receptor, which leads to hyperinsulinemia and hyperglycemia. (e.g.
Leprechaunism, congenital lipoatrophic disorders). Moreover, other
genetic syndromes associated with diabetes include chromosomal
abnormalities such as Prader-Willi syndrome, Wolfram’s syndrome,
Turner syndrome, etc.).
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iii)

Diseases of the exocrine pancreas such as pancreatitis, trauma,
pancreatectomy, neoplasia, fibrocalculous pancreatopathy, pancreatic
carcinoma, et al., result in damaged β-cells. Decreased β-cells in the
pancreas lead to reduced insulin secretion.

iv)

Endocrinopathies related to an excess amount of hormones antagonizing
insulin action such as growth hormone, cortisol, glucagon, epinephrine,
etc. (e.g. acromegaly, Cushing’s syndrome, thyrotoxicosis).

v)

Drug- or chemical-induced diabetes occurs when drugs and chemicals
impair insulin action or damage β-cells. (e.g. glucocorticoids, thiazides,
phenytoin, antiretroviral therapy).

vi)

Infections, especially viral infections, destroy β-cells. (e.g. congenital
rubella, Cytomegalovirus, HIV/AIDS, coxsackievirus B, mumps, et al.).

Uncommon forms of immune-mediated diabetes are the autoimmune disorder
interfering with the insulin receptor, such as anti-insulin receptor antibodies.
2.2.2 Criteria for diagnosis of type 2 diabetes mellitus
The American Diabetes Association updated the criteria for the diagnosis of type
2 diabetes mellitus in 2010 (145). Persons having HbA1c ≥ 6.5% or Fasting Plasma
Glucose (FPG) ≥ 126 mg/dl (7.0 mmol/l) or 2-hr plasma glucose ≥ 200 mg/dl (11.1
mmol/l) during an oral glucose tolerance test (OGTT) or random plasma glucose ≥ 200
mg/dl with hyperglycemic symptoms is diagnosed as having diabetes mellitus. In 2006
the World Health Organization (WHO) and the International Diabetes Federation
(IDF)(146) recommended Fasting Plasma Glucose (FPG) ≥ 126 mg/dl (7.0 mmol/l) or 2-
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hr plasma glucose ≥ 200 mg/dl (11.1 mmol/l) as the diagnostic criteria for diabetes.
Moreover, HbA1c ≥ 6.5% was recommended in 2011 by WHO for diagnosing diabetes
mellitus (147). WHO/IDF suggested Fasting Plasma Glucose (FPG) ≥ 126 mg/dl (7.0
mmol/l) and 2-hr plasma glucose ≥ 140 and 200 mg/dl (7.8-11.1 mmol/l) as the
diagnostic criteria for Impaired Glucose Tolerance (IGT), and Fasting Plasma Glucose
(FPG) > 110-125 mg/dl (6.1-6.9 mmol/l) for Impaired Fasting Glucose (IFG) (146).
2.2.3

Criteria for diagnosis of GDM

The American Diabetes Association (148) proposed one-step and two-step
approaches for diagnosing GDM. The one-step approach is based on a 75 gram OGTT at
24-28 weeks of gestation with fasting. The diagnosis of GDM is made when the plasma
glucose level ≥ 92 mg/dl (5.1 mmol/L) when fasting, or ≥ 180 mg/dl (10.0 mmol/L) at 1
hour after loading, or ≥ 153 mg/dl (8.5 mmol/L) at 2 hours after loading. In addition, the
two-step approach is based on 50 gram at 24-28 weeks of gestation with non-fasting. If
the plasma glucose level at 1 hour after glucose loading is equal to or over 140 mg/dl (7.8
mmol/L), 100 gram OGTT is required. The diagnosis of GDM is made if at least two of
the four measured plasma glucose levels meet the criteria. The GDM criteria for 100
gram OGTT is ≥ 95 mg/dl (5.3 mmol/L) at fasting, ≥ 180 mg/dl (10.0 mmol/L) at 1 hour
after loading, ≥ 155 mg/dl (8.6 mmol/L) at 2 hours after loading, and ≥ 140 mg/dl (7.8
mmol/L) at 3 hours after loading. By the 2006 WHO criteria for diabetes (149), the
diagnosis of GDM is made if at least one criteria is met ≥ 126 mg/dl (7.0 mmol/L) at
fasting, and ≥ 140 mg/dl (7.75 mmol/L) at 2 hours after 75 gram OGTT loading.
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2.2.3 Epidemiology of diabetes mellitus
The International Diabetes Federation (IDF) reported that the global prevalence of
diabetes was 366 million in 2011 and estimated that the prevalence will be 552 million in
2030 (150). Additionally, the IDF estimated the global prevalence of diabetes in 2035
will be 600 million, which will be a 57% increase over the projection of 382 million for
2013 (151). Studies from China, Japan, and Sweden, supported the projected increase in
the prevalence of diabetes (152-154). Men show a higher prevalence of diabetes than
women in some but not all studies (198 million for men and 184 million for women)
(155). The Chinese study by Wang C also reported that the prevalence of diabetes was
higher in males (42.75%) compared to females (26.9%) in 2012 (153). However, a study
done in Southern Iraq reported the prevalence of diabetes in women to be slightly higher
than for men (52.6% for women and 47.3% for men) (156).
The National Diabetes Statistics Report (157) released in June 2014 stated that in
2012, 29.1 million or 9.3% of the American population had diabetes, which is a 12.8%
increase over 2010. Moreover, it is estimated that 8.1 million (27.8%) people have
undiagnosed diabetes. In the American population, Indians/Alaskan Natives have the
highest rate of diabetes (15.9%) followed by non-Hispanic blacks (13.2%) and Hispanics
(12.8%). The IDF (151) reported that the western pacific region has the highest number
of people with diabetes, but the diabetic population in Africa, the Middle East and North
America, and South-East Asia will increase 100%, 96%, and 71% respectively by 2035.
The Hispanic Community Health Study/Study of Latinos (HCHS/SOL) reported that the
prevalence of diabetes was 10.2% in South Americans and 13.4% in Cubans, increasing
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to 17.7% in Central Americans, 18.0% in Dominicans and Puerto Ricans, and 18.3% in
Mexicans. The prevalence of diabetes is negatively associated with educational levels and
household incomes (158).
The percentage of women suffering from GDM is close to type 2 diabetes
mellitus prevalence. The IDF (151) reported the global prevalence of hyperglycemia in
pregnancy is 16.9%. The International Association of Diabetes and Pregnancy Study
Groups (IADPSG), an international consensus group with representatives from multiple
obstetrical and diabetes organizations, including the American Diabetes Association
(ADA) also reported more than 200,000 GDM cases each year, or around 7% of all
pregnancies (ranging from 1 to 14%, depending on the population and the diagnostic
criteria) were diagnosed with GDM (159). The South-East Asian regions have the highest
prevalence (25%) while the lowest prevalence is found in North America and the
Caribbean (10.4%). In addition, the prevalence of GDM in Haryana, India, was 13.9%,
which is higher than the prevalence in the United States (8.5%) during 2009-2010 (160).
The GDM prevalence in Australia in 2000-2009 was 5.1% for the indigenous population
and 4.5% for the non-indigenous, an increase from 1999 (154). The results of these
studies show that the majority of cases of hyperglycemia during pregnancy occurred in
low- and middle-income countries.
2.2.4

Risk factors of diabetes mellitus

a) Age
A Turkish study reported on the positive correlation between maternal age
and the incidence of type 2 diabetes. The incidence of individuals over age 50
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developing type 2 diabetes is higher than it is for individuals between the ages of
20-49 years old (OR: 4.53, 95% CI: 1.98-10.33, P 0.0003) (161). The TromsØ
study reported that increased age increased the risk of diabetes (OR: 1.3, 95% CI:
1.1-1.5) (162).
A positive correlation between age and risk of GDM has been reported,
similar to the correlation seen in type 2 diabetes. IDF reported that the age of the
mother is associated with the prevalence of hyperglycemia in pregnancy; mothers
over 45 years old having the highest prevalence (47.7%) (151). The Nurses’
Health Study II presented similar results (163). Increased maternal age increased
the risk of GDM (age ≥ 40 years vs 25-29 years, RR: 2.24, 95% CI 1.26-3.98, ptrend <0.01). A Chinese study by Yang H reported that, when compared to
mothers less than 30 years ole, mothers age 30 years or older had an increased
risk of GDM (OR: 2.18, 95% CI: 1.88-2.52) (164). This is similar to the results of
a study done in Iran (OR: 3, 95% CI: 1.8–5) (165).
b) Family history
A study in Japan examined the incident risk of type 2 diabetes over a 7
year period. The study showed that participants with a family history of diabetes
had an increased risk of diabetes when compared with participants without a
family history of diabetes (HR 1.82; 95% CI: 1.36-2.43) (166). Moreover,
participants with only the mother having diabetes showed a higher rate of type 2
diabetes than those with a family history of diabetes (HR: 2.6; 95% CI: 1.713.97). The MONICA (Monitoring of Trends and Determinants in Cardiovascular
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Disease) Augsburge cohort study reported a significant association between
family history of diabetes and the risk of diabetes (167).
A family history of diabetes has also been reported as a risk factor for
GDM (168). Pregnant women with a history of diabetes in their family have a
higher risk of GDM when compared to women without a family history of
diabetes (RR: 1.68, 95% CI: 1.39-2.04) (163). Moreover, data from the National
Health and Nutrition Examination Survey III, provided similar results (169) .
Women with maternal, paternal, or sibling histories of diabetes had an increased
risk of developing GDM (OR: 3.0, 95% CI: 1.2- 7.3; OR: 3.3, 95% CI: 1.1-10.2;
OR: 7.1, 95% CI: 1.6 -30.9, respectively). A history diabetes in family increased
risk of type 2 diabetes and GDM.
c) Body weight
Many studies have reported the positive correlation between body weight
and risk of type 2 diabetes. The Nurses’ Health Study reported that both
overweight (BMI 25-30 kg/m2) and obese (BMI ≥ 30 kg/m2) individuals showed a
statistically significant increase in the risk of type 2 diabetes (170). The Finnmark
study followed subjects for 12 years and found that increased BMI increased risk
of type 2 diabetes in both genders (BMI ≤ 27 as a reference, BMI ≥ 35 kg/m2 RR:
27.89; 95% CI: 12.27-63.42 for men; RR: 11.07, 95% CI: 4.63-26.46 in women)
(171). Studies in Lebanon and Qatar also found that mother having BMI ≥ 30
kg/m2 increased the risk of type 2 diabetes (OR: 2.29, 95% CI: 1.74-3.02, and OR:
1.5, 95% CI: 1.2-1.9, respectively) (172, 173).
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Pre-pregnancy bodyweight has been shown to have a strong association
with the risk of GDM. A meta-analysis study (174) pooling the data from 70
studies, also revealed that when compared with women of normal weight (2024.9kg/m2), the odds ratio for overweight (25-29.9≤ 30 kg/m2), moderate obesity
(30-34.9kg/m2), morbid obesity (≥ 35 kg/m2) were 1.97 (95% CI 1.77- 2.19),
3.01 (95% CI 2.34-3.87) and 5.55 (95% CI 4.27- 7.21) respectively. Moreover,
the study also presented a protective effect of being underweight (≤ 20 kg/m2) on
the incidence of GDM (OR: 0.75, 95% CI: 0.69-0.82). A retrospective study in
Poland (175) reported that increased BMI significantly increased the risk of GDM
(BMI > 35 kg/m2 vs BMI 18.5-20.9 kg/m2, OR 9.01, 95% CI 3.47-23.3, p-trend
0.027). Many studies have been confirmed that high pre-pregnancy BMI increases
the risk of GDM (164, 165, 168, 176-179). Nevertheless, a study in Thailand
(180) reported the obese women did not have an increased risk of GDM when
compared with normal weight women (RR: 0.9, 95% CI: 0.6-1.4). Individuals
with overweight or obesity have a tendency to increase risk of type 2 diabetes and
GDM.
d) Hypertension
The 8 year follow up of the San Antonio Heart Study, reported that
participants who converted to non-independent diabetes mellitus had higher
systolic blood pressure than subjects without diabetes in both men and women,
the results were statistically significant (181). The Augsburge study showed a
similar correlation between high blood pressure and the risk of diabetes. The

45
study stated that diabetic subjects had both higher systolic and diastolic blood
pressure than non-diabetic subject (167). A study in Norway showed that subjects
developing diabetes had higher systolic blood pressure than non-diabetics (162).
A study from Qatar reported the positive association of type 2 diabetes with
systolic blood pressure (SBP) (OR = 1.5, 95% CI = 1.2 – 2.0 for SBP 120–
139 mmHg, OR = 2.2, 95% CI = 1.6-3.1 for SBP 140–159 mmHg, and OR = 3.2,
95% CI = 2.0 – 5.3 for SBP > 160 mmHg) (172). In addition, the study in Western
Asia, Lebanon, also suggested that hypertension is a predictor of type 2 diabetes
(OR: 1.75, CI: 1.54-2.00, p-value < 2 × 10-16) (173). The association between high
blood pressure and GDM has not been reported. Hypertension is strongly
associated with diabetes. Both hypertension and type 2 diabetes are related to
metabolic syndrome, and have common risk factors (obesity, diet, and inactivity).
e) Smoking
Many cohort studies have reported the positive association between
smoking and the risk of type 2 diabetes and GDM. The studies showed that
tobacco smoking was correlated with the impairment of glucose metabolism,
insulin sensitivity, and insulin secretion (182, 183). Willi et al. (184) analyzed 25
cohort studies and reported that current smoking increases the risk of type 2
diabetes (OR: 1.44, 95% CI: 1.31-1.58). Moreover, heavy smokers (≥ 20
cigarettes/day) showed the highest incidence of diabetes (OR: 1.61, 95% CI: 1.431.80) when compared to lighter smoking (<20 cigarettes/day) (OR: 1.29, 95% CI:
1.13-1.48) and former smokers (RR: 1.23, 95% CI: 1.14-1.33). The high
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incidence of type 2 diabetes in heavy smokers was confirmed by studies in Japan
(OR: 1.37, 95% CI: 1.05-1.80)(185), Finland (OR: 1.57, 95% CI: 1.34-1.84 in
men and OR: 1.87, 95% CI: 1.36-2.59 in women) (186), and China (OR: 1.25,
95% CI: 1.00-1.56) (187). In addition, Kim et al. reported that early onset of
smoking increased the risk of type 2 diabetes in both Korean and US populations
(188).
However, some studies showed that the risk of type 2 diabetes increased
after 3-5 years of smoking cessation (189-191). As a consequence, smoking
cessation was associated with increased body weight, which is a risk factor of
type 2 diabetes. However, increased duration of smoking cessation significantly
decreased the risk of type 2 diabetes (191). A meta-analysis analyzing 4 cohort
studies reported that passive smoking increased the risk of type 2 diabetes (OR:
1.28, 95% CI: 1.14-1.44)(192).
A prospective study in the United States (163) reported that women who
smoked cigarettes had an increased risk of GDM (RR: 1.43, 95% CI: 1.14-1.80).
A prospective cohort study in Massachusetts (193) showed that women who
smoked prior to pregnancy had an increased risk of GDM when compared with
non-smokers, but the results did not show statistical significance.
f)

Gestational diabetes mellitus (GDM) and subsequent risk of DM
Women with previous GDM show increased risk of type 2 diabetes 17-

63% in 5-16 years after diagnosis of GDM (194). A study in northwestern Ontario
(195) reported that 70% of the women diagnosed with GDM developed type 2
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diabetes, and the average duration from diagnosis of GDM to type 2 diabetes was
three years. Sivaraman et al. (196) showed that women diagnosed with GDM had
a significantly increased risk of type 2 diabetes, finding 6.9% at five years (95%
CI: 3.8%-9.9%) and 21.1% at ten years (95% CI: 14.1%-27.5%) after diagnosis of
GDM. Lui et al. (197) showed that increased postpartum body weight (>7 kgs)
increased the risk of diabetes by 86% and pre-diabetes, impaired glucose
tolerance or impaired fasting glucose, by 32%, whereas decreased postpartum
body weight reduced the risk of pre-diabetes by 45%.
g) Dietary intake
The association between food intake and incidence of diabetes has been
showed to have both positive and negative effects. The Nurses’ Health Study
(198) reported the inverse association between dietary fiber intake and risk of type
2 diabetes (RR=0.72, 95% CI, 0.58-0.90, P trend=.001), this was confirmed by
the Health Professionals Follow-up Study (199), the Iowa Women’s Health Study
(200), and the Black Women's Health Study (201). The protective effect of fiber
intake against GDM was reported in the Nurses’ Health Study II, showing that the
risk of GDM was 0.67 (RR: 0.67, 95% CI: 0.51-0.9) when comparing the highest
quintile with the lowest quintile of total daily fiber intake (202). Moreover, each
10 g/day increase in total fiber intake decreased the risk of GDM 26% (RR: 0.74,
95% CI: 0.51-0.91). A study focusing on the association between fruit intake and
the risk of GDM reported that whole fruit consumption reduced the GDM risk
without statistical significance (203).
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The association between total carbohydrate intake and the risk of type 2
diabetes is controversial (198, 199, 204-206). The Nurses’ Health Study (207)
reported a positive correlation between glycemic index and the risk of type 2
diabetes (p-trend 0.001), and no association between glycemic load and the risk of
type 2 diabetes. However, the Health Professionals Follow-up Study (199), the
Japan Public Health Center-based Prospective Study (208), and a study in China
(204) reported that both glycemic index and glycemic load increased the risk of
type 2 diabetes. A cohort study in a US population, The Health Professionals
Follow-up Study and the Nurses’ Health Study I and II, stated that the high white
rice intake (≥ 5 serving per week) increased the risk of type 2 diabetes (OR: 1.17,
95% CI: 1.02-1.36), while high brown rice intake (≥ 2 serving per week) reduced
the risk of type 2 diabetes (OR: 0.89, 95% CI: 0.81-0.97) (209). This result
demonstrated the adverse effect of high glycemic index foods and the benefit of
fiber on the incidence of type 2 diabetes. The correlation between carbohydrate
intake and GDM was reported on a study by Bao W. and colleagues. The study
found that a low carbohydrate dietary pattern, with high protein and fat from
animals, has a negative association with the risk of GDM (p-trend 0.03) (210).
Additionally, the association between dietary fat intake (total, saturated,
polyunsaturated, and monounsaturated fat) and occurrence of diabetes is
inconsistent. The 14 year follow up of the Nurses’ Health Study (211) reported
the protective effect of polyunsaturated fat on type 2 diabetes; on the contrary, the
Health Professionals Follow-up Study (199) reported no correlation between
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polyunsaturated fat intake and the risk of type 2 diabetes. Bowers K. and
colleagues (212) reported that increased total fat intake, especially animal fat
increased the risk of GDM (p-trend 0.05). Analyzing the association between fatty
acid intake and GDM risk revealed that MUFA and cholesterol significantly
increased the risk of GDM (p-trend 0.04 for both MUFA and cholesterol). The
Alpha Case-Control Study (213) also showed an association between
consumption of cholesterol and the risk of GDM (Q4 (≥294 mg/day) vs Q1 (<151
mg/day) OR: 2.35, 95% CI: 1.35, 4.09, p-trend 0.021).
High fiber and low carbohydrate intake reduce the risk of both type 2
diabetes and GDM. The association dietary fat intake and risk of diabetes is
controversial.
h) Dietary pattern
The Multi-Ethnic Study of Atherosclerosis, MESA, (214) reported that a
dietary pattern characterized by high intake of tomatoes, beans, refined grains,
high-fat dairy, and red meat was associated with increased the risk of type 2
diabetes (OR: 1.18, 95% CI: 1.06-1.32, p-trend 0.004). This study showed that the
pattern characterized by high intake of whole grains, fruit, nuts/seeds, green leafy
vegetables, and low-fat dairy decreased the risk of type 2 diabetes (OR: 0.85, 95%
CI: 0.76-0.95, p-trend 0.005). The insulin Resistance Atherosclerosis Study
followed non-diabetics for five years and reported that food intake pattern (high
intake of dried beans, low-fiber bread and cereal, fried potatoes, tomato
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vegetables, red meat, eggs, and cheese and including low intake of wine) was
associated with the risk of the type 2 diabetes (215).
A cohort study in the US showed an association between the western
dietary pattern or a prudent dietary pattern and the risk of type 2 diabetes. The
study showed that the western dietary pattern increased the incidence of type 2
diabetes (OR: 1.59, 95% CI: 1.32-1.93), while the prudent dietary pattern
decreased the occurrence of type 2 diabetes (OR: 0.84, 95% CI: 0.70-1.00) (216).
The effect of prudent dietary pattern on the risk of type 2 diabetes was confirmed
by a study in Finland (217). The MESA study (218) reported that the
Mediterranean dietary pattern (high consumption of monounsaturated fatty acids,
fruits, vegetables, and whole grains as well as low fat dairy products intake)
reduced insulin levels, but had no significant association with incidence of
diabetes.
The effect of dietary pattern on the risk of GDM has been shown to be
similar to the effect seen on type 2 diabetes risk (protective effects: Prudent diet
and Mediterranean diet and negative effect: Western Diet). The Nurses’ Health
Study II (219) reported a protective effect of the prudent pattern (high intake of
fruit, green leafy vegetables, poultry and fish) on the GDM risk (p-trend 0.018).
In addition, the western dietary pattern, which is characterized by high intakes of
red meat, processed meat, sugary desserts, high-fat foods, and refined grains, is
positively associated with the risk of GDM (P-trend 0.0011). Tobias DK. and
colleagues (220) examined the association between GDM risk and dietary
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patterns, namely the alternate Mediterranean (aMED), Dietary Approaches to
Stop Hypertension (DASH), and alternate Healthy Eating Index (aHEI). When
comparing the highest with the lowest quartile of dietary pattern score, aMED,
DASH, and aHEI significantly decreased the risk of GDM (RR: 0.76, 95% CI:
0.60-0.95, P-trend = 0.004 for aMED; RR: 0.66, 95% CI: 0.53-0.82, P-trend =
0.0005 for DASH; RR: 0.54, 95% CI: 0.43-0.68, P-trend < 0.0001 for aHEI). The
cohort study in China (221) reported the protective effect of a vegetable dietary
pattern on the risk of GDM (T3 vs T1: RR: 0.79, 95% CI: 0.64-0.97, p-trend
0.036). Moreover, sweets and seafood dietary patterns increased the risk of GDM
(T3 vs T1: RR: 1.23, 95% CI: 1.02-1.49, p-trend 0.01).
Dietary patterns characterized by high fiber intake (whole grain, fruit, and
vegetable), and low animal fat such as Prudent diet, DASH diet, and
Mediterranean diet reduces risk of type 2 diabetes and GDM. The Western
dietary pattern (low intake of fiber (fruit and vegetable) and high intake of red
meat, high-fat foods, processed meat and sugar) increased the risk of diabetes.
i)

Physical inactivity
Several studies have reported the protective effect of physical activity and

the adverse effect of sedentary behaviors on the incidence of type 2 diabetes. The
Nurses' Health Study (222) showed that sedentary behaviors increased the risk of
type 2 diabetes. The studies showed that increased duration of sitting while
watching television increased the risk of diabetes (0-1 hr/week is reference, OR:
1.22; 95% CI: 1.06-1.42 for 2-5 hrs/week), OR: 1.42; 95% CI: 1.24-1.63 for 6-20
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hrs/week, OR: 1.65; 95% CI: 1.41-1.93 for 21-40 hrs/week, OR: 1.94; 95% CI:
1.51-2.49 for >40 hrs/week; p-trend <0.001), whereas increased standing or
walking around at home decreased the risk (0-1 hr/week is reference, OR: 0.99;
95% CI: 0.79-1.24 for 2-5 hrs/week), OR: 0.87; 95% CI: 0.70-1.08 for 6-20
hrs/week, OR: 0.78; 95% CI: 0.63-0.97 for 21-40 hrs/week, OR: 0.77; 95% CI:
0.61-0.97 for >40 hrs/week; p-trend <0.001). A survey in Lebanon (173) showed
that physical inactivity significantly increased the risk of type 2 diabetes. In
addition, physical activity significantly decreased the risk of type 2 diabetes (OR:
0.55, 95% CI: 0.37-0.81 for moderate activity, OR: 0.46, 95% CI: 0.24-0.88 for
heavy activity). The study in urban Shanghai, China (187) also showed a
significant inverse association between the incidence of type 2 diabetes and
metabolic equivalent values (METs), which is used to estimate intensity of
physical activity. Physical activity reduces the incidence of type 2 diabetes by
decreasing insulin resistance and improving insulin sensitivity (223).
However, the effect of physical activity on GDM development is
controversial. The Nurses' Health Study II (224) reported that the physical activity
score was inversely associated with the risk of GDM (p-trend 0.01). The study
showed that brisk or very brisk walking 4 hours a week decreased the risk of
GDM when compared with casual walking of the same duration (RR: 0.66, 95%
CI: 0.46-0.95). However, the Australian Longitudinal Study found no association
between physical activity and GDM risk (225). A case-control study determining
the relation between recreational physical activity and risk of GDM (226) showed
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an effect similar to brisk walking. For distances of ≤ 2 miles/day, brisk walking
significantly reduced the GDM risk when compared with casual walking, but
there was no significant protective effect in distances over 2 miles a day for either
intensity. This study also reported that women participating in recreational
physical activity during the year before pregnancy and during the first 20 weeks
of pregnancy reduced the risk of GDM (OR: 0.45, 95% CI: 0.28-0.74 and OR:
0.52, 95% CI: 0.33-0.80 respectively). Physical activity can prevent diabetes both
type 2 diabetes and GDM while physical inactivity increases the risk of diabetes.
2.3 Metabolic Syndrome
2.3.1 Overview
Metabolic syndrome is a major public health issue because it increases the risk of
cardiovascular diseases (CVD), type 2 diabetes mellitus, stroke, etc. Metabolic syndrome
is the grouping of visceral obesity, insulin resistance, hyperglycemia, dyslipidemia
(hypertriglyceridemia and hypo-HDL cholesterolemia), and hypertension. The definitions
of metabolic syndrome have been proposed by the World Health Organization (WHO),
the National Cholesterol Education Program, Adult Treatment Panel III (NCEP/ATP III),
the International Diabetes Federation (IDF), the American Heart Association/National
Heart, Lung and Blood Institute (AHA-NHLBI), the American Association of Clinical
Endocrinology (AACE), and the European Group for the Study of Insulin Resistance
(EGIR) (Table 3.1). AACE proposed the definition of metabolic syndrome by using
insulin resistance syndrome. The definition given by AACE can be applied to the
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diagnosis of metabolic syndrome; relying on clinical judgment in non-diabetic patients.
Genetic, hormonal, and lifestyle factors lead to the development of the syndrome.
Risk of metabolic syndrome among obese persons can be split into two groups:
metabolically healthy obesity (MHO) and metabolically unhealthy obesity (MUHO)
(227). Metabolically healthy obesity (MHO) means obese people without metabolic
abnormalities and have normal blood pressure, normal glucose tolerance, and normal
lipid profiles. MHO results from the interaction between genetic, environmental, dietary,
and behavioral factors associated with the accumulation and distribution of fat and insulin
resistance (228). Subcutaneous adipose tissue of MHO individuals has the propensity to
accumulate peripheral fat rather than visceral fat depots in MUHO which leads to insulin
resistance (227). A study of weight-discordant monozygotic twins (229) reported that the
obese co-twins in the ≥ 2% liver fat group presented significantly higher adipocyte
volume, AUC insulin and glucose, LDL-cholesterol, leptin, and CRP and lower HDLcholesterol than the non-obese co-twins. In the group with different liver fat <2%, obese
co-twin had higher adipocyte volume and leptin than lean co-twins. This study stated that
the MHO group (those with a low percentage of liver fat), had less inflammation, while
the excess liver fat group presented with insulin resistance, dyslipidemia, and
inflammation. This study of discordance among monozygotic twins indicates a role for
non-genetic factors influencing the risk of metabolic syndrome.
Metabolically unhealthy obesity is characterized by abdominal visceral fat
disposition, visceral and ectopic fat accumulation, and insulin resistance (228). Visceral
fat is intra-abdominal fat and a marker of ectopic fat which means the fat accumulating in
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and around the organs in abdominal cavity including the heart (230). Abdominal obesity
has an effect on metabolic processes by the intra-abdominal visceral fat which has higher
lipolysis rate than any other depots. Abdominal adipose tissue elevates free fatty acids
(FFA), cytokines (tumor necrosis factor alpha (TNF-𝛼) and interleukin-6 (IL-6)),
adipokines, and angiotensin II. Excess FFA circulation induces insulin resistance, which
results from reduced hepatic insulin clearance, decreased skeletal muscle insulin
sensitivity, increased hepatic cholesterol production with elevated triglycerides and very
low density lipoprotein (VLDL), and altered endothelial function. Elevated levels of
cytokines also impair insulin sensitivity. A similar result is seen with decreased
adiponectin level. Adiponectin has a protective effect by regulating lipid and glucose
metabolism, controlling energy metabolism, and increasing insulin sensitivity (231, 232).
Obesity increases not only adipose tissue but also the systemic renin angiotensin system,
which increases angiotensin II circulation. Angiotensin II causes decreased insulin
sensitivity and vasoconstriction (233).

Table 2.1 Definition of metabolic syndrome
WHO1(234)

NCEP/ATP III2(235)

IDF3(236)

Abnormal glycemia plus 2 or more
other criteria

3 or more criteria

Abdominal obesity plus 2 or
more other criteria

Abdominal obesity

BMI > 30 kg/m2 and/or Waist to hip
ratio > 0.9 (men)
> 0.85 (women)

Waist circumference
> 102 cm (men)
> 88 cm (women)

Waist circumference for US
population > 94 cm (men)
> 80 cm (women)

Glucose

Insulin resistance or impaired
glucose regulation or diabetes
< 35 mg/dL (men)
< 39 mg/dL(women)

Fasting plasma glucose > 110
mg/dL or previous diabetes
< 40 mg/dL (men)
< 50 mg/dL(women)

Fasting plasma glucose > 100
mg/dL or previous diabetes
< 40 mg/dL (men)
< 50 mg/dL(women)

≥ 140/90 mmHg
≥ 150 mg/dL
microalbuminuria (urinary albumin
excretion rate ≥ 20 µg/min or
albumin:creatinine ratio ≥ 30 mg/g)

≥ 130/85 mmHg
≥ 150 mg/dL

≥ 130/85 mmHg
≥ 150 mg/dL

Criteria

HDL-C

Hypertension
Triglyceride
Other
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Table 2.1 Definition of Metabolic Syndrome (Cont.)
AHA-NHLBI4(237)
Criteria

Abdominal
obesity
Glucose

HDL-C

AACE5(238)

EGIR6(239)

3 or more criteria

No specific number of criteria for
diagnosis; based on clinical judgment
(only for non-diabetic subjects)

Insulin resistance plus 2 or more
criteria (only for non-diabetic
subjects)

Waist circumference
> 102 cm (men)
> 88 cm (women)
Fasting plasma glucose > 110
mg/dL or mediation treatment for
controlling glucose
< 40 mg/dL (men)
< 50 mg/dL(women)
≥ 130/85 mmHg
≥ 150 mg/dL

BMI ≥ 25 kg/m2

Waist circumference
> 94 cm (men)
> 80 cm (women)
Insulin resistance or impaired glucose
regulation (but not diabetes)

Fasting plasma glucose 110-125
mg/dL or 2 hr post glucose challenge
140-200 mg/dL
< 40 mg/dL (men)
< 50 mg/dL(women)
≥ 130/85 mmHg
≥ 150 mg/dL
Other features of insulin resistance

Hypertension
Triglyceride
Other
1
World Health Organization
2
National Cholesterol Education Program, Adult Treatment Panel III
3
International Diabetes Federation
4
American Heart Association/National Heart, Lung and Blood Institute
5
American Association of Clinical Endocrinology, American College of Endocrinology
6
European Group for the Study of Insulin Resistance

< 39 mg/dL
≥ 140/90 mmHg
≥ 150 mg/dL
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Figure 2.1 The difference between metabolically healthy and unhealthy obesity (227,
228)
BP, blood pressure; LDL, low density lipoprotein; TG, triglyceride; HDL, high density
lipoprotein; TNF-α, tumor necrosis factor alpha; IL-1, interleukin 1; IL-1B, interleukin 1
beta; IL-6, interleukin 6
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Figure 2.2 Mechanism of metabolic unhealthy obesity
FFA, free fatty acid; VLDL, very low density lipoprotein: TNF-α, tumor necrosis factor
alpha; IL-6, interleukin 6
2.3.2

Epidemiology of metabolic syndrome

Global prevalence of metabolic syndrome is around 10% to 84%, which depends
on region, sex, age, and the definition of metabolic syndrome used (232). The prevalence
of metabolic syndrome in the United States was 27% during 1999-2000, and increased to
34.2% during 1999-2006 (240), 36.1% during 2007-2008, 34.2% during 2009-2010, and
34.7% during 2011-2012 (241). The MARE consortium collaborating among 10
countries in Europe (Lithuania, Greece, Spain, Germany, Netherlands, United Kingdom,
Italy, Portugal, Belgium, and Sweden) and the United States reported that overall
prevalence of metabolic syndrome is 24.3% (24.6% in women and 23.9% in mem) (242).
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This study also found that Lithuania had the highest prevalence of metabolic syndrome
(around 63%) and Italy presented the lowest prevalence (around 7%). Misra and Khurana
reported the prevalence of metabolic syndrome in developing countries (33.5% in South
Africa, 16.3% in Morocco, 21% for Oman, 33.4% in Turkey, 31.2% in Venezuela, 25.4
in Brazil, and 33.7% in Iran.) (243). The China Health and Nutrition Survey in 2009
presented that metabolic syndrome prevalence is 21.3% (95%CI: 20.3-22.2) for NCEP
ATPIII criteria and 18.2% (95%CI: 17.3-19.1) for IDF criteria after adjustment for age
(244). The prevalence of metabolism of rural women in Bangladesh and India is also as
high as the prevalence in other developing and developed countries (36.4% in India and
31.25% in Bangladesh) (245, 246).
Higher prevalence of metabolic syndrome in women than in men has been
reported in the United States, Germany, France, Greece, Finland, and Sweden (241, 242,
247) , but not in Northeast of China, Spain, Netherlands, Portugal (242, 247, 248). Data
from the National Health and Nutrition Examination Survey (NHANES) (2003-2012) in
the United States reported that the highest prevalence of metabolic syndrome was 38.6%
in Hispanic population, and 37.4% in Non-Hispanic Whites, 35.5% in Blacks, and 23.4 in
other races (241).
2.3.3

Risk factors of metabolic syndrome

a) Age
The NHANES (2003-2012) reported that prevalence of metabolic
syndrome increased when ages increased (18.3% among ages 20-39 years, and
46.7 among ages 60 years or over (241). The prevalence of metabolic syndrome is
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considered to increase with age. The LATIN America METabolic Syndrome
(LATINMETS) multicenter study in Brazil reported that increased age groups
increases risk of metabolic syndrome (20-29 years: OR:1.3, 95% CI: 0.5-3.2; 3039 years: OR:5.6, 95% CI: 0.8-11.9; and ≥ 40 years: OR:26.3, 95% CI: 4.5-48.1)
(249). The Chinese survey in 2009 (244) reported that risk of metabolic syndrome
increased three time in age ≥ 60 years (OR: 36.7, 95% CI: 34.7-38.7) when
compare with age 18-39 years (OR: 12.4, 95% CI: 10.9-13.9-38.7).
b) Body weight
A national Survey in the United States (1988-1994) (250) reported that
increased BMI increased the incidence of metabolic syndrome in both men and
women (BMI 18.5-24.9 is a reference, for men: BMI 25-29.9 kg/m2 (OR: 5.2,
95% CI: 3.9-6.9), BMI 30-34.9 kg/m2 (OR: 25.2, 95% CI: 19.3-32.9), BMI ≥ 35
kg/m2 (OR: 67.7, 95% CI: 40.5-113.3); for women: BMI 25-29.9 kg/m2 (OR: 5.4,
95% CI: 3.7-7.9), BMI 30-34.9 kg/m2 (OR: 14.0, 95% CI: 9.1-21.4), BMI ≥ 35
kg/m2 (OR: 34.5, 95% CI: 22.6-52.7)). Xi et al. found that overweight and
obesity significantly increased risk of metabolic syndrome (BMI < 25 kg/m2 is
reference; BMI 25-27.49 kg/m2: OR: 4.32, 95% CI: 3.77-4.95; BMI ≥ 27.5 kg/m2:
OR: 11.24, 95% CI: 9.53-13.26) (244).
c) Smoking
Smoking is associated with abdominal obesity and insulin resistance
(251). Studies in Norway and Korean found that smoking more than 20 cigarettes
per day increased risk of metabolic syndrome (HR: 1.25, 95% CI: 1.02-1.53, and
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OR: 1.79, 95% CI: 1.10-2.91, respectively) when compared with non-smoker
(252, 253). A population based cross-sectional study in China found that
increased smoking increased risk of metabolic syndrome (never is reference; OR:
0.79, 95% CI: 0.51-1.25 for ≤ 7.5 packs/year; OR: 1.12, 95% CI: 0.69-1.79 for ≤
20 packs/year, and OR: 1.81, 95% CI: 1.15-2.84 for > 20 packs/year; p-trend
0.045) (251). A study in Iran also reported the protective effect of smoking on
metabolic syndrome. (254)A study in China reported that high incidence of
metabolic syndrome in heavy smoker (≥11 cigarettes/day) (OR: 1.33, 95% CI:
1.04-1.71) when compare to lighter smokers (≤ 10 cigarettes/day) (244).
However, the study in Japan and Portugal that smoking had no association with
metabolic syndrome (255, 256).
d) Alcohol consumption
Light or moderate alcohol consumption can reduce risk of coronary heart
disease and stroke, but excessive consumption is toxic to many organs (257). The
association between alcohol consumption and risk of metabolic syndrome is
inconsistent. A meta-analysis study, analyzing 14 observational studies, found
that both men having alcohol consumption 0.1-39.9 g/day and women having
alcohol consumption 0.1-19.9 g/day had a lower prevalence of metabolic
syndrome when compared with non-drinkers (OR: 0.84, 95% CI: 0.75-0.94 for
men and OR: 0.75, 95% CI: 0.64-0.89 for women) (258). The Third National
Health and Nutrition Examination Survey in the United States also reported the
protective effect of alcohol consumption on the incidence of metabolic syndrome
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(< 1 drink/month is reference, OR: 0.65, 95% CI: 0.54-0.79 for 1-19
drinks/month: OR: 0.34, 95% CI: 0.26-0.47 for ≥ 20 drinks/month, p-trend =
0.0001) (259). A study in China (251) also reported the protective effect of
alcohol consumption (0 g/day is reference, OR: 0.81, 95% CI: 0.63-1.05 for ≤ 5.7
g/day: OR: 0.72, 95% CI: 0.56-0.94 for ≤17.7 g/day; OR: 0.73, 95% CI: 0.56-0.95
for > 17.7 g/day; p-trend <0.0001). However, a survey in China demonstrated that
increased alcohol intake increased metabolic syndrome risk (<1 time/month is
reference; 1-3 times/month (OR: 1.82, 95% CI: 1.21-2.75; 1-2 times/week (OR:
2.03, 95% CI: 1.35-3.05); 3.4 times/week (OR: 2.07, 95% CI: 1.31-3.27); 1
times/day (OR: 2.16, 95% CI: 1.45-3.22)) (244). A cross-sectional study in
Portugal reported no association between alcohol consumption and metabolic
syndrome (255).
e) Dietary intake
The NHANES (1988-1994) found that high carbohydrate intake increased
risk of metabolic syndrome in men (OR: 1.7, 95% CI: 1.2-2.5 in men and OR:
1.1, 95% CI: 0.8-1.4 in women) (250). A cross-sectional study in Finland found
that increased fish consumption reduced risk of metabolic syndrome (tertile 1 is
reference, tertile 2 (OR: 0.52, 95% CI: 0.32-0.83), tertile 3 (OR: 0.63, 95% CI:
0.4-1.0), p-trend 0.04 (260). This study also reported the protective effect of the
consumption of berries, legumes and nuts on the incidence of metabolic
syndrome. Many studies also reported the inverse association between fish
consumption and risk of metabolic syndrome (261-263). A study in France
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presented that increased consumption of cereal grains, and dairy products
decreased risk of insulin resistance (quintile 1 is reference, for cereal grains:
quintile 2 (OR: 1.24, 95% CI: 0.76-2.00), quintile 3 (OR: 0.79, 95% CI: 0.471.33), quintile 4 (OR: 0.55, 95% CI: 0.30-0.98), quintile 5 (OR: 0.76, 95% CI:
0.39-1.48), p-trend 0.05; for dairy products: quintile 2 (OR: 0.76, 95% CI: 0.461.23), quintile 3 (OR: 0.64, 95% CI: 0.39-1.07), quintile 4 (OR: 0.49, 95% CI:
0.28-0.83), quintile 5 (OR: 0.64, 95% CI: 0.37-1.09), p-trend 0.03) (262). This
study also found that meat consumption was positively associated with insulin
resistance (quintile 1 is reference, quintile 2 (OR: 0.96, 95% CI: 0.56-1.64),
quintile 3 (OR: 1.10, 95% CI: 0.64-1.88), quintile 4 (OR: 1.70, 95% CI: 0.992.90), quintile 5 (OR: 2.29, 95% CI: 1.30-4.02), p-trend 0.0007). The protective
effect of dairy consumption on insulin resistance was also reported in the
Coronary Artery Risk Development in Young Adults (CARDIA) study (264).
f) Physical activity
Increased physical activity has a protective effect on metabolic syndrome
because increased physical activity improves metabolic parameters by promoting
weight reduction (251). A population based cross-sectional study in China, The
Nantong Metabolic Syndrome Study (NMSS), reported that occupational physical
activity reduced the incidence of metabolic syndrome (no or sedentary work is
reference; light intensity (OR: 0.77, 95% CI: 0.55-0.88, moderate intensity (OR:
0.55, 95% CI: 0.57-0.90), and vigorous intensity (OR: 0.76, 95% CI: 0.63-0.91),
p-trend 0.005) (251). The Tromsø Study (252) reported that increased intensity of
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physical activity significantly decreased risk of metabolic syndrome, which is
similar to the result from NMSS. However, A study in Portugal reported no
association between physical activity and metabolic syndrome (255). A study in
Taiwan found that watching television ≥ 21 hours/week increased the incidence of
metabolic syndrome when compared with watching television ≤ 5 hours/week
(OR: 3.69, 95% CI: 1.05-12.95) (265). The Third National Health and Nutrition
Examination Survey in the United States (1988-1994) found that physical
inactivity increase risk of metabolic syndrome (OR: 1.4, 95% CI: 1.0-2.0 for men
and OR: 1.2, 95% CI: 1.0-1.4 for women) (250).
2.3.4

Metabolic syndrome and risk of diabetes mellitus

Pathogenic studies reported that obesity leads to insulin resistance, the
impairment of insulin sensitivity in sites of glucose disposal, which can develop into type
2 diabetes mellitus and GDM. Enlarged fat cells lead to increased free fatty acid level,
which result in insulin resistance and impaired insulin secretion. Enlarged fat cells cause
fat overflow to muscles, the liver, and the pancreas, which also affects insulin resistance
and impairs insulin secretion (266). In a study focusing on the correlation between type
of obesity and risk of diabetes, the presence of visceral fat, or the accumulation of fat in
the central abdominal area, was associated with diabetes (267). Moreover, other studies
presented waist circumference, correlating it with the level of abdominal visceral fat, as a
predictor of non-insulin independent diabetes mellitus (268-270).
Metabolic syndrome is a cluster of cardio-metabolic risk factors which increase
the risk of type 2 diabetes mellitus and cardiovascular disease. Many studies have
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reported that metabolic syndrome increased the risk of type 2 diabetes mellitus, including
the West of Scotland Coronary Prevention Study (RR: 7.26, 95% CI: 2.25-23.4 ) (271),
the Beaver Dam Study (RR: 9.37, 95% CI: 2.22-39.59) (272), the San Antonio Heart
Study (OR: 3.30, 95% CI: 2.27-4.80) (273), the Framingham Offspring Study (RR: 6.29,
95% CI: 4.47-10.81) (274), Australian Diabetes, Obesity, and Lifestyle (AusDiab) study
(RR:7.8, 95% CI: 5.5–11.0) (275), and the Insulin Resistance Atherosclerosis Study (OR:
4.14, 95% CI: 2.79-6.16) (276). Insulin resistance and dyslipidemia in metabolic
syndrome are important factors in type 2 diabetes mellitus development. Insulin
resistance over time will develop to type 2 diabetes mellitus because of the inability of
pancreatic beta cells to produce sufficient insulin to compensate for insulin resistance
(232). Moreover, hypertriglyceridemia and hypo HDL-C as a risk factor for pancreatic
beta cell dysfunction contribute to type 2 diabetes by reducing insulin secretion (277).
Most studies have reported the development of metabolic syndrome after
gestational diabetes mellitus (GDM). Studies reported the risk factors of GDM,
including: high fasting plasma glucose, insulin resistance, high systolic blood pressure,
high triglyceride level, low HDL-C level at the first trimester of pregnancy, and
overweight or obesity pre-gestation (174, 278-280). These factors are used for the
diagnosis of metabolic syndrome. Women with a history of GDM also have increased
risk of metabolic syndrome. A meta-analysis study (281), analyzing 17 studies, showed
that the risk of metabolic syndrome increased in women with a history of GDM (OR:
3.96, 95% CI: 2.98-5.26). In addition, the subgroup analysis by ethnicity showed that
Caucasian women have higher odds of developing metabolic syndrome after GDM than
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Asian women (OR: 4.54, 95% CI: 3.78 -5.46 in Caucasian; and OR: 1.28, 95% CI: 0.64
to 2.56 in Asian). The subgroup analysis by BMI showed that women with prior GDM
had an increased risk of metabolic syndrome (OR: 5.39, CI: 4.47- 6.50). This result may
be explained by a study which reported that women with a history of diabetic pregnancy
had higher CRP levels and lower adiponectin levels compared to controls (282).
Moreover, higher level of CRP and IL-6 were present in women with metabolic
syndrome and a history of GDM compared with the control group and women with a
history of GDM, but who did not have metabolic syndrome (283, 284). Therefore,
inflammation and adipose tissue relating to insulin sensitivity may be the link between
GDM and metabolic syndrome.
Metabolic syndrome is not only a consequence of, but a risk factor for gestational
diabetes mellitus. A study in Greece by Chatzi et al. (285) found that women with
metabolic syndrome in early pregnancy increased the risk of GDM (RR: 3.17, 95% CI:
1.06-9.50).
2.3.5

Biochemical markers related to diabetes mellitus and metabolic syndrome

Biochemical markers are hormones, enzymes, antibodies, or other substances in
urine, blood, tissue, or other body fluids. These biomarkers have been used to detect
abnormality or disease. Fasting plasma glucose (FBG), oral glucose tolerance test
(OGTT), glycated hemoglobin (HbA1c), and random plasma glucose are the common
biochemical markers for screening and diagnosing diabetes (145). The association
between first trimester biomarker and the risk of developing GDM has been studied in
lipid profiles, inflammatory biomarkers, and ferritin levels.
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a) Glucose and Insulin
Plasma glucose is a parameter for diagnosing diabetes by the American
Diabetes Association, WHO, and IDF (145, 146). The homeostatic model
assessment (HOMA) was proposed to assess insulin resistance (HOMA-IR) and
β-cells function (HOMA-B) (286). HOMA model has been used to predict type 2
diabetes development. QUICKI (quantitative insulin sensitivity check index) was
proposed later by Katz et al. in order to assess insulin sensitivity. Chen et al.
determining the predictive accuracy of QUICKI concluded that QUICKI is an
accurate index for assessing insulin sensitivity (287).
HOMA-IR = [Fasting plasma glucose (mmol/L) x Fasting plasma insulin
(mU/L)]/22.5
HOMA-B = [20x Fasting plasma insulin (mU/L)]/ [Fasting plasma glucose
(mmol/L)-3.5]%
QUICKI = 1/[log(fasting plasma insulin (μU/ml))+log(fasting plasma glucose
(mg/dl))]
The Women’s Health Initiative Observation Study (288), a multiethnic
cohort of women in the United States, found that diabetic cases had higher
HOMA-IR and lower HOMA-B than controls. This study reported the strong
association between diabetes and HOMA-IR and HOMA-B in all ethnic groups
(HOMA-IR; RR: 3.05, 95% CI: 2.63-3.53 for overall; RR: 3.79, 95% CI: 2.944.88 for Whites; RR: 2.59, 95% CI: 2.03-3.30 for Blacks; RR: 2.66, 95% CI:
1.80-3.91 for Hispanics; RR: 4.18, 95% CI: 2.18-8.04 for Asians; HOMA-B; RR:
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0.52, 95% CI: 0.46-0.58 for overall; RR: 0.50, 95% CI: 0.42-0.59 for Whites; RR:
0.48, 95% CI: 0.39-0.60 for Blacks; RR: 0.49, 95% CI: 0.35-0.68 for Hispanics;
RR: 0.59, 95% CI: 0.37-0.93 for Asians). The association between type 2 diabetes
and HOMA-IR and HOMA-B was reported in many population including
Mexican-American (289), non-Hispanic White (289), African-American (290),
Mexican (291), Japanese (292), and Chinese (293). Yokoyama et al. found that
type 2 diabetic patients had higher QUICKI than the healthy participants (294). A
five year follow-up study in Finland (295) found that increased QUICKI
increased risk of type 2 diabetes in obesity (tertile 1 is reference; tertile 2, OR:
5.29, 95% CI: 1.39-20.24; tertile 3, OR: 7.77, 95% CI: 1.63-37.04; p-trend 0.002).
Many studies found that pregnant women with GDM have higher HOMAIR and lower QUICKI and HOMA-B than pregnant women with normal glucose
tolerant (296-299). Ozcimen et al. suggested the cut-point of HOMA-IR in the
first trimester for predicting GDM is 2.60 (300). However, a prospective cohort
study in Turkey reported no association between HOMA-IR, HOMA-B, and
QUICKI and risk of GDM (301). Therefore, HOMA and QUICKI have
inconsistent correlations with the prevalence of type 2 diabetes and GDM.
A study in India conducted by Bhatnagar et al. reported that metabolic
syndrome group had higher both fasting and post-prandial plasma glucose and
serum insulin including HOMA-IR than the control group (302).

71
b) Lipid profiles
Both high triglyceride and low high-density lipoprotein levels are
associated with a pre-diabetic state, or insulin resistance syndrome (303). The San
Antonio Heart Study with an 8 year follow up, reported that participants who
converted to non-insulin dependent diabetes mellitus had higher triglyceride
levels and lower HDL levels than subjects without diabetes. These results were
statistically significant for both men and women (181). A longitudinal study in
Norway also reported that both high triglyceride and low HDL had a significant
association on the risk of diabetes (162). The Finnmark study with a 12 year
follow up, presented a significant inverse correlation between HDL levels and the
risk of diabetes mellitus only in women at not in men (HDL <1 mmol/l is
reference, HDL 1.0-1.49 mmol/l :RR = 0.6), HDL ≥ 1.5 mmol/L: RR = 0.17), Ptrend <0.0001)(171). In addition, a positive correlation between total cholesterol
and risk of diabetes was reported in the study from Qatar (total cholesterol ≥ 240
mg/dl OR: 1.4, 95% CI: 1.0-1.9) (172).
The triglyceride and HDL levels have an association with the development
of GDM. Pregnant women developing GDM have lower HDL levels and higher
triglyceride levels during the first trimester than control pregnancies when
adjusted for maternal age, BMI, gestational age at sampling, smoking, ethnicity,
parity, conception status, and previous GDM (279). Guanghui Li and colleagues
(304) studied the association between lipid profiles during the first trimester and
risk of developing GDM. The study reported on two groups, a lean group (BMI <
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24 kg/m2) and an obese group (BMI ≥ 24 kg/m2). After adjustment for age, parity,
gravidity, family history of diabetes, and level of education, the risk of developing
GDM had a positive association with triglyceride, LDL, and LDL/HDL ratio in
both groups. In addition, the negative correlation between HDL level and the risk
of GDM was found only in lean women. The results of this study were supported
by a meta-analysis study which found that higher triglyceride and LDL levels and
lower HDL levels during first trimester were associated with development of
GDM (305).
c) Fatty acids
Fatty acids have been used as biomarkers for dietary fat intake, obesity,
insulin resistance and diabetes. The Melbourne Collaborative Cohort Study
(MCCS), four year follow up, presented a positive association between the
incidence of type 2 diabetes and some plasma fatty acid proportions such as total
saturated fatty acid levels (OR: 3.76, 95% CI: 2.43- 5.81), stearic acid levels (OR:
4.14, 95% CI: 2.65- 6.49), palmitoleic acid levels (OR: 5.61, 95% CI: 3.65-8.60),
dihomo-γ-linolenic acid levels (OR: 9.65, 95% CI: 5.48-16.97), and inverse
association with linoleic acid levels (OR: 0.22, 95% CI: 0.14- 0.36), and trans
fatty acid levels (OR: 0.20, 95% CI: 0.12- 0.32) when compared highest quintile
with lowest quintile (306).
d) Inflammatory markers: cytokines and adipokines
Inflammatory markers and diabetes can be described with adipose tissue
functions. Obesity causes adipose tissue to promote inflammatory response

73
(increased leptin, resistin, visfatin, chemerin, tumor necrosis factor alpha (TNFα), interleukin-1 (IL-1), interleukin-6 (IL-6), interleukin-8 (IL-8), plasminogen
activator inhibitor 1, monocyte chemoattractant protein-1, and retinol binding
protein-4, and decreased adiponectin and interleukin-10 (IL-10)) (307).
Inflammatory markers have been proposed as predictors for the incidence
of type 2 diabetes. A meta-analysis study conducted by Wang et al. found that
interleukin-6 (IL-6) and C-reactive protein (CRP) had positive associations with
the risk of type 2 diabetes (RR: 1.31, 95% CI: 1.17-1.46 and RR: 1.26, 95% CI:
1.16-1.37, respectively) (308). The population-based MONItoring of trends and
determinants in CArdiovascular disease (MONICA)/Cooperative Research in the
Region of Augsburg (KORA) (309) studies found that increased interleukin-18
(IL-18) raised the risk of type 2 diabetes. The MONICA/KORA studies, however,
did not observe an association between type 2 diabetes and IL-6 and CRP. A year
later, the MONICA/KORA studies published result on the novel inflammatory
markers associated with type 2 diabetes, namely monocyte chemoattractant
protein-1 (MCP-1), interleukin-8 (IL-8) and interferon-gamma-inducible protein10 (IP-10) (310). A cohort study in the United Kingdom found that Interleukin-1
receptor antagonist (IL-1Ra) was positively associated with the risk of type 2
diabetes (OR: 1.48, 95% CI: 1.21-1.80) (311).
Adipokines have been reported to have an association with the incidence
of type 2 diabetes. The data from the Third National Health and Nutrition
Examination Survey (NHANES III) (312) showed that increases in leptin levels
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significantly increased the incidence of diabetes mellitus in both genders (Q4 vs
Q1; OR: 4.36, 95% CI: 2.15-8.85 for men, OR: 2.76, 95% CI: 1.32-5.77 for
women, and OR: 3.79, 95% CI: 2.05-7.00 for overall) after adjustment for
diabetes risk factors (age, sex, race/ethnicity, education, smoking, alcohol intake,
hypertension, serum cholesterol and C-reactive protein). However, plasma leptin
level had no association with diabetes mellitus after adjustment for diabetes risk
factors and body mass index (Q4 vs Q1; OR: 1.07, 95% CI: 0.59–1.94 for men,
OR: 0.86, 95% CI: 0.49–1.51 for women, and OR: 0.98, 95% CI: 0.56–1.72 for
overall). A meta-analysis study (313) analyzing 24 articles presented that an
increase in leptin levels of 1-log ng/ mL significantly increased the risk of type 2
diabetes only in men (RR: 1.37, 95% CI: 1.13-1.66 in men, and RR: 0.96, 95%
CI: 0.90-1.03 in women) after adjustment for type 2 diabetes risk factors and body
mass index. The British Regional Heart Study (314) , a prospective study of
cardiovascular disease in men aged 60-79 years, reported that type 2 diabetes
mellitus had a negative correlation with adiponectin (RR: 0.33, 95% CI: 0.190.56) and a positive correlation with leptin (RR: 4.98, 95% CI: 2.75-9.04) after
adjusting for type 2 diabetes risk factors. The 10 year follow-up study in
Aboriginal Canadian population (315) showed that type 2 diabetes mellitus had a
positive association with leptin (OR: 1.50, 95% CI: 1.02-2.21) and a negative
association with adiponectin (OR: 0.63, 95% CI: 0.48-0.83) and adiponectin-toleptin ratio (OR: 0.54, 95% CI: 0.37-0.77), after adjustment for age, sex,
triglycerides, HDL cholesterol, hypertension, and impaired glucose tolerance.
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However, only adiponectin significantly correlated with the risk of type 2 diabetes
(OR: 0.68, 95% CI: 0.51-0.90) after additional adjustment with waist
circumference and body mass index.
Prospective studies have found that GDM is related to decreased
adiponectin and anti-inflammatory cytokines (IL-4 and IL-10) and increased
leptin and pro-inflammatory cytokines (IL-6 and TNF-α) (316). Pregnancies with
GDM have higher IL-6 concentrations during the first trimester than pregnancies
without GDM (317). Adiponectin levels during the first trimester have a negative
correlation with the risk of developing GDM (OR: 1.13, 95% CI: 1.03-1.24 per 1
µg/ml decrease) after adjustment for age and waist circumference (318). When
compared to the highest quantile, pregnant women with first trimester adiponectin
concentrations ranging in the lowest quantile were 10.2 times (95% CI: 1.13-78.7)
more likely to develop GDM (319). Other studies confirmed that pregnant women
developing GDM have lower adiponectin level and higher leptin and CRP levels
than women in the control group (279, 320-323). Increased first trimester CRP
concentration increased the risk of developing GDM after adjusting for age,
race/ethnicity, parity, blood pressure, smoking, and gestational age (T3:T1, OR:
3.6, 95% CI: 1.2-11.4, p-trend < 0.01) (324). Qui C and colleagues (323) reported
that leptin levels during the first trimester of pregnancy were positively associated
with the risk of developing GDM when adjusted for parity, family history of type
2 diabetes, and pre-pregnancy BMI (T3:T1, OR: 4.90, 95% CI: 1.40-17.5, p-trend
< 0.02) (325).
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The positive association between CRP and risk of metabolic syndrome
was found in studies in the United States (326), Spain (327), Korea (328), India
(329), and Iran (330). A study in Poland (331) reported the increased hs-CRP, IL6, and TNF- α increased a number of metabolic syndrome components. This study
also presented a negative association between adiponectin and a quantity of
metabolic syndrome parameters. The Indian Atherosclerosis Research Study
(IARS) (332) found that hs-CRP levels was associated with risk of developing
metabolic syndrome (OR: 1.49, 95% CI: 1.14-1.95), but the association between
IL-6 and metabolic syndrome was not found. A study in Japan by Matsushita et
al. presented that increased TNF- α and CRP, including deceased adiponectin
were associated with metabolic syndrome (OR: 1.27; 95% CI: 1.00-1.60, OR:
1.49; 95% CI: 1.19-1.87, and OR: 2.03, 95% CI: 1.55-2.66, respectively) (333). A
negative association of adiponectin and positive associations of leptin and CRP on
metabolic syndrome were reported in a population-based cross-sectional study in
Kuwait (334) and Spain (335). However, the Framingham Heart Study (336)
reported no association between risk of metabolic syndrome and inflammatory
biomarkers (CRP, IL-6, and TNF- α).
e) Liver enzymes
Liver functions maintain glucose levels during fasting and in the
postprandial period. The liver enzymes are used to evaluate of liver function:
aspartate aminotransferase (AST), alanine aminotransferase (ALT), and gamma-
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glutamyltransferase (GGT). AST and ALT are considered as hepatocellular
health markers while GGT can indicate biliary tract function (337).
The correlation between liver enzymes and risk of type 2 diabetes has
been reported for many decades, but the results are still inconclusive. The Insulin
Resistance Atherosclerosis Study, a multicenter observational epidemiologic
study (338) showed that AST had a significant positive association with the risk
of type 2 diabetes (OR: 1.98, 95% CI: 1.23–3.17; Q4 vs Q1–Q3). The association
between AST and incidence of type 2 diabetes was reported in the Mexico City
Diabetes Study (339) and the cohort study in China (340), but not in a Korean
(337), Japanese (341), or English (342) study. The Namwon study (337)
presented that after adjusting for diabetes risk factors, serum ALT concentration
were associated with type 2 diabetes in both males (OR: 1.95, 95% CI: 1.18-3.21)
and females (OR: 1.49, 95% CI: 1.03-2.16) when comparing the highest quartile
(ALT ≥ 30 units/l) to the lowest quartile (ALT ≤ 20 units/l). Many studies also
reported the association between ALT and incidence of type 2 diabetes (338, 340,
342-345). However, studies of middle-aged Japanese men (341) and a Mexican
population (339) reported no correlation between ALT and risk of type 2 diabetes
after adjusting for other diabetes risk factors. The Mexico City Diabetes Study
(339) reported that GGT was an independent predictor for type 2 diabetes when
controlling for diabetes risk factors, plasma proinsulin and 2 hour glucose levels
(OR:1.62, 95% CI:1.08–2.42). The study in Korea (337) also reported that
females in the highest GGT quartile (GGT ≥ 55 units/l) had a significantly
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increased risk of type 2 diabetes (OR: 1.85, 95% CI: 1.23-2.79) when compared
with the lowest quartile (GGT ≤ 19 units/l). Many studies (342, 344-346)
confirmed that increased GGT increased the risk of type 2 diabetes. The study in
middle-aged Japanese men (341) reported that increased serum alkaline
phosphatase significantly raised the risk of type 2 diabetes after adjustment for all
diabetes risk factors (OR: 2.04, 95% CI: 1.39-3.00 for Q4 vs Q1, p-trend <0.001).
A 5-year follow-up study in the United Stated (326) presented the
association between incidence of metabolic syndrome and ALT and AST/ALT
ratio (OR: 1.43, 95% CI: 1.15-1.77 and OR: 0.72, 95% CI: 0.57-0.90,
respectively). Meta-analysis studies (347, 348) considering prospective cohort
studies, reported that the highest category of GGT and ALT increased risk of
metabolic syndrome when compared with the lowest category (RR: 1.63, 95% CI:
1.43-1.82 and RR: 1.81, 95% CI: 1.49-2.14, respectively). These studies also
found that risk of metabolic syndrome was 1.09 per 5U/l increment of GGT levels
(95% CI: 1.06-1.13) and 1.13 per 5U/l increment of ALT levels (95% CI: 1.111.16).
f) Iron status
Body iron stores have been reported as an independent predictor of the
risk for type 2 diabetes. The EPIC (European Prospective Investigation of
Cancer)-Norfolk Cohort Study (349) and a study in China (350) reported that a
raised ferritin level increased the risk of type 2 diabetes during 5 years of followup. Montonen et al. examined the association between body iron stores and risk of
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type 2 diabetes among 27,548 participants during a 7 year follow-up. This study
found that serum ferritin concentrations were positively associated with the risk of
type 2 diabetes (RR: 1.73, 95% CI: 1.15- 2.6, p-trend 0.002), while there was no
correlation between transferrin receptors and the risk of type 2 diabetes (351). The
Camden study reported that first trimester serum ferritin levels were positively
associated with the risk of GDM (OR: 2.35, 95% CI: 1.06- 5.22, p-trend <0.05)
(322).
g) Amino acid profiles
The population-based Metabolic Syndrome in Men (METSIM) Study
(4.7-year follow-up) reported that alanine (OR 1.02, 95% CI: 1.01-1.04), leucine
(OR 1.05, 95% CI: 1.01-1.08), Phenylalanine (OR 1.06, 95% CI: 1.00-1.13),
isoleucine (OR 1.10, 95% CI: 1.05-1.15), tyrosine (OR 1.12, 95% CI: 1.05-1.19),
and glutamine (OR 0.97, 95% CI: 0.96-0.99) predicted the incidence of type 2
diabetes (352). Moreover, the increased level of alanine, leucine, isoleucine,
valine, phenylalanine, and tyrosine and decreased level of glutamine and histidine
increased fasting plasma glucose and 2 hour postprandial glucose, and decreased
insulin sensitivity.
2.3.6

Genes related to obesity and diabetes mellitus

Four hundred and sixteen genes were found that were associated with type 2
diabetes or GDM or obesity. These genes can be divided into two priority groups.
Twenty-eight genes classified into the first group having association between OFCs and
type 2 diabetes or GDM or obesity (Table 2.2). In the second group, three hundred and
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eighty-eight genes have association with significant association with type 2 diabetes or
GDM or obesity in human studies (Table 2.3).
The association between gene polymorphisms and the risk of diabetes differs
among populations. Polymorphisms in genes related to β-cell function, insulin sensitivity,
glucose transport, glucose homeostasis, cytokine, and obesity have been found to be
associated with the incidence of diabetes. Genes related to obesity were associated with
body mass index, waist circumference, waist-to-hip ratio, and fat distribution. Genes
classified in first priority group were described more in term of mechanisms and the
association with diabetes mellitus and obesity.
a) ABCC8 (ATP-binding cassette, sub-family C (CFTR/MRP), member 8)
ABCC8 influences the K-ATP channel function, which causes increased
insulin secretion by pancreatic β-cells. Elbein et al. reported a ABCC8 gene
mutation that decreased pancreatic β-cell compensation to reduced insulin
sensitivity (353).
A candidate gene study in the United States reported that the
polymorphism of rs4148643 and rs1799854 was associated with the risk of both
type 2 diabetes and GDM (354). A study in Turkish (355) and Finnish (354)
populations found that the variation at rs1799854 and rs1799859 in ABCC8 were
associated with type 2 diabetes. Additionally, the association between rs1799854
polymorphism and type 2 diabetes mellitus was confirmed in a Japanese
population (356).
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b) ADIPOQ (adiponectin, C1Q and collagen domain containing)
ADIPOQ gene has an influence on adiponectin concentration, which is
involved in increased glucose uptake via glucose transporter 4 (GLUT-4), and
increased fatty acid uptake and oxidation (357). Yamauchi reported that
adiponectin stimulated phosphorylation of acetyl coenzyme A carboxylase,
glucose uptake, lactate production, and fatty acid oxidation through activated 5prime-AMP-activated protein kinase (358). A human study found that low plasma
adiponectin levels was associated with hyperinsulinemia and insulin resistance
(359), and increased adiposity in children decreased insulin sensitivity (360).
The Chennai Urban Rural Epidemiology Study (CURES) in India reported
that ADIPOQ variation (rs17846866) was associated with type 2 diabetes (361).
The correlation between two SNPs in ADIPOQ (rs1063537 and rs16861194) and
the risk of type 2 diabetes was reported in a Chinese Han population (362, 363).
The meta-analysis from Western Australian cohort studies provided additional
SNPs (rs12637534, rs16861209, and rs17366568) associated with type 2 diabetes
(364). The genetic studies in Chinese Han and Japanese populations reported that
the SNPs rs2241766 and rs1501299 increased the risk of type 2 diabetes (365,
366). However, the former study in China reported no correlation between the
polymorphism in ADIPOQ (rs16861194, rs26672, rs12495941, rs2241766,
rs1501299, rs12629945, rs6444175, rs267729, rs2275738, rs1342387, rs1029629,
rs11061971, rs12342, and rs1044471) and the incidence of type 2 diabetes
mellitus. The study in Korea presented no association between type 2 diabetes and
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rs2241766 and rs1501299 (367). The association between type 2 diabetes and the
polymorphism at rs2241766, rs1501299, and rs822396 in ADIPOQ was
controversial in a Japanese population (368). However, the study in Bulgaria
(369) reported the association between GDM and ADIPOQ variant at rs266729,
rs2241766 and rs1501299. On the contrary, the study in Malaysia (370), China
(371) and Iran (372) reported that rs2241766 had correlation with GDM.
The genetic association study in Indians presented that ADIPOQ variants
at rs1501299, rs822396, and 2241767 had significant correlations with obesity
(373). A study in France reported that obesity was related to rs266729 and
rs1501299, but no association between obesity and rs17300539 and rs2241766
was found (374). A meta-analysis study reported that ADIPOQ polymorphism
(rs1501299, rs2241766, and rs17300539) had no correlation with obesity (375).
c) ADRB3 (Adrenoceptor beta 3)
ADRB3 is a member of beta adrenergic receptor family. Adrenergic
receptors mediates catecholamine-induced activation of adenylate cyclase through
G protein-coupled receptors (376). ADRB3 regulates energy balance through
lipolysis in adipocyte, free fatty acid mobilization from adipose cells to portal
vein and thermogenesis in skeletal muscle (377, 378). The mutation of ADRB3
gene is associated with decreased resting metabolic rate, obesity, obesity-related
diseases (diabetes and hypertension), calorigenic dysfunction, early onset of
diabetes mellitus, and increased body weight with aging (378, 379).
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The association of ADRB3 (rs4994) polymorphism on the risk of type 2
diabetes was presented in the Chinese Han (365) and Japanese populations (380).
Furthermore, the association between the similar SNP (rs4994) and GDM was
reported in the study in Austria (381). A study in Chinese population (382)
reported additional SNPs (rs72655364 and rs72655365) in ADRBP3 associated
with type 2 diabetes. However, the study in Taiwanese (383) and Italian (384)
populations reported that rs4994 variant had no correlation with GDM. In Asian
populations (385-387) found that SNP (rs4994) was associated with obesity.
Gagnon et al. analyzing the data from the Quebec Family Study (QFS) and the
Swedish Obese Subjects (SOS) reported that rs4994 mutation had no association
with obesity (377).
d) CDKAL1 (CDK5 regulatory subunit associated protein 1-like 1)
CDKAL1 is a marker of impaired insulin secretion, and increases risk of
type 2 diabetes. The role of CDKAL1 gene in the function of pancreatic β-cells is
unknown. A mouse study showed that CDKAL1 knockout mice impaired
conversion of proinsulin to insulin and decreased ATP generation in mitochondria
after glucose stimulation (388).
A genetic study in the Chinese Han population reported the association
between type 2 diabetes and CDKAL1 variants at rs10946398, but there was no
association at rs736425 and rs4712527 variant (389). The meta-analysis study
(390) presented the significant correlation between type 2 diabetes and CDKAL1
variant at rs7754840 and rs7756992 in Asian, Caucasian, African, and Arab
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populations, which is similar to the study in Japanese and Lebanese populations
(391-395). The association between rs10916398 and the diabetes in Asian,
Caucasian, and African populations was also reported in the meta-analysis study
(390). In addition, the study in a Caucasian population (the Wellcome Trust Case
Control Consortium (WTCCC) and Finland-United States Investigation of
NIDDM genetics (FUSION)) reported that the CDKAL1 variant (rs10916398)
increased the incidence of type 2 diabetes (396, 397). Additional SNPs
(rs4712524, rs9295475, and rs9460546) associated with type 2 diabetes were
reported in East Asian and European populations (398). A GWAS of a Japanese
population reported the association between type 2 diabetes and rs2237892 (399).
Moreover, a GWAS of a Caucasian population found that rs7754840 variant
increased the risk of type 2 diabetes (400).
The polymorphisms in CDKAL1 at rs7756992 and rs7754840 increase
risk of GDM (401). The association between the SNP in CDKAL1 (rs7754840)
and GDM was confirmed in GWAS in a Korean population (402). However, the
study in the Chinese population reported that the SNP rs7754840 had no
association with GDM (403). In addition, the study in Danish populations added
more SNP (rs7756992) which have a correlation with GDM (404).
The GWA study in a Japanese population reported the association between
CDKAL1 (rs2206734) and BMI (405). The study in a Chinese population found
that the polymorphism at rs10946398 was not associated with BMI (406).
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e) CDKN2A/2B (Cyclin-dependent kinase inhibitor 2A/B)
CDKN2A/2B gene is located on chromosome 9p2, which is located
between CDKN2A and CDKN2B. CDKN2A and CDKN2B genes are involved in
cell cycling control in tumor of lung, breast, brain, bone, skin, bladder, kidney,
ovary, and lymphocyte (407, 408). The function of CDKN2A/2B on diabetes has
not reported.
A study of a Dutch population reported the association between the risk of
type 2 diabetes and rs1412829 in CDKN2A/2B (409). A study of a Japanese and
Malay populations (395, 410) reported an additional SNP (rs10811661) associated
with type 2 diabetes. The association between type 2 diabetes and rs10811161
mutation was found in the Chinese, Indian, Korean, and Han Chinese populations
(394, 411-413), but not in the African American and Lebanese populations (392,
414). Both WTCCC and FUSION studies reported that variation at rs10811661
and rs564398 increased the risk of type 2 diabetes (396, 397). Moreover, the
meta-analysis study also reported an association between type 2 diabetes and
rs10811661 in Asian and Caucasian populations, and rs564398 in Caucasian
populations (390). In GWA study, the association between type 2 diabetes and
rs10811661 was found in Caucasian populations (400).
Wang Y. reported the association of the CDKN2A/2B variant at
rs2383208 with GDM in a Chinese population (403). The study found
CDKN2A/2B variation (rs10811661) associated with GDM, which was
confirmed by a study in a Korean population (401). However, no association
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between GDM and rs10811661 (Danish population) (404) and rs10757261
(Korean population) (402) was reported.
f) FTO (Fat mass and obesity associated)
Gerken et al. (415) reported that FTO shared sequence with iron- and 2oxoglutarate-dependent oxygenases, and FTO mRNA level found in
hypothalamus was regulated by feeding and fasting. A mouse study by Gao et al.
(416) found that mice with FTO mutation had postnatal growth retardation (lower
body weight, shorter body length, and lower bonne mineral density) and
decreased insulin-like growth factor 1 (IGF-1) levels. FTO variants disrupt AT
rich interactive domain 5B (MRF1-like) (ARID5B)-mediated repression of
iroquois homeobox 3 (IRX3) and iroquois homeobox 5 (IRX5). The depression of
IRX3 and IRX5 leads to a cell-autonomous shift from white adipocyte browning
and mitochondrial thermogenesis, which result in increased fat storage and body
weight (417).
The Wellcome Trust Case Control Consortium (WTCCC) and FinlandUnited States Investigation of NIDDM Genetics (FUSION) reported that the
variation in FTO (rs8050136) was associated with the risk of type 2 diabetes in
European populations (396, 397). The correlation between type 2 diabetes and
FTO polymorphism (rs8050136 and rs17817449, except rs1121980) was reported
in a Lebanese Arab population (418). The meta-analysis study based on European
and East Asian populations (419) found the association between type 2 diabetes
and variation in FTO at rs9939609, which is similar to the study in Norwegian
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and Swedish populations after adjusting for age, sex, and BMI (420). In addition,
polymorphism at rs9939609 increased the risk of GDM in the study in Spain
(421). The study in a Chinese population reported additional SNPs associated
with type 2 diabetes, namely rs6499640 and rs3751812 (422). However, the
genetic studies reported no association between the diabetic risk and rs9939609 in
a Japanese population (391), including rs8050136 in African American and
Chinese populations (411, 414). The study in Denmark found that there was no
association between the SNP rs9939609 and GDM (404).
A large prospective study in the United States found the association
between obesity and rs9939609 in white-Americans and rs1421085 in AfricanAmericans (423).A meta-analysis confirmed that polymorphism in the FTO gene
at rs9939609 increased the risk of both overweight and obese subjects (424-426).
The GWAS study of Scuteri A and colleagues found the correlation between
obesity and many SNPs in FTO namely rs9930506, rs8050136, rs1121980,
rs7193144, rs9939609, rs9926289, rs6602024, rs7907949, rs965670, rs1188445,
and rs6965526 (427). Later GWAS in a European population provided another
FTO variant (rs1421085) that was associated with obesity (428).
g) GCK (Glucokinase)
GCK gene has an important role in glucose homeostasis by censoring
insulin release in pancreatic β cells (429). In mouse study, mice with isolated
pancreatic islets of heterozygous GCK knockout had impaired glucose sensitivity
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and impaired ability of β cells to secrete insulin for maintaining glucose
homeostasis (430, 431).
The association between rs2284779 variant and the risk of type 2 diabetes
was stated in the genetic study of a population with Caucasian ancestry (432). The
study of Finns reported other GCK polymorphism correlated with type 2 diabetes
(rs2244164, rs12534623, rs2268573, and rs882020) (433).
Moreover, studies in Sweden (434) and China (435) presented the
association of the variant rs1799884 with risk of GDM. The HAPO
(Hyperglycemia and Adverse Pregnancy Outcome) study, a collaboration among
United Kingdoms, Australia and Thailand, confirmed the association between the
SNP rs1799884 and GDM (436). However, studies in the United States (437) and
the United Kingdom (438), found no significant association between rs1799884
mutation and GDM. The variation at rs4607517 has no association with GDM in a
study of a Chinese population (403).
h) GNPDA2 (Glucosamine-6-phosphate deaminase 2)
GNPDA2 gene encodes an enzyme catalyzing the reversible action:
converting D-glucosamine-6-phosphate into D-fructose-6-phosphate and
ammonium (439). GNPDA2 is involved in nucleotide metabolic process of
nucleotide sugar, amino sugar, carbohydrate, and N-acetylglucosamine (439).
The association between GNPDA2 variant at rs10938397 and type 2
diabetes was reported in the meta-analysis study in European and East Asian
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population (419) and the study in a Chinese population (422). The association of
GNPDA2 on the risk of GDM has not been presented.
The candidate gene study in Chinese proposed the rs10938397 variant has
significant association with central obesity (426). The meta-analysis of GWA
data reported that GNPDA2 (rs10938397) was associated with BMI (425). The
meta-analysis in African ancestry found the additional SNP (rs348465) to be
associated with body mass index (440).
i) HHEX (Haematopoietically expressed homeobox)
HHEX gene encodes a transcription factor related to Wnt signaling for cell
growth and development. A mouse study found that HHEX knockout mice had
impaired forebrain, cardiovascular, thyroid, and liver development (441, 442).
The variation at rs1111875, rs7923837, and rs5015480 in HHEX
associated with both type 2 diabetes in Han Chinese, Korean, Chinese, and
Japanese populations (389, 391, 394, 395, 410), and GDM in a Korean
population (401). A genetic study in India confirmed that rs1111875 variant
increased the risk of type 2 diabetes (413). Moreover, the WTCC study reported
that the SNP rs5015480 was associated with type 2 diabetes (396). Nevertheless,
no correlation between HHEX (rs1111875) variation and type 2 diabetes was
reported by the study in the Netherlands (409). The GWA study in French and
Finnish, Caucasian populations reported the association between type 2 diabetes
and the polymorphism in HHEX (rs1111875 and rs7923837) (397, 400, 443).
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j) HNF1A (Hepatocyte Nuclear Factor 1 homeobox A)
HNF1A, a homeodomain containing transcription factor, is expressed in
liver, pancreas, intestine, and kidney (444). Mutation of HNF1A gene related to
hepatic adenomas familial (HEPAF), maturity-onset diabetes of the young 3
(MODY3), and insulin-dependent diabetes mellitus (IDDM). According to
HNF1A mutation, β-cell dysfunction in MODY3 results from impaired DNA
binding, reduced transcriptional activation, and impaired subcellular localization
of pancreatic β-cells (444, 445).
HNF1A (rs1169288) variant was associated with both type 2 diabetes and
GDM (434, 446, 447). The GWA study in a Hispanic population reported that two
SNPs in HNF1A (rs7305618 and rs21573907) were associated with type 2
diabetes (448). The Finnish case-control study reported additional SNP
(rs2701175) variant increased the risk of type 2 diabetes (449). A study
combining GWA data of European population found that that variant rs7957197
increased the incidence of type 2 diabetes (450).
k) HNF1B (Hepatocyte nuclear factor 1-beta)
HNF1B, a member of homeodomain containing transcription factor, is
expressed in liver, pancreas, bile ducts, thymus, genital tract, lung, and gut (451).
Many studies reported functions of HNF1B including epithelial differentiation
during human organogenesis (452), renal tubulogenesis regulation (453), hepatic
insulin sensitivity control (454), and pancreatic endocrine cell generation (455).
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Moreover, HNF1B gene is also associated with pancreatic β cell dysfunction and
insulin resistance (454).
The study in Caucasian reported the association between type 2 diabetes
and five SNPs in HNF1B (rs6422978, rs11263755, rs2285741, rs10962, and
rs3110641) (432). The genetic study in the United States found that the
polymorphism in HNF1B (rs12450628 and rs1008284) was associated with type 2
diabetes (433). The study in a Japanese population presented the association
between type 2 diabetes and the SNPs rs1016991 and rs2688, not at rs757210,
rs757211, rs718960, and rs2689 (356). The cohort study in the United States
present no association between type 2 diabetes and the variation in HNF1B
(rs11649743, rs4430796, and rs7501939) (456). However, the association
between the SNP rs4430796 and type 2 diabetes was reported in the GWAS of a
European population (450). Only polymorphism in rs7903146 is associated with
GDM in a Danish population (404).
l) IGF2BP2 (Insulin-like growth factor 2mRNA binding protein 2)
IGF2BP2 is a family of mRNA-binding protein (IMP1, IMP2, and IMP3),
which relates to RNA stability, localization, and translation. IMPs are expressed
in developing cells, especially in neuronal and epithelial cells in mid-gestation.
IGF2BP2 mRNA is found in many organs (brain, gut, testis, liver, pancreas, bone
marrow, kidney, lung, and muscle) during perinatal period and in adult tissues
(457). IGF2BP2 variant was associated with impaired pancreatic β cell function
(458, 459), and impaired insulin sensitivity (460).
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Genetic studies presented the association between type 2 diabetes and the
polymorphism in IGF2BP2 at rs4402960 and rs1470579 in Japanese, Chinese,
Korean and Indian populations (391, 394, 395, 410, 461), and at rs7651090 in a
Chinese population (411). The genetic study in East Asian and European
populations found that the IGF2BP2 variation (rs4376068 and rs6769511)
increased the risk of type 2 diabetes (398). However, The WTCC and FUSION
study (396, 397) and the genetic studies in Dutch, Chinese Han, and Japanese
populations (368, 389, 409) reported no association between type 2 diabetes and
the SNP rs4402960. The correlation between the variant rs1470579 in IGF2BP2
and type 2 diabetes was confirmed by the GWAS in a Japanese population (399).
The GWAS in a Caucasian population also reported that type 2 diabetes was
associated with the SNPs rs1470579 and rs4402960 (400).
The association between the rs4402960 polymorphism and GDM was
reported in the candidate gene approach in China (403) and Korea (462). The
GWAS in the Korean population reported that the SNP in IGF2BP2 (rs1470579)
was correlated with GDM (402). The association between rs4402960 and GDM
was not significant in the Danish population (404).
m) IL-10 (Interleukin-10)
IL-10 gene encoded anti-inflammatory cytokine, a T helper 2 mediated
cytokine, which inhibits cytokine production by t helper 1 cells (463). Il-10 gene
expression is important for inflammatory response and disease progression.
Dysregulation of IL-10 increased inflammatory response and risk of developing
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autoimmune diseases such as Crohn’s disease, hepatitis, Systemic Lupus
Erythematosus (SLE), and allergic asthma (464). A mouse study by Pennline et
al. (465) found that IL-10 can prevented the onset of diabetes in non-obese
diabetic (NOD) mice by inhibiting interferon-γ synthesis. This study reporter that
NOD mice receiving IL-10 treatment reduce the severity of insulitis, prevent
pancreatic islet cell infiltration, and promote normal insulin production. Esposito
et al. (466) found that low IL-10 levels was associated with metabolic syndromes
while high IL-10 concentration was associated with obesity.
A meta-analysis study, based on Asian and European populations,
presented that the variation at rs1800872 was associated with type 2 diabetes
(467). The association between GDM and the polymorphism in IL-10
(rs1800872) was reported in a Malaysian population (468). However, the genetic
study in North Indian and Taiwanese population reported no correlation between
type 2 diabetes and two SNPs in IL-10 (rs1800872 and rs1800871) (469, 470).
A candidate gene study in Caucasians reported that the variant in IL-10 at
rs1800872 was associated with increased BMI and waist-to-hip ratio (471).
n) IRS (Insulin receptor substrate-1)
IRS1 gene, the insulin receptor substrate protein family, encoded a
signaling adapter protein. IRS1 has a key role in transmitting signals from the
insulin and insulin-like growth factor 1 receptors to intracellular phosphoinositide
3-kinase/protein kinase B pathway and extracellular signal-regulated kinases
mitogen-activated protein kinase pathway (472). A mouse study found that IRS
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knockout mice reduced insulin content of β-cells and decreased glucosestimulated insulin secretion leading to glucose intolerance (473).
The genetic studies in Mexican (474), Indian (475) , and Dutch (476)
populations reported the variant rs1801278 in IRS1 was associated with type 2
diabetes. A meta-analysis study analyzing data from ten articles (3428 GDM and
4637 controls) showed that the polymorphism in IRS1 (rs1801278) also related to
GDM (477). This was also reported in Greek (478), Italian (384), and Saudi (479)
populations. Moreover, the meta-analysis study in French found that the
rs2943641 variant increased the risk of type 2 diabetes (480). However, there is
no association between the IRS1 variation (rs1801278) and type 2 diabetes in the
African-American population (481), and GDM in the Scandinavian population
(482). A case-control study in the African-American population reported that the
polymorphism in IRS1 at rs1801278 was associated with higher BMI (481).
o) KCNJ11 (Potassium channel, inwardly rectifying subfamily J, member
11)
KCNJ11 gene is a family of the potassium channel gene. KCNJ11 gene
encodes an inward-rectifier potassium ion channel (Kir6.2) protein, which is
subunit of the ATP-sensitive potassium (KATP) channel. Increased glucose
concentration increases potassium flow into cell through the KTAP channel, and
ATP binds to Kir6.2 in order to increase intracellular potassium ion concentration.
Increased intracellular potassium concentration activating calcium ion channel
leads to increase intracellular free calcium ion levels which trigger other
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components of insulin secretion pathway. KCNJ11 gene mutation can lead to
diabetes by disrupting Kir6.2 protein activity, reducing ATP sensitivity of KTAP
channel activity and suppression of insulin secretion (483).
The association between type 2 diabetes and KCNJ11 polymorphism at
rs5215 was reported in the Chinese Han population (389) and at rs5219 in
Chinese (411), Japanese (410), and Indian (461) populations. However, the study
in Turkey reported no association between type 2 diabetes and the SNPs in
KCNJ11 (rs5215, rs5219, rs5218, rs5216, and rs1800467) (355). The GWA study
in a Caucasian population found that the variant rs5219 in KCNJ11 increased the
incidence of type 2 diabetes (400). In addition, the GWA study in a Finnish
population (397) confirmed the correlation between type 2 diabetes and the SNP
rs5215.
The variation at rs5219 also has a correlation with GDM in a Scandinavian
population (482). However, the studies in Korea (401) and Denmark (404)
presented no significant association between GDM and two SNPs in KCNJ11
(rs5215 and rs5219).
p) KCNQ1 ((Potassium channel, voltage gated KQT-like subfamily Q,
member 1)
KCNQ1 encodes a pore-forming alpha-subunit of the voltage-gated K
channel (KvLQT1). KCNQ1 is expressed in a wide variety of tissue including:
heart, lung, liver, kidney, adipose tissue, brain, skeleton muscle and pancreas
(484). KCNQ1 controls ventricular repolarization process, which lead to cardiac
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conduction abnormality (485). A complex interaction between ATP-sensitive K+
(KATP) channels and voltage-dependent K+ (Kv) channels regulated insulin
secretion from pancreas. The Electronic mechanism at KATP and Kv channels
triggers and maintains glucose-stimulated insulin secretion. This effect may lead
to impair pancreatic β-cell function (486).
A meta-analysis of GWAS in African American population reported the
association between two SNP (rs231356 and rs2283228) in KCNQ1 and type 2
diabetes (487). A meta-analysis in Mexican-American population (448) and a
GWAS in Japanese population (488) found that rs2237892 variation increased
risk of type 2 diabetes. Another meta-analysis study including Japanese, Chinese,
and Korean population also reported that rs2074196, rs2237892 and rs2237895
polymorphisms (SNP) was significantly associated with type 2 diabetes (489).
The association between rs2237895 and type 2 diabetes was reported in a GWAS
in Han Chinese population (490) and the Punjabi cohort study (Indians living in
India and the United States) (484). A case-control study in Lebanese population
also found that KCNQ1 variation (rs2237892 and rs2237895) was associated with
type 2 diabetes (418).
A-meta-analysis study from multi-ethnic population (Korean, Chinese,
French, Greek, Swede, Brazilian, Dane, Turkish, and American), reported that
rs2237892 associated with GDM (491). A candidate gene study in Chinese
population found that KCNQ1 polymorphism at rs2237895 and 2237896)
increased risk of GDM but there is no association between rs2237892 had GDM
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(492). Candidate gene studies in Korean population presented that the KCNQ1
polymorphism at rs2074196 and rs2237892 and rs2237895 increased risk of
GDM (493, 494).
q) LEP (Leptin)
LEP gene encodes leptin hormone regulating body weight through leptin
receptors. The more fat accumulates, the more leptin is produced because fat cells
release leptin in proportion to their size. Leptin is involved in food intake
inhibition, energy expenditure regulatory, energy and glucose homeostasis, bone
formation, immune and inflammatory response, angiogenesis, hematopoiesis, and
would healing. The activation of leptin receptor mediates transcriptional
regulation of the melanocortin pathway in hypothalamus and downregulates
endocannabinoid expression in order to control food intake and energy balance
(495). The peripheral actions of leptin are inhibition of insulin synthesis and
secretion in pancreatic β-cell insulin biosynthesis (496). A study found that
obesity may result from downregulation of leptin receptor expression and
unresponse of leptin signal. A mouse study reported that leptin deficient mice
(obese mice and lipodystrophic mice) presented hyperinsulinemia leading to
downregulate insulin receptor in liver and adipose tissue (497).
LEP gene has correlation with obesity and BMI. Leptin regulates glucose
uptake and fatty acid oxidation and inhibits insulin secretion. The study in Korean
women showed that the polymorphism of LEP at rs10954173 and rs11761556
increased the risk of type 2 diabetes (498). The LEP variation (rs7799039) had no
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association with type 2 diabetes in a Chinese population (499). Enquobahrie DA
and colleagues, analyzing genotype from placenta, reported the LEP expression in
GDM group was significantly different from the control (500).
A candidate gene study in South Africans found the association between
BMI and LEP polymorphism (rs10954174 and rs6966536) (501). However, the
study in Finland (502), and Italy (503) presented no association between
rs2167270 and obesity. A meta-analysis study reported no association between
obesity and rs2167270 and rs7799039 (375).
r) LEPR (Leptin receptor)
LEPR encoded a single transmembrane protein mediating the action of
leptin. LEPR gene mutation causes impaired receptor signaling of leptin, and
related to obesity, hyperleptinemia, and atherogenic lipid profiles (504). A study
found that LEPR mutation in obese patients resulted in severe obesity, immune
dysfunction, pituitary dysfunction, hyperphagia, and delayed puberty (505, 506).
The meta-analysis study, analyzing data form 16 studies, presented the
significant correlation between polymorphism at rs1137101 in LEPR and the risk
of type 2 diabetes (507). The polymorphisms at rs1892534 and rs2211651 are
associated with early onset type 2 diabetes mellitus in a Taiwanese population
(508). No association between LEPR polymorphism was reported in Korean or
Chinese Han populations (362, 498). Moreover, the correlation between LEPR
and GDM has not been reported.
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The gene association study found that BMI was significantly related to the
polymorphism in LEPR at rs1137100, rs1137101, rs12033452, rs3790419, and
rs7518632 (498). Other candidate gene studies in Caucasians presented the
correlation between rs1137101 and rs9436746 and BMI (509, 510). Meta-analysis
studies found that the LEPR gene (rs1137101, rs1137100, rs8179183, and
rs62589000, rs10889567, rs3790437) was not associated with obesity (375, 510).
s) MTNR1B (Melatonin receptor 1B)
MTNR1B encodes melatonin 2 protein (MT2), a receptor for melatonin,
which is expressed in β-cells. MT2 is involved in insulin secretion in β-cells
because melatonin inhibits adenylate cyclase/cyclic the guanylate cyclase/cyclic
adenosine monophosphate (AC/cAMP), guanosine monophosphate (GC/cGMP),
and 1,4,5-trisphosphate (IP3) signal pathways (511). Many studies reported that
MT2 receptor was associated with decreased glucagon secretion and alterative
glucose metabolism (512-515). Therefore, MTNR1B polymorphisms affect
pancreatic glucose sensing, insulin secretion, and glucose tolerance (513, 514).
MTNR1B is associated with fasting plasma glucose levels in type 2 diabetes
(514).
A meta-analysis study reported the MTNR1B (rs10830963) increases the
risk of type 2 diabetes (514). This SNP is also associated with GDM in a Czech
Republic study (516). Other candidate gene approaches in Han Chinese (517) and
Greek (518) populations found similar SNP results to the study from the Czech
Republic. In addition, the study in the Korean population (519) showed that the
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variation at rs10830963 and rs1387153 in MTNR1B was associated with GDM.
This was supported by the results of a meta-analysis of ten articles (3428 GDM
and 4637 controls) with the same SNPs (477). The GWAS in the Korean
population proposed the new SNP (rs10830962) associated with GDM (402).
However, Wang Y presented no association between MTNR1B (rs10830963) and
GDM (403).
t) PPARG (Peroxisome proliferator-activated receptor gamma)
The PPARG gene is associated with insulin action, adipocyte
differentiation, lipid storage, and fat-specific gene expression (520). Kim et al.
(521) reported that PPARG activates glucose transporter 2 and glucokinase in
liver and pancreatic β-cells, which improves glucose homeostasis. Moreover,
PPARG increases insulin sensitive in peripheral tissue and glucose sensitivity of
liver and pancreatic β-cells. In a mouse study, PPARG knockout mice higher
insulin-induced increase in glucose disposal rate and greater insulin-induced
suppression of hepatic glucose production than in wildtype mice (522).
The candidate gene studies in Chinese (411), Japanese (523), and Indian
(461) populations and the GWAS in Finnish (397) and Caucasian populations
(400) found that the PPARG variant (rs1801282) increased the risk of type 2
diabetes. However, a genetic study in the Chinese Han population reported no
association between type 2 diabetes and PPARG variants at rs1801282,
rs12636454, and rs11128597 (389). The WTCCC study in England, reported a
controversial association between rs1801282 and type 2 diabetes mellitus (396).
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The association between GDM and PPARG variant (Both rs1801282 and
rs3856806) was found in the study in French (524). However, a candidate gene
approach in Sweden, Denmark and Korea did not report the association between
PPARG variation (rs3856806 and rs1801282) and GDM (401, 404, 525). The
association between rs1801282 and total body fat mass was proposed in
menopause women (526).
u) SLC30A8 (Solute carrier family 30 (zinc transporter), member 8)
SLC30A8, a member of zinc transporter (ZNT) family, encodes zinc
transporter (ZnT8). ZnT proteins transport zinc out of cells when zinc is excess,
and sequester cytoplasmic zinc into cell when zinc is replete. Zinc facilitates the
formation of dense core granules for insulin crystallization in pancreatic β-cell
and has a positive influence on insulin gene transcription (527). A mouse study
(528) showed that ZnT8 knockout mice reduced zinc content in pancreatic β-cell
insulin-secretory granules affecting insulin processing and crystallization.
Reduced zinc concentration in the secretory granules leads to increased proinsulin
to insulin ratio in blood circulation and decreased glucose-induced insulin
secretion (527).
Studies in Lebanese (418), Japanese (391) and Dutch (409) populations
reported no association between type 2 diabetes and the polymorphism in
SLC30A8 (rs3802177 and rs13266634). Studies of Chinese, British and Indian
populations (396, 411, 461) including the GWAS in French and Caucasian
populations (400, 443) found that the polymorphism at rs13266634 was
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associated with type 2 diabetes. This SNP was also associated with GDM in a
Korean population (401). In addition, the genetic study of the Han Chinese
population found an association between type 2 diabetes and SLC30A8 at
rs3802177 rs11558471, and rs13266634 (389). However, the rs13266634
mutation had no significant association with type 2 diabetes in an African
American population (414).
v) TCF7L2 (Transcription factor 7-like 2)
The TCF7L2 gene encodes a high mobility group box-containing
transcription factor related to blood glucose homeostasis. Yi et al. reported that
TCF7L2 regulated proglucagon by repressing the glucagon gene in
enteroendocrine cells via Wnt signaling pathway (529). TCF7L2 gene is related to
pancreatic cells development and glucose-induced insulin secretion (530). A study
in human found that patients with type 2 diabetes decreased TCF7L2 protein
levels in pancreas when compared with healthy controls. This study proposed that
interaction between TCF7L2 and glucagon-like peptide-1 (GLP1R) and glucosedependent insulinotropic polypeptide (GIPR) may regulate pancreatic β-cell
function and survival (531).
In Dutch, Han Chinese, British, Korean, Chinese, African American,
Arabic and Indian populations, the polymorphism in TCF7L2 (rs7903146)
increases the risk of type 2 diabetes (394, 396, 409, 412, 414, 461, 532) and
increases in risk of GDM in Scandinavian (525), Korean (401), Danish (404), and
Czech (533) women. The study in China (389) also reported an association
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between type 2 diabetes and two SNP (rs7903146 and rs6585205). The
association between the SNP rs10885409 and type 2 diabetes was reported in a
North Indian population (413). However, a study in Netherland reported no
correlation between the variant rs4430796 in TCF7L2 gene (450). The association
between type 2 diabetes and rs7903146 was confirmed in the GWAS in French,
Finnish and Caucasian population (397, 400, 443). Moreover, the Japanese
GWAS reported that additional SNP rs7901695 increased the incidence of type 2
diabetes (399). A Meta-analysis of GWAS in African American population found
additional SNP (rs114748339) associated with type 2 diabetes (487).
Candidate gene studies in Austria (534), Spain (421), and the Czech
Republic (533) reported additional SNPs (rs12255372, rs4506565, and
rs7901695, respectively) related to GDM. However, the same study in Korea
(401) and Denmark (404) also showed that variation at rs12255372 in TCF7L2
had no correlation with GDM.
w) TNF-α (Tumor necrosis factor alpha)
TNF-α encoded a cell signaling protein produced at inflammatory site.
TNF-α also activates multiple protein kinases and phosphoprotein phosphatases.
A mouse study found that TNF-α caused insulin resistance because TNF-α
infusion activated protein kinase A, which inhibited the tyrosine kinase activity of
insulin receptor (535). TNF-α is interferes insulin signaling in adipose cell,
muscle, and liver. TNF-α inhibit glucose-induced insulin secretion (536). A cell
study by Tsiotra et al. (537) found that TNF-α suppressed both basal and glucose-
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induced insulin secretion and proinsulin mRNA transcription. Hotamisligil et al.
(535)described the mechanism of TNF-α-induced insulin resistance, TNF-α
reduced GLUT4 mRNA levels in adipocyte and myocyte and inhibited insulinstimulated glucose transport.
The study in a Finnish population reported that the polymorphism in TNFα at rs1800610 increased the risk of type 2 diabetes (449). Additional SNP
(rs361525) associated with type 2 diabetes was found in a Mexican population
(538), but not in Taiwanese and British populations (539, 540). The study in
China (541) and Mexico (542) presented that GDM was associated with the
variant rs1800629 in TNF-α. However, the study in Malaysia (468) and Brazil
(543), reported no significant association between TNF-α variation (rs1800629)
and GDM. Additionally, the study in Tunisia, Taiwan, and Mexico presented no
association between the variant rs1800629 in TNF-α and type 2 diabetes mellitus
(538, 539, 544). A meta-analysis study based on Asian and Caucasian population
and the large-scale study in a British population confirmed the association
between the SNP rs1800629 and the diabetes (540, 545).
The study in a European population (Ireland and France) reported that the
TNF-α polymorphism (rs1800629) increased the risk of obesity (BMI >30 kg/m2)
(546). The association between rs1800629 and obesity was confirmed with a
meta-analysis study (375). However, other studies in Caucasian population
presented no correlation between TNF-α variation and obesity (544, 547-549).
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2.4 Genetic Study in Epidemiology
2.4.1

Overview

Genetic epidemiology aims to explain the role of genetic variation leading to
disease risk in populations. The study of genetic epidemiology relies on biometrical work
and statistical methods (segregation analysis, linkage analysis, association analysis, and
simulation methods). Genetically influenced diseases can be divided into monogenic
diseases (diseases resulting from a single gene mutation) and complex or multifactorial
diseases (diseases occurring with genetic and environmental factors) and each uses a
different method of analysis.
When information about DNA was unavailable, scientists used the Mendelian
laws of inheritance to study the correlation between genetic variation and diseases.
Nowadays, with extensive data on the human genome, the genome scan and candidate
genes approach have been used to analyze the association between complex diseases and
genes.
2.4.2

Genetic epidemiology approaches

a) Candidate gene approaches
i)

Segregation analysis
Segregation analysis is useful in the study of monogenic diseases.

This approach uses phenotypic data within pedigrees to determine the
pattern of inheritance of major genes influencing a phenotype and to
estimate the parameters of the genetic model (recessive, dominant, codominant), which is based on a probability calculation to observe the
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phenotype on parameters in genetic models and on family structure. The
most likely model nested within a general model is selected by likelihoodratio test. Moreover, complex segregation analysis may be used for
multifactorial disease. However, segregation analysis is not useful in the
case of non-major genes and a few moderately influenced genes (550).
ii)

Linkage analysis
Linkage studies assess on which part of the chromosome a disease

gene is located. Linkage analysis investigates the association between a
marker and a disease in related individuals. This approach aims to
examine the linkage between a susceptible locus and disease, and
estimates the recombination rate. There are two methods for linkage
analysis namely model-based (parametric or “lod score”) and model free
(nonparametric). The lod score method is based on the likelihood of the
observed marker and disease in a family under the model for distribution
of the unobserved disease gene. Nonparametric methods compare the
proportion of alleles shared IBD (identical by descent) by pairs of affected
relatives with the proportion expected based on their relationship. The
degree of complexity of the disease has an effect on the genetic model
assumption (550).
iii)

Linkage disequilibrium (genetic association methods)
Association studies investigate which allele or genotype of genes

are associated with disease. The case-control study design compares allele
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or genotype frequencies in a group of unrelated affected individuals with a
group of unrelated unaffected individuals. However, populations
consisting of two or more subgroups with different allele frequencies,
different confounding factors, and different baseline rates of disease, may
cause increased false positive associations and biased relative risk
estimation. Therefore, matching or adjusting for race can be used to
control for the problems arising from a variety in a population
stratification.
The family-based study design was created to determine the
association between suspected alleles of diseases with internal control of
confounding. There are two types of controls in family-based study
designs; sibling controls or case-parent-trios (parental control or pseudosiblings). The data analysis is based on a standard conditional logistic
regression model. The case-sibling study design asserts that affected
individuals are cases and their unaffected siblings are controls. In a caseparent-trio study design, only cases and their parents are genotyped and
form the set of hypothetical pseudo-sibling consisting of the three other
genotypes which could have been transmitted from the parents. The casepseudo sibling sets are analyzed as 1:3 matched case-control design. The
internal control in the model comes from the two parental alleles that are
not transmitted to the affected child. The common test for case-parent-trio
study design is the Transmission Disequilibrium test (TDT), which
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compares the transmitted alleles with non-transmitted alleles from
heterozygous parents to child. The TDT is a test of both likage and
association together. This design avoids possible bias from inadequate
controls and population stratifications (550).
b) Genome-Wide Association Studies (GWAS)
GWAS is a standard approach for exploring the basis of complex genetic
diseases from hundreds of thousands of single-nucleotide polymorphisms (SNPs)
by the case-control, population-based prospective and cross-sectional study
designs. Due to the ability to assay more than a million SNPs, GWAS has become
a new and powerful tool in searching for novel biological insights to explain
susceptibility for diseases (550).
The power of GWAS to identify true genetic associations depends on the
quality of the database. In the beginning of GWAS, the most associations
discovered in GWAS were indirectly casual because a small fraction of the
genetic variation in the genome was detected. With the extensive availability of
genome variation data, GWAS can infer the genotypes for most of the common
variants in the genome by using an imputation technique. However, many
associations between SNPs and diseases are weak with the odd ratios around 1.21.6. In order to avoid false positive claims, the genome-wide level of significance
(p-value < 5 x 10-8) was calculated from the Bonferroni correction for one million
SNPs. Moreover, ethnic variation in a population also may result in a biased
interpretation. To help deal with this problem the STRUCTURE program (the
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adjustment for an estimate of global ancestry from a finite set of founding
populations using ancestry informative marker), and the EIGENSTRAT program
(applying the principal components from all or subset of the markers) have been
proposed to control for false positives in a heterogeneous population. Due to a
limited genome database and statistic dependency, GWAS requires a large sample
size and multiple replications of similarly large samples in order to effectively
provide evidence of genetic association (215).
The associations between genes and disease from GWAS explain a small
proportion of the genetic causes of disease. Therefore, secondary analysis of
GWAS data including targeted hypothesis testing, gene-gene interaction, and
gene-environment interaction analysis may further our understanding of the
etiology of genotype and phenotype and improve the ability to detect relevant
genetic polymorphisms.
c) Gene-Environment interaction
The effects of genetic variants may depends on environment exposures or
the effect of an environment factors depends on an individual genotype. G-E
interaction model may increase the power to detect novel genes or environmental
factors that influence the trait through the interaction. In term of statistics, G-E
interaction is defined as a deviation from a model on a particular scale by using
linear regression models for quantitative traits and logistic regression models for
binary traits (551).
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d) Gene-Gene (G-G) interaction
G-G interaction may be analyzed by pathway-based approaches. Pathway
analysis determines association between phenotype and sets of genes
corresponding to biological pathways, which provide larger effects, the greater
power of discovery, and natural connections to biological mechanisms. Pathwaybased approaches may determine environmental factors interacting with the set of
genes, which leads to a complex phenotype (552).

Figure 2.3 Guideline for pathway analysis (552).

Table 2.2 Summary of candidate genes with established associations with orofacial clefts found in dissertation literature review to
have published links with type 2 diabets, gestational diabetes mellitus, or obesity.
Gene ID
ADAMTS9

ESR1

Gene name
ADAM metallopeptidase with
thrombospondin type 1 motif, 9
Cystathionine-beta-synthase
Catechol-O-methyltransferase
Cytochrome P450, family 1,
subfamily B, polypeptide 1
Estrogen receptor 1

ETV5

Ets variant 5

F13A1

Coagulation factor XIII, A1
polypeptide
Fas (TNFRSF6) associated factor
1
Growth differentiation factor 15
Glutathione S-transferase theta 1
Major histocompatibility
complex, class I, B
Kruppel-like factor 9
LIM homeobox transcription
factor 1, beta
V-maf avian musculoaponeurotic
fibrosarcoma oncogene homolog
Methylenetetrahydrofolate
reductase (NAD(P)H)

CBS
COMT
CYP1B1

FAF1
GDF15
GSTT1
HLA-B
KLF9
LMX1B
MAF
MTHFR

Chromosome
3p14.1

OFCs1
(553)a

GDM3
-

Obesity
(555)

(556, 557)b
(560, 561)b
(563)b

T2DM2
(409, 418,
554)
(558)
-

21q22.3
22q11.21
2p22.2

-

(559)
(562)
(564)

6q25.1

(565)b

(566)

-

-

3q28

-

-

(569)

6p25.3-p24.3

(422, 567,
568)b
(570-572)b

-

-

(573)

1p33

(574)a

(575)

-

-

19p13.11
22q11.23
6p21.3

(576)b
(134, 577)b
(579)b

(578)
(487)

(500)
-

-

9q13
9q33.3

(580)b
(581)a

-

-

(405)
(582)

16q22-q23

(139)b

-

-

(428)

1p36.3

(583-586)b

(558, 587)

-

(559)
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Table 2.2 Summary of candidate genes with established associations with orofacial clefts found in dissertation literature review to
have published links with type 2 diabets, gestational diabetes mellitus, or obesity (Cont.)
Gene name
Chromosome
OFCs1
T2DM2
b
5-methyltetrahydrofolate1q43
(588, 589)
(558)
homocysteine methyltransferase
PAX6
Paired box 6
11p13
(590)b
b
PCYT1A
Phosphate cytidylyltransferase 1,
3q29
(592, 593)
choline, alpha
PEMT
Phosphatidylethanolamine N17p11.2
(592)b
(587)
methyltransferase
RBP4
Retinol binding protein 4, plasma
10q23.33
(595)b
RPS7
Ribosomal protein S7
2p25
(597)b
b
SLC8A1
Solute carrier family 8
2p22.1
(598)
(599)
(sodium/calcium exchanger),
member 1
STK11
Serine/threonine kinase 11
19p13.3
(600)b
(601)
TCN2
Transcobalamin II
22q12.2
(602)b
(558, 559)
TFAP2B
Transcription factor AP-2 beta
6p12
(603)b
(activating enhancer binding
protein 2 beta)
TGFB1
Transforming growth factor, beta
19q13.1
(604-606)b
1
THADA
Thyroid adenoma associated
2p21
(139, 608)b
(609-611)
a
VEGFA
Vascular endothelial growth
6p12
(612)
factor A
1
OFCs Orofacial clefts; 2T2DM, type 2 diabetes mellitus; 3GDM, gestational diabetes mellitus
Genes associated with OFCs: a, animal study; b, human study
Genes associated with T2DM, GDM, and obesity base on human study
Gene ID
MTR

GDM3
-

Obesity
(558, 559)

-

(569, 591)
(594)

-

(594)

(596)
(500)
-

-

-

(558, 559)
(569, 591)

(541)

(607)

-

(555)
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Table 2.3 Summary 416 genes found in dissertation literature review to be associated with type 2 diabetes, gestational diabetes
mellitus, or obesity related to obesity and/or diabetes mellitus.
Gene ID

Gene name

Chromosome

T2DM1

GDM2

Obesity

17q12

-

-

(573)

-

-

(573)

(354-356)

(354)

(613)
(616)
(611, 617)
(618)
(619)

(500)
(500)
-

(614, 615)
(573)
(440)
-

(361-366)

(369-372)

(373, 374)

(620)
(365, 380,
382)
(622)

-

(385)

(381)

(385, 386)

(500)
-

(621)
(623)

AATF

Apoptosis antagonizing transcription factor

ABCC1

ATP-binding cassette, sub-family C (CFTR/MRP),
member 1
ATP-binding cassette, sub-family C (CFTR/MRP),
member 8
Angiotensin I converting enzyme

16p13.1

Actinin, alpha 2
ADAM metallopeptidase domain 12
Adenylate cyclase 10 (soluble)
Adenylate cyclase 3
Adenylate cyclase 5
Adducin 2 (beta)
Adiponectin receptor 1
Adiponectin, C1Q and collagen domain
containing
Adrenoceptor beta 2, surface
Adrenoceptor beta 3, surface

1q42-q43
10q26
1q24
2p23.3
3q21.1
2p13.3
1q32.1
3q27

ABCC8
ACE
ACTN2
ADAM12
ADCY10
ADCY3
ADCY5
ADD2
ADIPOR1
ADIPOQ
ADRB2
ADRB3
AGPAT4
AGRP
AGT

1-acylglycerol-3-phosphate O-acyltransferase 4
Agouti related neuropeptide
Angiotensinogen (serpin peptidase inhibitor, clade
A, member 8)

11p15.1
17q23.3

5q31-q32
8p12
6q26
16q22
142.2
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Table 2.3 Summary 416 genes found in dissertation literature review to be associated with type 2 diabetes, gestational diabetes
mellitus, or obesity related to obesity and/or diabetes mellitus (Cont.)
Gene ID
AGTR1
AKAP1
ALX4
ANAPC13
ANGPTL6
ANKRD50
ANXA4
AP3S2
APCS
APLP2
APOC1
APOE
AQP3
ARAP1
ARHGAP44
ARID1B
ARL15
AZGP1
BCDIN3D
BCL11A
BCL2
BCL2A1

Gene name
Angiotensin II receptor, type 1
A kinase (PRKA) anchor protein 1
ALX homeobox 4
Anaphase promoting complex subunit 13
Angiopoietin-like 6
Ankyrin repeat domain 50
Annexin A4
Adaptor-related protein complex 3, sigma 2
subunit
Amyloid P component, serum
Amyloid beta (A4) precursor-like protein 2
Apolipoprotein C-I
Apolipoprotein E
Aquaporin 3 (Gill blood group)
ArfGAP with RhoGAP domain, ankyrin repeat
and PH domain 1
Rho GTPase activating protein 44
AT rich interactive domain 1B (SWI1-like)
ADP-ribosylation factor-like 15
alpha-2-glycoprotein 1, zinc-binding
BCDIN3 domain containing
B-cell CLL/lymphoma 11A (zinc finger protein)
B-cell CLL/lymphoma 2
BCL2-related protein A1

Chromosome
3q24
17q22
11p11.2
3q22.2
19p13.2
4q28.1
2p13
15q26.1

T2DM1
(622)
(418)
(616)
(449)
(626)

GDM2
(500)
-

1q21-q23
11q24
19q13.2
19q13.2
9p13
11q13.4

(627)
(450)

(500)
-

(625)
(582)
(582)
(607, 628)
-

17p12
6q25.1
5p15.2
7q22.1
12q13.12
2p16.1
18q21.3
15q24.3

(599)

-

(582)
(629)
(582)
(426)

(575)
(450)
(630)
-

Obesity
(582, 624)
(582)
(625)
-
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Table 2.3 Summary 416 genes found in dissertation literature review to be associated with type 2 diabetes, gestational diabetes
mellitus, or obesity related to obesity and/or diabetes mellitus (Cont.).
Gene ID
BDNF

Gene name
Brain-derived neurotrophic factor

BHLHE40
C15orf41
C16orf62
C1D
C2CD4A/4B
CADM2

Basic helix-loop-helix family, member e40
Chromosome 15 open reading frame 41
Chromosome 16 open reading frame 62
C1D nuclear receptor corepressor
C2 calcium-dependent domain containing 4A/4B
Cell adhesion molecule 2

CALM1
CAPN10
CARHSP1
CASP9
CCDC102B
CCDC80
CCL2
CD63
CD93
CD96

Calmodulin 1 (phosphorylase kinase, delta)
Calpain 10
Calcium regulated heat stable protein 1, 24kDa
Caspase 9, apoptosis-related cysteine peptidase
Coiled-coil domain containing 102B
Coiled-coil domain containing 80
CD276 molecule
CD63 molecule
CD93 molecule
CD96 molecule

CDH12
CDKAL1

Cadherin 12, type 2 (N-cadherin 2)
CDK5 regulatory subunit associated protein 1like 1
Cyclin-dependent kinase inhibitor 2A

CDKN2A

T2DM1
(419, 631,
632)
(450)
-

GDM2
(500)
(500)
-

Obesity
(426, 591,
633, 634)
(582)
(573)
(569)

14q32.11
2q37.3
16p13.2
1p36.21
18q22.1
3q13.2
15q23-q24
12q12-q13
20p11.21
3q13.13-q13.2

(475, 635)
(617)
(617)
(599)

(500)
(500)
(500)
(500)
-

(569, 591)
(636)
(573)
(573)
-

5p14.3
6p22.3

(389-398,
400, 405)
(461)

(401, 402,
404)
-

(582)

Chromosome
11p13
3p26
15q14
16p12.3
2p13-p12
15q22.2
3p12.1

9p21

-
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Table 2.3 Summary 416 genes found in dissertation literature review to be associated with type 2 diabetes, gestational diabetes
mellitus, or obesity related to obesity and/or diabetes mellitus (Cont.).
Gene ID
CDKN2A/2B

Gene name
Cyclin-dependent kinase inhibitor 2A/2B

CEBPA
CES1
CFB
CHCHD2P9

CCAAT/enhancer binding protein (C/EBP), alpha
Carboxylesterase 1
Complement factor B
Coiled-coil-helix-coiled-coil-helix domain
containing 2 pseudogene 9
Choline dehydrogenase
Cholinergic receptor, nicotinic, alpha 5 (neuronal)
Cholinergic receptor, nicotinic, beta 2
Cholinergic receptor, nicotinic, beta 4
Cell death-inducing DFFA-like effector a
Claudin 7
Calmin (calponin-like, transmembrane)
C-Maf inducing protein
Cyclic nucleotide gated channel beta 3
Canopy FGF signaling regulator 2
Contactin 1
contactin associated protein-like 4
Collagen, type XIII, alpha 1
Collagen, type XVII, alpha 1
Collagen, type VIII, alpha 1
Carboxypeptidase E

CHDH
CHRNA5
CHRNB2
CHRNB4
CIDEA
CLDN7
CLMN
CMIP
CNGB3
CNPY2
CNTN1
CNTNAP4
COL13A1
COL17A1
COL8A1
CPE

Chromosome
9p21

19q13.1
16q22.2
6p21.3
9q21.31
3p21.1
15q24
1q21.3
15q24
18p11.21; 18
17p13.1
14q32.13
16q23
8q21.3
12q15
12q11-q12
16q23.1
10q22
10q24.3
3q12.3
4q32.3

T2DM1
(390, 394397, 400,
409-413)
(450)

GDM2
(401, 403)

Obesity
-

(500)
-

(624)
(637)
-

(558)
(638)
(638)
(638)
(639)
(599)

(500)
(500)
(500)
-

(558)
(573)
(569, 573)
(582)
(582)
(621)

(599)
(418)
-
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Table 2.3 Summary 416 genes found in dissertation literature review to be associated with type 2 diabetes, gestational diabetes
mellitus, or obesity related to obesity and/or diabetes mellitus (Cont.).
Chromosome
5q21

T2DM1
-

GDM2
-

Obesity
(555)

CPVL
CRTC2
CSN3
CTSA
CWC22
CXCL12
DAPK2

Gene name
Cytoplasmic polyadenylation element binding
protein 4
Carboxypeptidase, vitellogenic-like
CREB regulated transcription coactivator 2
Casein kappa
Cathepsin A
CWC22 spliceosome-associated protein
Chemokine (C-X-C motif) ligand 12
Death-associated protein kinase 2

7p15.1
1q21.3
4q21.1
20q13.1
2q31.3
10q11.1
15q22.31

(601)
(599, 616)
(599)
-

(500)
-

(573)
(629)
(564)
(573)

DARS
DBC1

Aspartyl-tRNA synthetase
Ddeleted in bladder cancer 1

(616)

-

(582)
(582)

DBI

Diazepam binding inhibitor (GABA receptor
modulator, acyl-CoA binding protein)
DnaJ (Hsp40) homolog, subfamily C, member 15
DnaJ (Hsp40) homolog, subfamily C, member 27
Dopamine receptor D2
Dual specificity phosphatase 9
Dynein, light chain, LC8-type 1
Dystonia 7, torsion (autosomal dominant)
Ephrin-A5
Early growth response 2
Eukaryotic translation initiation factor 4B

2q21.3
chromosome:
15
2q12-q21

-

-

(564)

13q14.1
2p23.3
11q23
Xq28
12q24.23
18p
5q21
10q21.1
12q13.13

(450)
(642)
(616)
-

(500)
(500)

(582)
(569)
(640, 641)
(582)
-

Gene ID
CPEB4

DNAJC15
DNAJC27
DRD2
DUSP9
DYNLL1
DYT7
EFNA5
EGR2
EIF4B
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Table 2.3 Summary 416 genes found in dissertation literature review to be associated with type 2 diabetes, gestational diabetes
mellitus, or obesity related to obesity and/or diabetes mellitus (Cont.).
Gene ID
Gene name
Chromosome
T2DM1
GDM2
Obesity
EIF4E3
Eukaryotic translation initiation factor 4E family
3p14
(582)
member 3
EIF4EBP1
Eukaryotic translation initiation factor 4E binding
8p12
(573)
protein 1
ENPP1
Ectonucleotide pyrophosphatase/
6q22-q23
(365, 449,
phosphodiesterase 1
643)
EPB41L3
Erythrocyte membrane protein band 4.1-like 3
18p11.32
(616)
ESRRG
Estrogen-related receptor gamma
1q41
(599)
ETV5
Ets variant 5
3q28
(569)
EXT2
Exostosin glycosyltransferase 2
11p12-p11
(644)
FABP2
FAIM2

Fatty acid binding protein 2, intestinal
Fas apoptotic inhibitory molecule 2

4q28-q31
12q13

(645)
(419)

-

FAM129A
FAM19A5

Family with sequence similarity 129, member A
Family with sequence similarity 19 (chemokine
(C-C motif)-like), member A5
Fanconi anemia, complementation group L
F-box and leucine-rich repeat protein 17
Fermitin family member 1
Fragile histidine triad
Formin homology 2 domain containing 3
Fms-related tyrosine kinase 1
FOS-like antigen 2
Forkhead box A2
Forkhead box N3

1q25
22q13.32

(599)

-

(628)
(569, 582,
646)
-

-

-

(582)

(599)
(599)
(397)

(500)
(500)
(500)
-

(569)
(582)
(582)
(582)

FANCL
FBXL17
FERMT1
FHIT
FHOD3
FLT1
FOSL2
FOXA2
FOXN3

2p16.1
5q21.3
20p12.3
3p14.2
18q12
13q12
2p23.3
20p11
14q31.3
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Table 2.3 Summary 416 genes found in dissertation literature review to be associated with type 2 diabetes, gestational diabetes
mellitus, or obesity related to obesity and/or diabetes mellitus (Cont.).
Gene ID
FTO

FXYD5
GABRA4

Gene name
Fat mass and obesity associated

GNPDA2

FXYD domain containing ion transport regulator 5
Gamma-aminobutyric acid (GABA) A receptor,
alpha 4
Polypeptide N-acetylgalactosaminyltransferase 10
Polypeptide N-acetylgalactosaminyltransferase 2
Growth arrest-specific 6
GATA zinc finger domain containing 2A
Glucosidase, beta, acid
Glucokinase
Glucokinase (hexokinase 4) regulator
Glial cell derived neurotrophic factor
G elongation factor, mitochondrial 1
Ghrelin/obestatin prepropeptide
Gastric inhibitory polypeptide receptor
GLIS family zinc finger 3
Glucagon-like peptide 1 receptor
Guanine nucleotide binding protein (G protein),
gamma 7
Glucosamine-6-phosphate deaminase 2

GP2

Glycoprotein 2 (zymogen granule membrane)

GALNT10
GALNT2
GAS6
GATAD2A
GBA
GCK
GCKR
GDNF
GFM1
GHRL
GIPR
GLIS3
GLP1R
GNG7

GDM2

Obesity

(421)

(423-428)

19q13.12
4p12

T2DM1
(396, 397,
418-420,
422, 423)
(647)

(500)
-

-

5q33.2
1q41-q42
13q34
19p13.11
1q21
7p15.3-p15.1
2p23
5p13.1-p12
3q25
3p26-p25
19q13.3
9p24.2
6p21
19p13.3

(630)
(432, 433)
(611, 618)
(616)
(599)
(356, 639)
-

(500)
(500)
(434-436)
(500)

(440)
(440)
(564)
(621, 648)
(405, 591)
(621)
-

4p12

(419, 422)

-

16p12

-

-

(425, 426,
440)
(591)

Chromosome
16q12.2
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Table 2.3 Summary 416 genes found in dissertation literature review to be associated with type 2 diabetes, gestational diabetes
mellitus, or obesity related to obesity and/or diabetes mellitus (Cont.).
Gene ID
GPC5
GPRC5B

Gene name

HDGF
HES1
HHEX

Glypican 5
G protein-coupled receptor, class C, group 5,
member B
Growth factor receptor-bound protein 10
Growth factor receptor-bound protein 14
Glutamate receptor, ionotropic, kainate 1
Glutamate receptor, ionotropic, N-methyl Daspartate 2B
G protein-coupled receptor kinase 5
Glutamate receptor, metabotropic 3
Glycophorin C (Gerbich blood group)
Hydroxyacyl-CoA dehydrogenase/3-ketoacyl-CoA
thiolase/enoyl-CoA hydratase (trifunctional
protein), alpha subunit
Hyperpolarization activated cyclic nucleotide
gated potassium channel 4
Hepatoma-derived growth factor
Hes family bHLH transcription factor 1
Haematopoietically expressed homeobox

HMG20A
HMGA2
HNF1A

High mobility group 20A
High mobility group AT-hook 2
HNF1 homeobox A

GRB10
GRB14
GRIK1
GRIN2B
GRK5
GRM3
GYPC
HADHA

HCN4

Chromosome
13q32
16p12

T2DM1
(599)
-

GDM2
-

Obesity
(569)

7p12.2
2q22-q24
21q22.11
12p12

(599)
(626)
(616)
-

-

(555)
(582)

10q26.11
7q21.1-q21.2
2q14-q21
2p23

(649)
(616)
-

-

(582)
(564)

15q24.1

-

-

(582)

1q23.1
3q28-q29
10q23.33

(389, 391,
394-397,
400, 410,
413, 443)
(626)
(450, 487)
(446-450)

(500)
(401)

(564)
-

(434)

-

15q24
12q15
12q24.2
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Table 2.3 Summary 416 genes found in dissertation literature review to be associated with type 2 diabetes, gestational diabetes
mellitus, or obesity related to obesity and/or diabetes mellitus (Cont.).
Gene ID
HNF1B

Gene name
Hepatocyte nuclear factor 1-beta

HNF4A
HOXB1
HOXB5
HOXC13
HPSE2
HSPA1B
HTR2A

Hepatocyte nuclear factor 4-alpha
Homeobox B1
Homeobox B5
Homeobox C13
Heparanase 2 (inactive)
Heat shock 70kDa protein 1B
5-hydroxytryptamine (serotonin) receptor 2A, G
protein-coupled
Insulin-degrading enzyme
Interferon, gamma-inducible protein 30
Immunoglobulin kappa constant
Insulin-like growth factor 2mRNA binding protein
2

20q13.12
17q21.3
17q21.3
12q13.3
10q23-q24
6p21.3
13q14-q21

Interleukin-10
Interleukin 18 receptor accessory protein
Interleukin-1 beta
Interleukin 1 receptor, type I
Interleukin-1 receptor antagonist
Interleukin-4
Interleukin-6

1q31-q32
2q12
2q14
2q12
2q14.2
5q31.1
7p21

IDE
IFI30
IGKC
IGF2BP2

IL10
IL18RAP
IL1β
IL1R1
IL1RN
IL4
IL6

Chromosome
17q12

10q23-q25
19p13.1
2p12
3q27.2

T2DM1
(356, 432,
433, 450)
(450, 626)
(616)
-

GDM2
(404)

Obesity
-

-

(582)
(650)
(555)

(651)
(652)
(391, 394,
395, 398400, 410,
411, 461)
(467)
(653, 654)
(654, 655)
(655, 656)
(449, 544,
657, 658)

(402)
(500)
(402, 403,
462)

-

(468)
-

(471)
(564)
(564)
(375, 544,
659)

(547)
(621)
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Table 2.3 Summary 416 genes found in dissertation literature review to be associated with type 2 diabetes, gestational diabetes
mellitus, or obesity related to obesity and/or diabetes mellitus (Cont.).
T2DM1
(474, 475,
480)
(409, 609,
651)
(599)

GDM2
(500)
(384)
(384, 477479)
-

Obesity
(564)
(629)
(481)

-

(564)
-

(500)
(482)

-

6p21.2-p21.1

(651)
(389, 397,
400, 410,
411, 461)
(356, 639)

-

-

11p15.5-p15.4

(489)

(491-494)

-

19q13.11

-

-

(569)

4p13

(611, 647)

-

-

17p13.2

-

(500)

-

Gene ID
IL6ST
INHA
INS
IRF5
IRS1

Gene name
Interleukin 6 signal transducer
Inhibin, alpha
Insulin
Interferon regulatory factor 5
Insulin receptor substrate-1

Chromosome
5q11.2
2q35
11p15.5
7q32
2q36

IVNS1ABP
JAZF1

Influenza virus NS1A binding protein
JAZF zinc finger 1

1q25.1-q31.1
7p15.2-p15.1

JUN
KCND2

Jun proto-oncogene
Potassium channel, voltage gated Shal related
subfamily D, member 2
Kv channel interacting protein 3, calsenilin
Potassium channel, inwardly rectifying subfamily
J, member 11

1p32-p31
7q31

Potassium channel, two pore domain subfamily K,
member 16
Potassium channel, voltage gated KQT-like
subfamily Q, member 1
Potassium channel tetramerization domain
containing 15
Potassium channel tetramerization domain
containing 8
Kinesin family member 1C

KCNIP3
KCNJ11

KCNK16
KCNQ1
KCTD15
KCTD8
KIF1C

2q21.1
11p15.1

(573)
-
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Table 2.3 Summary 416 genes found in dissertation literature review to be associated with type 2 diabetes, gestational diabetes
mellitus, or obesity related to obesity and/or diabetes mellitus (Cont.).
Gene ID
KLF9
KLF14
KLHL32
LEP
LEPR

Gene name
Kruppel-like factor 9
Kruppel-like factor 14
Kelch-like family member 32
Leptin
Leptin receptor

LIMCH1
LINGO2
LPIN1
LPL
LPP

LIM and calponin homology domains 1
Leucine rich repeat and Ig domain containing 2
Lipin 1
Lipoprotein lipase
LIM domain containing preferred translocation
partner in lipoma
Low density lipoprotein receptor-related protein
1B
Lymphotoxin alpha
Lymphocyte antigen 86
Lysophospholipase-like 1
Membrane-associated ring finger (C3HC4) 4, E3
ubiquitin protein ligase
Macrophage erythroblast attacher
Melanoma antigen family A9
Mitogen-activated protein kinase kinase 5
Microtubule-associated protein, RP/EB family,
member 2
Matrilin 3

LRP1B
LTA
LY86
LYPLAL1
MARCH4
MAEA
MAGEA9
MAP2K5
MAPRE2
MATN3

Chromosome
9q13
7q32.3
6q16.1
7q31.3
1p31

T2DM1
(450)
(498)
(507, 508)

GDM2
(660, 661)
-

4p13
9p21.2
2p25.1
8p22
3q28

(616)
(575)

-

Obesity
(405)
(440)
(501-503)
(498, 509,
510)
(582)
(569)
(625)
(628)
-

2q21.2

-

-

(569, 646)

6p21.3
6p25.1
1q41
2q35

(397, 662)
-

-

(555)
(555)
(582)

4p16.3
Xq28
15q23
18q12.1

(663)
(664)

(500)
-

(569, 591)
-

2p24-p23

-

-

(582, 591)
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Table 2.3 Summary 416 genes found in dissertation literature review to be associated with type 2 diabetes, gestational diabetes
mellitus, or obesity related to obesity and/or diabetes mellitus (Cont.).
Gene ID
MBL2
MCF2L2
MC4R

MC5R
MIF
MINA
MMADHC
MPHOSPH9
MRC1
MSH6
MSRA
MT1A
MTCH2
MTHFD1L
MTIF3
MTHFSD
MTNR1A

Gene name
Mannose-binding lectin (protein C) 2, soluble
MCF.2 cell line derived transforming sequencelike 2
Melanocortin 4 receptor

Chromosome
10q11.2
3q27.1

T2DM1
(368)

GDM2
(665)
-

Obesity
-

18q22

(611)

-

Melanocortin 5 receptor
Macrophage migration inhibitory factor
(glycosylation-inhibiting factor)
MYC induced nuclear antigen
Methylmalonic aciduria (cobalamin deficiency)
cblD type, with homocystinuria
M-phase phosphoprotein 9
Mannose receptor, C type 1
MutS homolog 6
Methionine sulfoxide reductase A
Metallothionein 1A
Mitochondrial carrier 2
Methylenetetrahydrofolate dehydrogenase
(NADP+ dependent) 1-like
Mitochondrial translational initiation factor 3
Methenyltetrahydrofolate synthetase domain
containing
Melatonin receptor 1A

18p11.2
22q11.23

-

(500)

(405, 428,
440, 569,
591, 666)
(667)
-

3q11.2
2q23.2

(611)

-

(582)
-

12q24.31
10p12.33
2p16
8p23.1
16q13
11p11.2
6q25.1

(575)
(599)
(478, 668)
(669)
(558)

-

(573, 629)
(569)
(558)

13q12.2
16q24.1

(599)

-

(569)
-

4q35.1

-

(517)

-
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Table 2.3 Summary 416 genes found in dissertation literature review to be associated with type 2 diabetes, gestational diabetes
mellitus, or obesity related to obesity and/or diabetes mellitus (Cont.).
Gene ID
MTNR1B

Gene name
Melatonin receptor 1B

MYT1L
NAA25
NAP5

Myelin transcription factor 1-like
N(alpha)-acetyltransferase 25, NatB auxiliary
subunit
Non-intrinsic ABC protein 5

NCKAP5
NCOA1
NEGR1
NEUROD1
NEUROG3
NFE2L3
NKX2-2
NKX6-1
NOTCH2
NPC1
NPY
NPY1R
NPY2R
NPY5R
NRF1
NRP1
NRXN1
NRXN3

NCK-associated protein 5
Nuclear receptor coactivator 1
Neuronal growth regulator 1
Neuronal differentiation 1
Neurogenin 3
Nuclear factor, erythroid 2-like 3
NK2 homeobox 2
NK6 homeobox 1
Notch 2
Niemann-Pick disease, type C1
Neuropeptide Y
Neuropeptide Y receptor Y1
Neuropeptide Y receptor Y2
Neuropeptide Y receptor Y5
Nuclear respiratory factor 1
Neuropilin 1
Neurexin 1
Neurexin 3

Chromosome
11q21-q22
2p25.3
12q24.13
chromosome:
1
2q21.2
2p23
1p31.1
2q32
10q21.3
7p15.2
20p11.22
4q21.33
1p13-p11
18q11.2
7p15.1
4q32.2
4q31
4q32.2
7q32
10p12
2p16.3
14q31

T2DM1
(514, 517,
518)
-

GDM2
(402, 477,
516, 519)
-

Obesity
-

-

-

(582)

(599)
(433, 449)
(670)
(356)
(356)
(609, 610)
(672)
(599)
-

-

(564)
(569, 634)
(555)
(428)
(509, 623)
(621, 624)
(386, 671)
(621)
(582)
(569, 582)

(582)
(573)
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Table 2.3 Summary 416 genes found in dissertation literature review to be associated with type 2 diabetes, gestational diabetes
mellitus, or obesity related to obesity and/or diabetes mellitus (Cont.).
Gene ID
NUDT3

Chromosome
6p21.2

T2DM1
-

GDM2
-

Obesity
(569)

13q14.3
9q31.1

(616)

-

(646, 650)
(440)

9q13-q21.2
11p15.4
4q32.3
12q24.32

-

-

(582)
(582)
(573)
(673)

OSTF1
OVCH2
PALLD
P2RX4

Gene name
Nudix (nucleoside diphosphate linked moiety X)type motif 3
Olfactomedin 4
Olfactory receptor, family 13, subfamily D, member
1
Osteoclast stimulating factor 1
Ovochymase 2 (gene/pseudogene)
Palladin, cytoskeletal associated protein
Purinergic receptor P2X, ligand gated ion channel, 4

PANK4
PARD3B
PCDH20
PCK1
PCSK1

Pantothenate kinase 4
Par-3 family cell polarity regulator beta
Protocadherin 20
Phosphoenolpyruvate carboxykinase 1 (soluble)
Proprotein convertase subtilisin/kexin type 1

1p36.32
2q33.3
13q21
20q13.31
5q15-q21

(617)
(449)
-

-

PCSK2
PDX1
PEPD
PFKFB3

Proprotein convertase subtilisin/kexin type 2
Pancreatic and duodenal homeobox 1
Peptidase D
6-phosphofructo-2-kinase/fructose-2,6biphosphatase 3
Pleckstrin homology-like domain, family B,
member 1
Polycystic kidney and hepatic disease 1
Plakophilin 1

20p11.2
13q12.1
19q13.11
10p15.1

(676)
(432)
(356, 639)
-

-

(582)
(582)
(591, 674,
675)
(629)

11q23.3

(616)

-

-

6p12.2
1q32

-

-

(582)
(582)

OLFM4
OR13D1

PHLDB1
PKHD1
PKP1
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Table 2.3 Summary 416 genes found in dissertation literature review to be associated with type 2 diabetes, gestational diabetes
mellitus, or obesity related to obesity and/or diabetes mellitus (Cont.).
Gene ID
PLA2G16
PLA2G1B
PLIN2
PMEPA1
PMS2P3
POC5
POLG2
PON1
PPARA
PPARD
PPARG

PPARGC1A
PPIB
PPP1R3A
PPP1R3B
PRC1
PRKD1
PRKG2
PRLR

Gene name
Phospholipase A2, group XVI
Phospholipase A2, group IB (pancreas)
Perilipin 2
Prostate transmembrane protein, androgen induced
1
PMS1 homolog 2, mismatch repair system
component pseudogene 3
POC5 centriolar protein
Polymerase (DNA directed), gamma 2, accessory
subunit
Paraoxonase 1
Peroxisome proliferator-activated receptor alpha
Peroxisome proliferator-activated receptor delta
Peroxisome proliferator-activated receptor gamma

Chromosome
11q12.3
12q24.31
9p22.1
20q13.31q13.33
7q11.23

T2DM1
-

GDM2
(500)
(500)
-

Obesity
(673)
(629)

-

-

(637)

5q13.3
17q

-

(500)

(569, 582)
-

7q21.3
22q13.31
6p21.2
3p25

(462)
(524)

(559)
(677)
(526)

Peroxisome proliferator-activated receptor gamma,
coactivator 1 alpha
Peptidylprolyl isomerase B (cyclophilin B)
Protein phosphatase 1, regulatory subunit 3A
Protein phosphatase 1, regulatory subunit 3B
Protein regulator of cytokinesis 1
Protein kinase D1
Protein kinase, cGMP-dependent, type II
Prolactin receptor

4p15.1

(559)
(396, 397,
400, 411,
461, 523)
(365)

-

(625)

15q21-q22
7q31.1
8p23.1
15q26.1
14q11
4q13.1-q21.1
5p13.2

(652)
(652)
(450)
(647)
(599)
-

(500)
(678)

(569, 646)
127

Table 2.3 Summary 416 genes found in dissertation literature review to be associated with type 2 diabetes, gestational diabetes
mellitus, or obesity related to obesity and/or diabetes mellitus (Cont.).
Gene ID
PROCR
PROX1
PSMD6

Gene name
Protein C receptor, endothelial
Prospero homeobox 1
Proteasome 26S subunit, non-ATPase 6

PTBP2
PTDSS2
PTER
PTPRD
PYY
QPCTL
RALGPS2
RASGRP1

Polypyrimidine tract binding protein 2
Phosphatidylserine synthase 2
Phosphotriesterase related
Protein tyrosine phosphatase, receptor type, D
Peptide YY
Glutaminyl-peptide cyclotransferase-like
Ral GEF with PH domain and SH3 binding motif 2
RAS guanyl releasing protein 1 (calcium and
DAG-regulated)
Rap guanine nucleotide exchange factor (GEF) 1
RNA binding protein, fox-1 homolog (C. elegans)
1
RNA binding motif, single stranded interacting
protein 1
RFNG O-fucosylpeptide 3-beta-Nacetylglucosaminyltransferase
Regulating synaptic membrane exocytosis 1
Ribonuclease, RNase A family, 4
Ring finger protein 13
Ring finger protein 138, E3 ubiquitin protein ligase
Renalase, FAD-dependent amine oxidase

RAPGEF1
RBFOX1
RBMS1
RFNG
RIMS1
RNASE4
RNF13
RNF138
RNLS

GDM2
(500)
-

Obesity
-

1p21.3
11p15.5
10p12
9p23-p24.3
17q21.1
19q13.32
1q25.2
15q14

T2DM1
(618)
(356, 449,
639)
(490)
(616)
(649)

-

(569)
(594)
(428)
(671)
(569)
-

9q34.3
16p13.3

(672)
-

-

(679)

2q24.2

(680)

-

-

17q25

-

(500)

-

6q12-q13
14q11
3q25.1
18q12.1
10q23.31

(599)
(433)
(599)

(500)
-

(573)
(629)
(582)
-

Chromosome
20q11.2
1q41
3p14.1
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Table 2.3 Summary 416 genes found in dissertation literature review to be associated with type 2 diabetes, gestational diabetes
mellitus, or obesity related to obesity and/or diabetes mellitus (Cont.).
Gene ID
RORA
RPL27A
RPS29
RSPO3
SASH1
SAMD12
SCG3
SDCCAG8
SDF2L1
SEC16B

Gene name
RAR-related orphan receptor A
Ribosomal protein L27a
Ribosomal protein S29
R-spondin 3
SAM and SH3 domain containing 1
Sterile alpha motif domain containing 12
Secretogranin III
Serologically defined colon cancer antigen
Stromal cell-derived factor 2-like 1
SEC16 homolog B, endoplasmic reticulum export
factor

SGCG

Sarcoglycan, gamma (35kDa dystrophinassociated glycoprotein)
SH2B adaptor protein 1

SH2B1
SH3BGRL
SIDT1
SLC15A4
SLC24A3
SLC2A1

SH3 domain binding glutamate-rich protein like
SID1 transmembrane family, member 1
Solute carrier family 15 (oligopeptide transporter),
member 4
Solute carrier family 24
(sodium/potassium/calcium exchanger), member 3
Solute carrier family 2 (facilitated glucose
transporter), member 1

Chromosome
15q22.2
11p15
14q
6q22.33
6q24.3
8q24.12
15q21
81q43
22q11.21
1q25.2

T2DM1
(616)
(664)
(599)
(616)
-

GDM2
(500)
-

13q12

(681)

-

16p11.2

(419)

-

Xq13.3
3q13.2
12q24.32

(599)
(368)

-

(569, 634,
682)
(573)
-

20p13

(616)

-

-

1p34.2

(573, 683)

-

-

Obesity
(569)
(555)
(637)
(666)
(405, 440,
569, 591,
646)
-
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Table 2.3 Summary 416 genes found in dissertation literature review to be associated with type 2 diabetes, gestational diabetes
mellitus, or obesity related to obesity and/or diabetes mellitus (Cont.).
Gene ID
SLC2A2

T2DM1
(449, 672)

GDM2
-

Obesity
-

(401)

-

4q24
1p21.3
11p15.4p15.1
20q11.23
17q25.3
21q22.11
10q23.33
4q34.2
17p11.2

(389, 391,
396, 400,
409, 411,
418, 443,
461)
(664)
-

(500)

(569, 646)
-

(684)
(616)
(599, 611)

(500)
-

(573)
(621)
-

16p13.3

-

-

(573)

17p11.2

-

-

(685)

7q21.1
17p13
7q21

(490)
-

(500)
(403)
(500)

-

SLC30A8

Gene name
Chromosome
Solute carrier family 2 (facilitated glucose
3q26.1-q26.2
transporter), member 2
Solute carrier family 30 (zinc transporter), member 8
8q24.11

SLC39A8
SLC44A3
SMPD1

Solute carrier family 39 (zinc transporter), member 8
Solute carrier family 44, member 3
Sphingomyelin phosphodiesterase 1, acid lysosomal

SNHG11
SOCS3
SOD1
SORBS1
SPCS3
SPECC1

Small nucleolar RNA host gene 11
Suppressor of cytokine signaling 3
Superoxide dismutase 1, soluble
Sorbin and SH3 domain containing 1
Signal peptidase complex subunit 3
Sperm antigen with calponin homology and coiledcoil domains 1
SplA/ryanodine receptor domain and SOCS box
containing 3
Sterol regulatory element binding transcription
factor 1
Sorcin
Serine racemase
Serrate, RNA effector molecule

SPSB3
SREBF1
SRI
SRR
SRRT
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Table 2.3 Summary 416 genes found in dissertation literature review to be associated with type 2 diabetes, gestational diabetes
mellitus, or obesity related to obesity and/or diabetes mellitus (Cont.).
Gene ID
ST3GAL6
ST6GAL1
STAT3
STEAP4
STRIP1
SV2C
TAZ
TCEB1
TCF7L2

TFAP2B
THSD7B
TLE4
TMBIM6
TMEFF2
TMEM101

Gene name
ST3 beta-galactoside alpha-2,3-sialyltransferase 6
ST6 beta-galactosamide alpha-2,6-sialyltranferase 1
Signal transducer and activator of transcription 3
(acute-phase response factor)
STEAP family member 4
Striatin interacting protein 1
Synaptic vesicle glycoprotein 2C
Tafazzin
Transcription elongation factor B (SIII), polypeptide
1 (15kDa, elongin C)
Transcription factor 7-like 2

Chromosome
3q12.1
3q27.3
17q21.31

T2DM1
(626)
-

GDM2
-

Obesity
(573)
(621)

7q21.12
1p13.3
5q13.3
Xq28
8q21.11

(599)

(500)
-

(582)
(582)
(629)
(607)

10q25.3

(401, 404,
421, 525,
533, 534)

Transcription factor AP-2 beta (activating enhancer
binding protein 2 beta)
Thrombospondin, type I, domain containing 7B
Transducin-like enhancer of split 4
Transmembrane BAX inhibitor motif containing 6
Transmembrane protein with EGF-like and two
follistatin-like domains 2
Transmembrane protein 101

6p12

(389, 394,
396, 397,
399, 400,
409, 412414, 443,
461, 487,
532)
-

2q22.1
9q21.31
12q13.12
2q32.3

(450)
(397, 616)

-

(569, 591,
646)
(436, 634)
-

17q21.31

-

-

(573)

-
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Table 2.3 Summary 416 genes found in dissertation literature review to be associated with type 2 diabetes, gestational diabetes
mellitus, or obesity related to obesity and/or diabetes mellitus (Cont.).
Gene ID
TMEM154
TMEM160
TMEM163
TMEM18

Gene name
Transmembrane protein 154
Transmembrane protein 160
Transmembrane protein 163
Transmembrane protein 18

TNF-α

Tumor necrosis factor alpha

TNNI3K
TP53
TP53INP1
TRPS1
TSPAN8
TUSC3
UBE2E2
UCK2
UCK3
UCP1
UCP2

TNNI3 interacting kinase
Tumor protein p53
Tumor protein p53 inducible nuclear protein 1
Trichorhinophalangeal syndrome I
Tetraspanin 8
Tumor suppressor candidate 3
Ubiquitin-conjugating enzyme E2E 2
Uridine-cytidine kinase 2
None
Uncoupling protein 1
Uncoupling protein 2 (mitochondrial, proton
carrier)
Utrophin
Uncoupling protein 3 (mitochondrial, proton
carrier)
Urotensin 2
very low density lipoprotein receptor

UTRN
UCP3
UTS2
VLDLR

Chromosome
4q31.3
19q13.32
2q21.3
2p25.3

T2DM1
(575)
(686)
(419)

GDM2
-

6p21.3

(541, 542)

1p31.1
17p13.1
8q22
8q24.12
12q14.1-q21.1
8p22
3p24.2
1q23
3p24.2
4q28-q31
11q13

(449, 538,
540, 545)
(672)
(450)
(599)
(610)
(399)
-

6q24
11q13.4

(616)
(691)

-

(569, 646)
(625, 689)
(385, 628,
685, 690)
(385, 628)

1p36
9p24

-

(500, 692)
-

(624)

(500)
(688)
(500)
(500)
-

Obesity
(569)
(582)
(569, 634,
646, 666,
687)
(375, 546)
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mellitus, or obesity related to obesity and/or diabetes mellitus (Cont.).
Gene ID
VPS13B
VPS26A
WFS1

Gene name
Vacuolar protein sorting 13 homolog B (yeast)
VPS26 retromer complex component A
Wolfram syndrome 1

WWOX
WW domain containing oxidoreductase
ZBED3
Zinc finger, BED-type containing 3
ZC3H4
Zinc finger CCCH-type containing 4
ZFAND3
Zinc finger, AN1-type domain 3
ZFAND6
Zinc finger, AN1-type domain 6
ZNF169
Zinc finger protein 169
ZNF608
Zinc finger protein 608
ZNF718
Zinc finger protein 718
1
T2DM, type 2 diabetes mellitus
2
GDM, gestational diabetes mellitus
Genes associated with T2DM, GDM, and obesity base on human study

Chromosome
8q22.2
10q21.1
4p16.1
16q23
5q13.3
19q13.32
6p21.2
15q25.1
9q22.32
5q23.2
4p16.3

T2DM1
(626)
(409, 418,
693)
(639)
(450)
(356, 639)
(450)
-

GDM2
-

Obesity
(637)
-

-

(582)
(405)
(569)
(582)
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CHAPTER 3
THE ASSOCIATION BETWEEN MATERNAL PRE-PREGNANCY WEIGHT AND
MATERNAL DIABETES AND OROFACIAL CLEFTS IN THE UTAH POPULATION

3.1 Abstract
Background: The inconsistent association between pre-pregnancy weight and
maternal diabetes and risk of orofacial clefts has been reported in a few studies.
Objective: To determine the association between maternal pre-pregnancy weight
and maternal diabetes mellitus and the risk of orofacial clefts (OFCs) in a populationbased case-control study of birth certificate data in Utah.
Methods: Cases of OFCs during 1995-2011 were ascertained by the state-wide
Utah birth defects registry. Controls were randomly selected from Utah birth certificates
at a ratio of 4:1 to cases, matched by birth month and year. Odds ratios (ORs) and 95%
confidence intervals (CIs) were calculated to estimate the relative risk for cleft subtypes
associated with maternal pre-pregnancy weight and maternal diabetes. Multiple logistic
regression analysis was used to adjust for the potential confounding effects of maternal
age, education, body mass index (BMI), depression, and maternal diabetes. Pre-existing
diabetes, gestational diabetes mellitus (GDM), and all diabetes were evaluated as
mediating variables in the association between maternal obesity and risk of OFCs.
Results: Results are based on 1,451 live-born cases with registry diagnoses.
Obesity increased risk of both non-isolated and isolated OFCs (adjusted odds ratios
(aOR): 1.41, 95%CI: 1.07-1.87 and aOR: 1.23, 95% confidence interval (CI): 1.01-1.50,
respectively). Underweight mothers had a reduced risk of cleft lip only (CLO) (aOR:
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0.46, 95%CI: 0.24-0.88), and an increased risk of cleft palate only (CPO) (aOR: 1.50,
95%CI: 1.04-2.16). Maternal depression increased risk of all OFCs (aOR: 1.31, 95%CI:
1.00-1.73). Pre-existing diabetes increased risk of all OFCs (aOR: 2.19, 95% CI: 1.184.09) with a larger effect for non-isolated OFCs (aOR: 3.83, 95%CI: 1.71-8.58) vs
isolated OFCs (aOR: 1.54, 95%CI: 0.70-3.41). GDM mothers had an increased risk of all
OFCs (aOR: 1.48, 95%CI: 1.05-2.09) with a larger effect for non-isolated OFCs (aOR:
2.29, 95%CI: 1.41-3.72) vs isolated OFCs (aOR: 1.15, 95%CI: 0.75-1.77). Mediation
analysis indicated that obesity had a direct effect of increasing the risk of OFCs without
the mediating effect of known maternal diabetes.
Conclusion: Extremes of maternal pre-pregnancy weight were associated with
risk of OFCs in Utah with obese mothers having an increased risk of all types of OFCs,
while underweight mothers having a decreased risk of CLO and increased risk of CPO.
Maternal depression was also associated with OFC risk. Both pre-existing and
gestational diabetes were associated with OFC risk, with strongest effects for nonisolated OFCs. Both stratification and mediation analyses suggest an effect of obesity on
OFCs apart from known maternal diabetes. The growing epidemics of obesity and
diabetes and the challenge of early detection and treatment of GDM underscore the
public health importance of further research in this area.
3.2 Introduction
Orofacial clefts (OFCs) are congenital deformations of the lip, palate, or both.
Genetic and environmental factors and interaction between both have been reported as
the causes of OFCs. OFCs are an important health issue in both developed and
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developing countries. The global incidence of OFCs is one in every 500-2500 births
depending on geographic location, racial and ethnic groups, maternal age, environmental
exposures, and socioeconomic status (1). OFCs affect on average one in every 750 births
in the United States and the highest incidence among states with state-wide birth defect
registers is in Utah (1 in 450 births) (2).
Maternal obesity increases health risks for both mother and child (3, 4). Maternal
obesity has been associated with fetal malformations such as neural tube defects,
congenital heart defects, and orofacial clefts (4). Obesity-related birth defect mechanisms
include hyperglycemia, insulin resistance, and poor folate status (4, 5). Case-control
studies (6-8) and a meta-analysis study (9) reported a positive association between
maternal obesity and the occurrence of OFCs while other studies have not (10-12).
However, the associations with various cleft phenotypes and the role of maternal
underweight are less well studied. An international consortium of OFC case-control
studies found associations between both maternal obesity and underweight risk of cleft
palate with or without cleft lip, but not with cleft lip alone (13).
Diabetes mellitus is a disorder of the regulation of blood glucose. Hyperglycemia
is a characteristic of diabetes mellitus resulting from a defect in insulin secretion or
insulin action or both (14). Diabetes mellitus also stimulates the production of adverse
metabolic factors including ketone bodies, branched chain amino acid and advanced
glycation end products and these factors may disrupt normal embryonic development (15,
16). Maternal diabetes leads to altered expression levels of specific genes and increases
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the variation of gene expression levels which may also disrupt embryonic development
(17, 18).
Human studies have reported associations between maternal diabetes and the risk
of OFCs. Data from a large international consortium from the U.S., Denmark, and
Norway confirmed that maternal diabetes increased the incidence of OFCs after adjusting
for maternal age, education levels, multivitamin use, maternal BMI categories, and
history of smoking (19). The Atlanta Birth Defects Case-Control Study (20) showed that
being an insulin-dependent diabetic mother increased the risk of cleft palate. The data
from the National Birth Defect Prevention Study (NBDPS) found that both pregestational (type 1 or 2) and gestational diabetes mellitus increased the risk of isolated
cleft lip with or without cleft palate (CL/P) and cleft palate only (CPO) (21). Moreover,
two large studies reported that maternal diabetes increased the incidence of OFCs (19,
22). However, another study from NBDPS did not find an association between gestation
diabetes mellitus (GDM) and risk of cleft lip with cleft palate or cleft lip only (23).
The inconsistent association between pre-pregnancy weight and maternal
diabetes and risk of OFCs has been reported in a few studies. Few studies have presented
the association between maternal obesity and diabetes and risk of OFCs based on
subtypes of clefts (non-isolated vs isolated and combinations of lip and palate).
Moreover, there is no previous study that has reported the effect of maternal obesity on
risk of OFCs mediated by maternal diabetes. The investigation of maternal weight and
diabetes may confirm or provide additional information regarding OFC associations.
Thus, this study aims to determine the association between pre-pregnancy weight and
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maternal diabetes and risk of OFCs in the Utah population using a complete sample from
a state-wide birth defects registry linked to birth certificates.
3.3 Subjects and Methods
3.3.1 Study design, population, and data sources
The study design is a case-control study. The study protocol was reviewed and
approved by the institutional review boards of Utah State University (USU), the
University of Utah, and the Utah Department of Health.
Cases of OFCs were ascertained by the Utah Birth Defect Network (UBDN),
operated by the Utah Department of Health (UDOH). UBDN, a statewide populationbased surveillance system, identifies all prenatal or postnatal major structural birth
defects in fetuses and neonates (24). The OFC classifications used in the data analyses
were based on the final UBDN diagnoses based on a review by a medical geneticist. OFC
cases resulting from pregnancy outcomes (live birth, stillbirth, or pregnancy termination)
were divided into cleft lip alone, cleft palate alone, cleft lip without cleft palate, and cleft
lip with cleft palate and classified as isolated, syndromic, or multiple birth defect cases.
The case mothers of a child with an OFC during 1995-2011 were linked to the Utah
Population database (UPDB) (24). The UPDB provides information for research on
genetics, epidemiology, demography, and public health. The database represents Utah’s
population appearing in administrative records from the late 18th century to the present
and receives annual updates from birth and death certificates, hospitalization and
ambulatory surgery records, and driver licenses. Controls were randomly selected from
Utah birth certificates at a ratio of 4:1 to live-born cases matched by birth month and
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year. The anonymized identification numbers of cases and controls from UPDB were
linked to the Utah Birth Certificate database. In addition, the UPDB provided information
on OFC cases noted in fetal and neonatal death records.
Utah birth certificate forms were revised in 1991, 1997, 2003, and 2009 and these
were used to collect data on cases and controls born during 1995-2011. The birth
certificate data consists of information on newborns (sex, date of birth, birth weight and
length, and birthplaces) and their parents (race/ethnicity, ages, and marital status, and the
number of children born to the mother, etc.), including delivery complications, maternal
medical risk factors, congenital malformations, and birth injuries.
Relevant changes in birth certificates were in the classification of maternal and
paternal education, maternal alcohol consumption, maternal smoking, maternal medical
risk factors, and notation of congenital anomalies. In the years of 1991- 2008, maternal
and paternal education levels were recorded as the number of highest grades completed,
and changed to be eight categories of the highest degree of school completed in 2009 (8th
grade or less, 9th-12th grade, high school graduate, some college credit but no degree,
associate degree, Bachelor’s degree, Master’s degree, and Doctorate or professional
degree). Maternal smoking and alcohol consumption were recorded as average number of
cigarettes per day and average number of drinks per week in each trimester of gestation.
In 2009, a question about maternal tobacco use three months before pregnancy was added
and a question on maternal alcohol use was deleted. Questions on history of gestational
diabetes mellitus and pre-existing diabetes were added in 1997 in order to replace a more
general question on unspecified diabetes. Many medical risk factors were added in 2009
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including depression. Cleft lip, cleft palate, and cleft lip and palate were separately coded
after 2008 on birth certificate instead of cleft lip/palate in previous forms under the
question of congenital anomalies of child. Medical risk factors were noted primarily by
text fields and ICD-9-CM codes. Due to the non-specific question on diabetes mellitus
on birth certificate forms during 1995-1996, these years were excluded from analyses.
3.3.2 Statistical analysis
The Statistical Package for Social Sciences (IBM SPSS) statistics version 22 for
Windows was used for data analyses. Descriptive analyses were conducted to determine
the distribution of maternal characteristics (age, body mass index (BMI), smoking status,
education level, and diabetic status) by OFC case-control status. Chi-square testing was
used to assess the association between OFCs and categorical variables. Multivariable
logistic regression was used to determine the odds ratio estimating the association
between maternal BMI categories, diabetes mellitus, gestational diabetes mellitus, and
depression and the risk of orofacial clefts with adjustment for potentially confounding
variables. Stratified analyses were conducted to evaluate effect measure modification.
Mediation analysis was conducted using the approach introduced by Vanderweele
et al. (25). This approach is based on the counterfactual framework of mediation analysis
(26), and extends mediation analysis for a dichotomous outcome with exposure-outcome
confounders, mediator-outcome confounders, and exposure-mediator interaction. Pregestational diabetes mellitus, GDM and hyperglycemia combined during pregnancy were
considered as mediators of the association between maternal overweight and obesity and
risk of OFCs.
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3.4 Results
A total of 1,750 cases of OFCs were ascertained from the UBDN including live
births (n=1596, 91.2%), stillbirths (n=59, 3.4%), terminations (n=81, 4.6%), and
spontaneous abortions (n=14, 0.8%)). 1,611 OFC live-born cases were linked to the birth
certificate records; 139 cases were excluded from the case-control study because they
were not live-births (n=136) or non-Utah maternal residences (n=3). Overall prevalence
of OFCs based on the UBDN registry data, trended to decline over the period 2000-2011
(average 2.09 per 1000 live births) and the decline appeared to be due to a decline in
isolated OFCs while the prevalence of non-isolated OFCs appeared relatively constant
(Figure 3.1). Birth certificates reported 77.6% OFC cases (n=1,250) determined by the
UBDN registry (n=1,611) and the completeness of reporting improved from 71.1%
during 1995 to 91.9% during 2011.
Among OFC cases born during 1997-2011, non-isolated OFCs accounted for
29.8% (n=432), isolated OFCs accounted for 70.2% (n=1091) of all OFC cases; 34.3%
were cleft palate only (CPO) (n=497), 25.3% were cleft lip only (CLO) (n=367), and
40.5% were cleft lip with cleft palate (CLP) (n=587).
Mean of maternal age at birth of non-isolated cases but not isolated cases was
higher than controls (27.65.9 years vs 27.15.5 years). There was no significant
difference between controls and all OFCs cases in the mean of paternal age at birth of
index child or parity. Maternal age greater than 35 years increased risk of non-isolated
OFCs when compared with mother age of 20-35 years (OR: 1.62, 95% CI: 1.18-2.23).
The association between paternal age and risk of OFCs was not found. There was no
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association between mothers and fathers of age nineteen or younger and risk of OFCs
(Table 3.2). Mothers of all OFCs and isolated OFCs had higher mean BMI than control
mothers (Table 3.1). The prevalence of depression, pre-existing DM and GDM in both
non-isolated and isolated OFCs were higher than controls.
Higher maternal and paternal education levels (higher than bachelor degree vs
high school diploma or less) were associated with a decreased risk of both all and isolated
OFCs (maternal education; OR: 0.85, 95% CI: 0.73-0.98, p-trend = 0.03 and OR: 0.82,
95% CI: 0.69-0.98, p-trend = 0.03 respectively and paternal education: OR: 0.76, 95%
CI: 0.63-0.92, p-trend = 0.01 and OR: 0.75, 95% CI: 0.60-0.95, p-trend = 0.01
respectively) (Table 3.2). The education associations appeared stronger for isolated OFCs
compared to non-isolated OFCs.
The birth certificate data for maternal smoking and alcohol consumption after
1999 had missing rates over than 90%, thus, these data after 1999 were excluded from
analysis. Mothers with depression had an increased risk of all OFCs (OR: 1.38; 95% CI:
1.06-1.80) and the estimates were similar, but with wider confidence intervals for the
sub-groups of non-isolated OFCs (OR: 1.60; 95% CI: 1.60 -2.43) (Table 3.2).
Obesity (BMI > 30 kg/m2) compared to normal weight increased risk of all OFCs,
non-isolated, and isolated OFCs with p-trends < 0.0001, 0.01, and 0.01, respectively
(Table 3.2). The adjusted odds ratio for obese mothers (BMI ≥ 30 kg/m2) was 1.29 (95%
CI: 1.09-1.53) for all OFCs, 1.41 (95% CI: 1.07-1.87) for non-isolated OFCs, and 1.23
(95% CI: 1.01-1.50) for isolated OFCs when compared to mothers with normal BMI.
Maternal underweight was associated with a decreased risk of isolated CLO (aOR
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(adjusted odds ratio): 0.42; 95% CI: 0.20-0.85) and increased risk of all CPO (aOR: 1.50;
95% CI: 1.04-2.16) after adjustment for maternal age, education, depression, and all
diabetes (Table 3.3). The associations between maternal obesity and all, non-isolated, and
isolated OFCs were only slightly less after adjustment for maternal age, education,
depression, and all diabetes (Table 3.4). Linear regression analysis showed that the slope
of prevalence of maternal obesity during 1997-2011increased every year for both OFC
groups and controls. The slope of the regression line of case mothers was significantly
higher than the slope of control mothers (p-value = 0.028) (Figure 3.2).
Mother with pre-existing diabetes had an increased risk of all OFCs (aOR: 2.19;
95% CI: 1.18-4.09) with a stronger effect for non-isolated OFCs (aOR: 3.83; 95% CI:
1.71-8.58) vs isolated OFCs (aOR: 1.54; 95% CI: 0.70-3.41) when adjustment for
maternal age, maternal education, depression, and BMI (Table 3.5). Based on cleft
subtypes, pre-existing diabetes increased risk of non-isolated CLP, CL/P (cleft lip
with/without cleft palate) and cleft palate with or without cleft lip (CP/L) (aOR: 6.23;
95% CI: 2.31-16.81, aOR: 4.64; 95% CI: 1.74-12.40, and aOR: 4.41; 95% CI: 1.96-9.90,
respectively). GDM mothers had an increased risk of all OFCs (aOR: 1.48, 95%CI: 1.052.09) with a larger effect for non-isolated OFCs (aOR: 2.29, 95%CI: 1.41-3.72) vs
isolated OFCs (aOR: 1.15, 95%CI: 0.75-1.77) (Table 3.6). Associations between GDM
and risk of non-isolated CPO and CP/L were found (aOR: 2.91; 95% CI: 1.59-5.32, and
aOR: 2.22; 95% CI: 1.32-3.73, respectively). All diabetes had an increased risk of all
OFCs (aOR: 1.52; 95% CI: 1.14-2.04) with a stronger effect for non-isolated OFCs (aOR:
2.38; 95% CI: 1.58-3.59) vs isolated OFCs (aOR: 1.18; 95% CI: 0.82-1.71) (Table 3.7).
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In addition, all diabetes increased risk of non-isolated CPO, CLP, CL/P, and CP/L (aOR:
2.71; 95% CI: 1.59-4.62, aOR: 2.08; 95% CI: 1.06-4.07, aOR: 2.05; 95% CI: 1.13-3.72
and aOR: 2.43; 95% CI: 1.58-3.74, respectively)
Mediation analyses adjusting for maternal age and education indicated that there
are direct effects of maternal obesity on all, non-isolated, and isolated OFCs not mediated
through maternal diabetes (OR: 1.31; 95% CI: 1.11-1.55, OR: 1.45; 95% CI: 1.09-1.92,
OR: 1.25; 95% CI: 1.03-1.53, respectively) (Table 3.8). There was no apparent
interaction between obesity and maternal diabetes. The odds ratio for the indirect
(mediation) effect of pre-existing diabetes was 1.02 (95% CI: 1.00-1.04) for all OFCs and
1.06 (95% CI: 1.01-1.12) for non-isolated OFCs. However, there was no apparent
mediation effect of GDM and all DM on risk of OFCs (all, non-isolated, and non-nonisolated OFCs). Stratified analyses based on logistic regression with the same covariates
revealed similar associations between obesity and OFC risk for both non-diabetic (aOR:
1.33; 95%CI: 1.12-1.57) and diabetic (aOR: 1.38; 95%CI: 0.67-2.85). Moreover,
maternal diabetes increased risk of OFCs in both normal weight and obese mothers (aOR:
1.45; 95% CI: 0.83-2.52 and aOR: 1.37; 95% CI: 0.86-2.19, respectively)
3.5 Discussion
This study found that obese mothers had an increased risk of both non-isolated
and isolated OFCs, while underweight mothers had a decreased risk of CLO and an
increased risk of CPO. An association between maternal depression and risk of OFCs was
also found in this study. In addition, mothers with pre-existing diabetes had an increased
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risk for having a child with non-isolated CLP, CL/P, and CP/L, and GDM mothers were
associated with non-isolated CPO and CP/L.
The study was population-based and relatively robust against selection bias. OFC
cases were drawn from the state-wide Utah birth defects registry, which provided
exhaustive case-finding from multiple sources and determination of OFC diagnosis by
medical geneticist review. Birth certificates were obtained for 99.7 percent of live-born
registry cases. OFC cases that were not live-born were excluded from the case-control
analysis because of the difficulty of selecting appropriate controls but were included in
the estimates of overall rates of OFCs in Utah. Cleft diagnoses from birth certificate
records included 77.6% of cases found by the registry over the entire study period,
however the completeness of cleft diagnoses from birth certificate records tended to
improve over time thus birth certificate diagnoses may be used to analyze OFC
occurrence in areas that lack registries but that have high-quality completion of birth
certificates. Data on maternal medical conditions (diabetes mellitus, GDM, depression,
and hypertension) and potential confounders were obtained from birth certificate records,
and these conditions are likely under-reported. We found a large amount of missing data
on smoking and alcohol use, thus we were unable to control for the potential confounding
by these factors. The prevalence of OFCs has been decreasing, yet the rate of OFC risk
factors including obesity, and diabetes have been increasing. This indicates that only one
environmental risk factor cannot explore or predict the OFC occurrence.
This study found that underweight mothers had a significantly decreased risk of
CLO, but increased risk of CPO. To our knowledge the protective effect of maternal
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underweight on risk of CLO has not been previously reported and is inconsistent with the
previous study by Kutbi et al (27), which reported that maternal underweight marginally
increased risk of isolated CLO and CPO. The characteristic of underweight mothers in
OFCs requires further study. Moreover, we found an increased risk of CPO, CLP, CL/P,
and CP/L with maternal obesity, which is consistent with a previous study by Kutbi et al
suggesting that obesity has a specific effect on palate formation but not lip formation
(27). A recent meta-analysis by Blanco et al also presented that maternal obesity
increased risk of CPO and CL/P (28).
The association between maternal diabetes and risk of non-isolated OFCs is
consistent with limited previous studies (19, 21). Correa et al. using the data from the
National Birth Defect Prevention Study (NBDPS) during 1997-2003 showed an
association between both pre-existing diabetes (type 1 or 2) and GDM and risk isolated
OFCs, while only pre-existing diabetes was associated with syndromic OFCs (21).
Correa et al. also reported higher estimates of odds ratios and wider confidence intervals
than our Utah study (non-isolated CPO, OR: 10.73, 95% CI: 3.99-28.86 and non-isolated
CL/P, OR: 8.07, 95% CI: 3.05-21.39). Data from a large international consortium of
case-control studies from the U.S., Denmark, and Norway (19) found an association
between GDM and syndromic OFCs and CPO. A prospective study by Moore et al (10)
reported suggestive associations between pre-existing (type 1 or 2) and GDM and risk of
OFCs but also with very wide confidence intervals that included 1.0 (prevalence ratios
(PR): 8.9, 95% CI: 0.85-46.5; and PR: 2.6, 95% CI: 0.82-8.5, respectively).
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The data on pre-existing diabetes and GDM in our Utah study are based on the
birth certificate record and may be underreported. A study by DeSisto et al. (29)
comparing prevalence of GDM in the United States from birth certificates and the
Pregnancy Risk Assessment Monitoring System (PRAMS) reported that prevalence of
GDM in Utah from PRAMS (6.4%) was higher than the prevalence from birth certificates
(4.0%) in 2010. A study by Owen-Gary and War reported that only 44.8% of the
confirmed GDM cases had a GDM diagnosis in their medical records (30). The
discrepancies among birth certificates, PRAMS, and medical records may result from
under diagnosis and from poor quality of transcription or documenting medical record
data on birth certificates. The current gold standard for GDM screening, oral glucose
tolerance tests (OGTT), is applied during 24th -28th week of gestation. However, there is
no clear agreement on the diagnostic criteria for GDM using oral glucose tolerance tests
(OGTT) because different organizations have provided different guidelines and
thresholds (31). These reasons lead to under-diagnosing and unclear-documenting of
GDM on birth certificates. Therefore, the association between GDM and risk of nonsyndromic OFCs may be underestimated because of underreported GDM on birth
certificates.
We found a direct effect of obesity and small indirect (mediating) effect of preexisting diabetes on risk of OFCs. Both stratification and mediation analyses indicated
that the effect of obesity on increasing risk of OFCs apart from the presence of known
maternal diabetes. However, mediation analysis may not be a powerful method when
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there is a small sample size of pregnancies exposed to diabetes and the presence of
undetected diabetes in the population.
Based on stratified analysis, diabetic mothers with normal BMI (18.5-24.9 kg/m2)
also have an increased risk of OFCs. This relevance of this further finding can be
appreciated by considering studies of non-obese diabetics (BMI 18-24.9 kg/m2). A cohort
study in the United States minority populations (32) found that about 13% of participants
were normal weight diabetics (BMI 17-25 kg/m2); Asians had a five-times higher
prevalence of diabetes in the normal weight group when compared to the obese group
(17% vs 4%). This study also reported that normal weight diabetics had more rapid
pancreatic beta cell failure than obese diabetics, which is also supported by the
observation of impaired pancreatic insulin secretion in normal weight diabetics from a
prospective study in the United Kingdom (33). Moreover, a case-control study in
Portugal (34) reported that normal weight diabetic patients had higher chemerin levels
than controls. Chemerin is an adipokine regulating adipocyte development and
differentiation and glucose metabolism in liver and skeletal muscle tissue. The
pathophysiology of normal weight diabetes and the association between chemerin and
other metabolic factors require further study.
Due to the complex relationship between BMI and diabetes it is difficult to
establish that BMI and diabetes are entirely independent causes of effects on OFCs. From
stratified analysis, maternal underweight had a protective effect on the formation of lip
alone which happens during 4th-8th week of gestation, while both maternal diabetes and
obesity had an effect of an increased risk of cleft palate which occurs during 6th-12th week
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of gestation. BMI and maternal diabetes might have effects on facial formation in a
variety of pathways. BMI is a rather crude measurement of body composition and is not a
precise indicator of fat mass, fat distribution, or metabolic status. Abdominal obesity has
a higher lipolysis rate than peripheral fat depots and is associated with adverse conditions
of the metabolic syndrome including elevated free fatty acids (FFA), cytokines, and
adipokines (35, 36). In addition, obesity increases activity of cytochrome P450 (CYP)
2E1, which may lead to poor folate status (37). Several epidemiological studies have
reported that obesity increases the risk of inadequate folate status (38-41); BMI may have
an adverse effect on cellular uptake and tissue distribution of folate. Obesity leads to
insulin resistance, the impairment of insulin sensitivity in sites of glucose disposal, which
can develop to type 2 diabetes mellitus and GDM (42). Many studies (43-45) reported
that obese women increased risk of developing GDM.
The mechanisms explaining the relationship between maternal diabetes and
orofacial clefts are unknown. Elevated blood glucose and insulin stimulates the
production of many adverse metabolic factors including ketone bodies, branched chain
amino acid, inflammatory markers, advanced glycation end products, altered expression
levels of specific genes, and increase the variation of gene expression levels (15-18).
These factors may disrupt normal embryonic development.
Our results suggest that in Utah maternal obesity, depression, and diabetes are
associated with increased risk of OFCs, and underweight mothers had a decreased risk of
CLO. Mechanistic studies are needed to understand the causal effects of maternal obesity,
underweight, depression, metabolic abnormalities, and diabetes on OFCs risk. Effective
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interventions are needed for promoting healthy body weight and metabolic status in
reproductive age women in order to reduce the risk of OFCs. Effective early screening
for GDM risk is needed for the periconceptional period and in the first month of gestation
in order to allow early interventions for controlling hyperglycemia, hyperinsulinemia and
other associated metabolic abnormalities to prevent OFCs and other congenital
malformations.

Table 3.1 Demographic characteristics of orofacial cleft cases and controls (1997-2011)
Parameters
Age of father
Age of mother
Number of previous live births now
still live
Maternal BMIa
Maternal BMIa category
Underweight (<18.5 kg/m2)
Normal (18.5-24.9 kg/m2)
Overweight (25-29.9 kg/m2)
Obese (≥30 kg/m2)
Maternal Race/ethnicity
White, non-Hispanic
Black, non-Hispanic
Asian or Pacific Islander
American Indian
Hispanic
Unknown
Paternal Race/ethnicity
White, non-Hispanic
Black, non-Hispanic
Asian or Pacific Islander
American Indian
Hispanic
Unknown

Control
N = 5804
29.66.0
27.15.5
1.41.4

All_OFCs
n = 1451
29.66.2
27.25.6
1.41.5

Non-isolated OFCs
n = 432
29.75.9
27.65.9*
1.41.6

Isolated OFCs
n = 1091
29.56.2
27.05.5
1.31.4

24.55.5

25.05.7**

25.05.9

24.95.6**

348 (6.2%)
3252 (58.2%)
1212 (21.7%)
777 (13.9%)

78 (5.7%)
757 (55.1%)
293 (21.3%)
245 (17.8%)

27 (6.7%)
219 (54.8%)
73 (18.3%)
81 (20.3%)

51 (5.2%)
538 (55.3%)
220 (22.6%)
164 (16.9%)

4668 (80.4%)
45 (0.8%)
118 (2.0%)
71 (1.2%)
833 (14.4%)
58 (1.0%)

1150 (79.3%)
6 (0.4%)
28 (1.9%)
29 (2.0%)
210 (14.5%)
17 (1.2%)

330 (76.4%)
2 (0.5%)
8 (1.9%)
12 (2.8%)
69 (16.0%)
8 (1.9%)

820 (75.2%)
4 (0.4%)
20 (1.8%)
17 (1.6%)
141 (12.9%)
9 (0.8%)

4392 (75.7%)
56 (1.0%)
89 (1.5%)
38 (0.7%)
683 (11.8%)
155 (2.7%)

1089 (75.1%)
7 (0.5%)
20 (1.4%)
15 (1.0%)
168 (11.6%)
31 (2.1%)

308 (71.3%)
1 (0.2%)
8 (1.9%)
7 (1.6%)
59 (13.7%)
11 (2.5%)

781 (71.6%)
6 (0.5%)
12 (1.1%)
8 (0.7%)
109 (10.0%)
20 (1.8%)
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Table 3.1 Demographic characteristics of orofacial cleft cases and controls (1997-2011) (Cont.)
Parameters

Control
N = 5804

All_OFCs
n = 1451

Non-isolated OFCs
n = 432

Isolated OFCs
n = 1091

Maternal education
2402 (41.9%)
High school or less
633 (44.6%)
184 (43.9%)
449 (44.9%)
1812
(31.6%)
Some college or bachelor
447 (31.5%)
129 (30.8%)
318 (31.8%)
1520 (26.5%)
Higher than bachelor
340 (23.9%)
106 (25.3%)
234 (23.4%)
Paternal education
High school or less
1924 (36.4%)
502 (38.9%)
149 (39.0%)
353 (38.9%)
Some college or bachelor
2526 (47.8%)
623 (48.3%)
183 (47.9%)
440 (48.5%)
Higher than bachelor
831 (15.7%)
165 (12.8%)
50 (13.1%)
115 (12.7%)
a
373 (6.4%)
93 (6.4%)
31 (7.2%)
62 (6.1%)
Hypertension
224 (3.9%)
76 (5.2%)
26 (6.0%)
50 (4.9%)
Depression
b
29 (0.5%)
16 (1.1%)
8 (2.0%)
8 (0.8%)
Pre-existing diabetes mellitus
133 (2.3%)
49 (3.4%)
22 (5.2%)
27 (2.7%)
Gestational diabetes mellitusb
181 (2.8%)
69 (4.3%)
31 (6.5%)
38 (3.4%)
All diabetes mellitusc
a
Hypertension refers to chronic hypertension, pregnancy induced hypertension, pre-eclampsia, eclampsia, and toxemia
b
Based on data during 1997-2011
c
All diabetes mellitus refers to combination between pre-existing DM and GDM
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Table 3.2 Association between demographic factors and risk of OFCs
Characteristic

Maternal age
Less than 19 years
20-35 years
More than 35
Paternal age
Less than 19 years
20-35 years
More than 35
Maternal BMIa
Underweight (<18.5 kg/m2)
Normal (18.5-24.9 kg/m2)
Overweight (25-29.9 kg/m2)
Obese (≥30 kg/m2)
Maternal education
High school or less
Some college or bachelor
Higher than bachelor
Father education
High school or less
Some College or bachelor
Higher than bachelor

All OFCs
(N=1451)
OR (95%CI)
p-value
0.89 [0.70-1.11]
1 [Reference]
1.21 [0.98-1.50]

0.29

0.68 [0.44-1.06]
1 [Reference]
1.11 [0.94-1.30]

0.09

0.96 [0.74-1.25]
1 [Reference]
1.04 [0.89-1.21]
1.36 [1.15-1.60]
p-trend1 0.001

0.77

0.08

0.22

0.62
<0.001

Non-isolated OFCs
(N=432)
OR (95%CI)
p-value
0.78 [0.52-1.19]
1 [Reference]
1.62 [1.18-2.23]

0.25
0.003

0.39 [0.14-1.07]
1 [Reference]
1.06 [0.80-1.40]

0.07

1.15 [0.76-1.74]
1 [Reference]
0.89 [0.68-1.18]
1.55 [1.19-2.02]
p-trend1 0.01

0.50

0.68

0.42
0.001

Isolated OFCs
(N=1091)
OR (95%CI)
p-value
0.93 [0.72-1.20]
1 [Reference]
1.04 [0.81-1.34]

0.56

0.81 [0.50-1.31]
1 [Reference]
1.13 [0.94-1.36]

0.38

0.89 [0.65-1.21]
1 [Reference]
1.10 [0.93-1.30]
1.28 [1.05-1.56]
p-trend1 0.01

0.44

0.77

0.21

0.29
0.01

1 [Reference]
0.94 [0.82-1.07]
0.85 [0.73-0.98]
p-trend 0.03

0.34
0.03

1 [Reference]
0.93 [0.74-1.17]
0.91 [0.71-1.17]
p-trend 0.43

0.54
0.46

1 [Reference]
0.94 [0.80-1.10]
0.82 [0.69-0.98]
p-trend 0.03

0.43
0.03

1 [Reference]
0.95 [0.83-1.08]
0.76 [0.63-0.92]
p-trend 0.01

0.40
0.01

1 [Reference]
0.94 [0.75-1.17]
0.78 [0.56-1.08]
p-trend 0.15

0.56
0.13

1 [Reference]
0.95 [0.82-1.11]
0.75 [0.60-0.95]
p-trend 0.03

0.50
0.01
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Table 3.2 Association between demographic factors and risk of OFCs (Cont.).
Characteristic

All OFCs
(N=1451)
OR (95%CI)
p-value
1.00 [0.79-1.26]
0.97
Hypertension
1.38 [1.06-1.80]
0.02
Depression
a
BMI (Body mass index) calculated as body weight (kg)/height (m2)
1
excluding underweight
Control = 5804

Non-isolated OFCs
(N=432)
OR (95%CI)
p-value
1.13 [0.77-1.65]
0.66
1.60 [1.05-2.43]
0.03

Isolated OFCs
(N=1091)
OR (95%CI)
p-value
0.95 [0.72-1.25]
0.69
1.29 [0.94-1.76]
0.11
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Table 3.3 Association between maternal underweight and risk of orofacial clefts (1997-2011)a
Cleft Group

Odds Ratios and 95% Confidence Intervals by Cleft Subtypes
OFCs
CLO
CPO
CLP
CL/P
CP/L
Crude
0.96
0.50
1.45
0.89
0.73
1.14
All
[0.74-1.25]
[0.27-0.92]
[1.01-2.08]
[0.60-1.32]
[0.52-1.03]
[0.86-1.50]
Model1
0.96
0.46
1.50
0.86
0.71
1.14
[0.74-1.24]
[0.24-0.88]
[1.04-2.16]
[0.58-1.29]
[0.50-1.00]
[0.86-1.50]
Model2
0.95
0.46
1.50
0.86
0.71
1.14
[0.74-1.24]
[0.24-0.88]
[1.04-2.16]
[0.58-1.29]
[0.50-1.00]
[0.86-1.50]
Crude
1.15
0.67
1.46
0.91
0.85
1.22
Non-isolated
[0.76-1.74]
[0.16-2.81]
[0.86-2.46]
[0.44-1.90]
[0.44-1.64]
[0.80-1.88]
Model1
1.21
0.80
1.54
0.91
0.89
1.26
[0.80-1.85]
[0.19-3.42]
[0.91-2.62]
[0.44-1.91]
[0.46-1.73]
[0.82-1.95]
Model2
1.22
0.80
1.54
0.92
0.89
1.27
[0.80-1.85]
[0.19-3.41]
[0.91-2.63]
[0.44-1.92]
[0.46-1.73]
[0.82-1.96]
Crude
0.89
0.47
1.44
0.88
0.70
1.09
Isolated
[0.65-1.21]
[0.24-0.93]
[0.90-2.32]
[0.56-1.40]
[0.47-1.03]
[0.78-1.53]
Model1
0.86
0.42
1.46
0.84
0.66
1.07
[0.63-1.17]
[0.20-0.85]
[0.91-2.36]
[0.53-1.34]
[0.44-0.98]
[0.76-1.51]
Model2
0.86
0.42
1.47
0.84
0.66
1.07
[0.63-1.17]
[0.20-0.85]
[0.91-2.36]
[0.53-1.34]
[0.44-0.98]
[0.76-1.51]
OFCs: orofacial clefts; CL: cleft lip only; CP: cleft palate only; CLP: cleft lip with cleft palate; CL/P: cleft lip with/without cleft
palate; CP/L: cleft palates with or without cleft lip.
a
All diabetes refers to combination between pre-existing DM and GDM
Model1: Covariates in multiple logistic regression models included maternal age, maternal education levels, and depression.
Model2: Covariates in multiple logistic regression models included maternal age, maternal education levels, depression, and all
diabetes.
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Table 3.4 Association between maternal obesity and risk of orofacial clefts (1997-2011)a
Cleft Group

Odds Ratios and 95% Confidence Intervals by Cleft Subtypes
OFCs
CLO
CPO
CLP
CL/P
CP/L
Crude
1.36
1.25
1.37
1.41
1.35
1.39
All
[1.15-1.60]
[0.93-1.68]
[1.05-1.78]
[1.12-1.79]
[1.11-1.63]
[1.16-1.68]
Model1
1.33
1.27
1.33
1.36
1.33
1.35
[1.12-1.57]
[0.94-1.72]
[1.01-1.74]
[1.07-1.73]
[1.09-1.61]
[1.12-1.63]
Model2
1.29
1.26
1.24
1.34
1.31
1.30
[1.09-1.53]
[0.93-1.70]
[0.94-1.64]
[1.05-1.71]
[1.07-1.59]
[1.07-1.57]
Crude
1.55
1.35
1.57
1.58
1.52
1.58
Non-isolated
[1.19-2.02]
[0.63-2.86]
[1.09-2.27]
[1.04-2.41]
[1.05-2.20]
[1.19-2.09]
Model1
1.55
1.47
1.59
1.51
1.50
1.56
[1.18-2.03]
[0.68-3.17]
[1.09-2.31]
[0.99-2.32]
[1.03-2.19]
[1.17-2.07]
Model2
1.41
1.42
1.42
1.40
1.41
1.41
[1.07-1.87]
[0.65-3.11]
[0.96-2.08]
[0.91-2.17]
[0.96-2.07]
[1.05-1.90]
Crude
1.28
1.24
1.20
1.35
1.30
1.29
Isolated
[1.05-1.55]
[0.90-1.70]
[0.83-1.73]
[1.02-1.78]
[1.05-1.61]
[1.03-1.62]
Model1
1.24
1.25
1.13
1.30
1.28
1.23
[1.02-1.51]
[0.90-1.72]
[0.78-1.64]
[0.98-1.73]
[1.03-1.60]
[0.98-1.56]
Model2
1.23
1.23
1.09
1.31
1.28
1.23
[1.01-1.50]
[0.89-1.71]
[0.75-1.59]
[0.99-1.74]
[1.02-1.60]
[0.97-1.55]
OFCs: orofacial clefts; CL: cleft lip only; CP: cleft palate only; CLP: cleft lip with cleft palate; CL/P: cleft lip with/without cleft
palate; CP/L: cleft palates with or without cleft lip
a
All diabetes refers to combination between pre-existing DM and GDM
Model1: Covariates in multiple logistic regression models included maternal age, maternal education levels, and depression.
Model2: Covariates in multiple logistic regression models included maternal age, maternal education levels, depression, and all
diabetes.
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Table 3.5 Association between pre-existing diabetes and risk of orofacial clefts (1997-2011)
Cleft Group

Odds Ratios and 95% Confidence Intervals by Cleft Subtypes
OFCs
CLO
CPO
CLP
CL/P
CP/L
Crude
2.25
1.10
2.50
2.76
2.12
1.68
All
[1.22-4.15]
[0.26-4.63]
[1.03-6.06]
[1.26-6.07]
[1.03-4.37]
[1.24-2.29]
Model1
2.24
1.07
2.49
2.76
2.11
2.63
[1.21-4.15]
[0.25-4.52]
[1.03-6.05]
[1.25-6.09]
[1.02-4.35]
[1.02-4.35]
Model2
2.19
1.02
2.54
2.64
2.03
2.59
[1.18-4.09]
[0.24-4.34]
[1.04-6.22]
[1.19-5.88]
[0.97-4.21]
[1.35-4.97]
Crude
3.89
N/A
2.89
6.48
4.91
4.42
Non-isolated
[1.77-8.56]
[0.87-9.55]
[2.47-16.97]
[1.88-12.81]
[2.00-9.73]
Model1
3.81
N/A
2.88
6.30
4.75
4.34
[1.72-8.42]
[0.87-9.58]
[2.39-16.64]
[1.81-12.47]
[1.96-9.62]
Model2
3.83
N/A
2.99
6.23
4.64
4.41
[1.71-8.58]
[0.89-10.10]
[2.31-16.81]
[1.74-12.40]
[1.96-9.90]
Crude
1.58
1.27
2.21
1.41
1.35
1.72
Isolated
[0.72-3.47]
[0.30-5.37]
[0.67-7.30]
[0.43-4.65]
[0.52-3.51]
[0.71-4.16]
Model1
1.59
1.24
2.20
1.43
1.36
1.73
[0.72-3.49]
[0.30-5.25]
[0.66-7.26]
[0.43-4.74]
[0.52-3.53]
[0.72-4.19]
Model2
1.54
1.19
2.21
1.35
1.30
1.68
[0.70-3.41]
[0.28-5.06]
[0.65-7.40]
[0.41-4.50]
[0.50-3.38]
[0.69-4.09]
OFCs: orofacial clefts; CL: cleft lip only; CP: cleft palate only; CLP: cleft lip with cleft palate; CL/P: cleft lip with/without cleft
palate; CP/L: cleft palates with or without cleft lip.
Model1: Covariates in multiple logistic regression models included maternal age, maternal education levels, and depression.
Model2: Covariates in multiple logistic regression models included maternal age, maternal education levels, depression, and body
mass index.
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Table 3.6 Association between gestational diabetes mellitus and risk of orofacial clefts (1997-2011)
Cleft Group

Odds Ratios and 95% Confidence Intervals by Cleft Subtypes
OFCs
CLO
CPO
CLP
CL/P
CP/L
Crude
1.50
1.32
2.09
1.13
1.20
1.57
All
[1.08-2.10]
[0.71-2.47]
[1.33-3.29]
[0.66-1.94]
[0.79-1.84]
[1.09-2.26]
Model1
1.45
1.35
1.92
1.11
1.20
1.48
[1.04-2.04]
[0.72-2.53]
[1.20-3.05]
[0.64-1.91]
[0.78-1.85]
[1.02-2.15]
Model2
1.48
1.41
2.07
1.04
1.18
1.50
[1.05-2.09]
[0.75-2.65]
[1.29-3.32]
[0.59-1.83]
[0.76-1.83]
[1.02-2.20]
Crude
2.33
2.65
2.94
1.41
1.71
2.29
Non-isolated
[1.47-3.70]
[0.82-8.61]
[1.66-5.19]
[0.57-3.50]
[0.83-3.54]
[1.40-3.74]
Model1
2.15
2.64
2.67
1.31
1.62
2.08
[1.33-3.45]
[0.80-8.69]
[1.47-4.82]
[0.53-3.27]
[0.78-3.37]
[1.25-3.45]
Model2
2.29
2.78
2.91
1.37
1.70
2.22
[1.41-3.72]
[0.83-9.32]
[1.59-5.32]
[0.55-3.46]
[0.81-3.57]
[1.32-3.73]
Crude
1.17
1.11
1.45
1.03
1.06
1.19
Isolated
[0.77-1.77]
[0.54-2.29]
[0.73-2.87]
[0.54-1.97]
[0.65-1.75]
[0.73-1.94]
Model1
1.16
1.14
1.36
1.03
1.08
1.17
[0.76-1.77]
[0.55-2.36]
[0.68-2.72]
[0.53-1.98]
[0.65-1.78]
[0.71-1.90]
Model2
1.15
1.18
1.46
0.92
1.03
1.13
[0.75-1.77]
[0.73-2.94]
[0.73-2.94]
[0.61-1.72]
[0.61-1.72]
[0.68-1.88]
OFCs: orofacial clefts; CL: cleft lip only; CP: cleft palate only; CLP: cleft lip with cleft palate; CL/P: cleft lip with/without cleft
palate; CP/L: cleft palates with or without cleft lip
1
based on data during 1997-2011
Model1: Covariates in multiple logistic regression models included maternal age, maternal education levels, and depression.
Model2: Covariates in multiple logistic regression models included maternal age, maternal education levels, depression, and body
mass index.
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Table 3.7 Association between all diabetes and risk of orofacial clefts (1997-2011)a
Cleft Group

Odds Ratios and 95% Confidence Intervals by Cleft Subtypes
OFCs
CLO
CPO
CLP
CL/P
CP/L
Crude
1.55
1.16
2.09
1.36
1.28
1.68
All
[1.17-2.06]
[0.65-2.05]
[1.41-3.09]
[0.89-2.08]
[0.90-1.83]
[1.24-2.29]
Model1
1.52
1.18
1.95
1.35
1.29
1.63
[1.14-2.02]
[0.66-2.10]
[1.31-2.91]
[0.88-2.08]
[0.90-1.85]
[1.19-2.22]
Model2
1.52
1.19
2.05
1.30
1.26
1.63
[1.14-2.04]
[0.67-2.13]
[1.36-3.08]
[0.83-2.02]
[0.87-1.82]
[1.19-2.24]
Crude
2.40
1.99
2.77
2.03
2.02
2.45
Non-isolated
[1.62-3.56]
[0.62-6.45]
[1.67-4.57]
[1.06-3.91]
[1.14-3.61]
[1.63-3.70]
Model1
2.27
1.98
2.55
1.97
1.97
2.30
[1.52-3.39]
[0.61-6.46]
[1.52-4.29]
[1.02-3.81]
[1.10-3.53]
[1.51-3.50]
Model2
2.38
1.97
2.71
2.08
2.05
2.43
[1.58-3.59]
[0.59-6.54]
[1.59-4.62]
[1.06-4.07]
[1.13-3.72]
[1.58-3.74]
Crude
1.20
1.03
1.56
1.11
1.08
1.28
Isolated
[0.85-1.72]
[0.54-1.96]
[0.88-2.77]
[0.65-1.90]
[0.70-1.65]
[0.86-1.92]
Model1
1.21
1.05
1.49
1.12
1.10
1.27
[0.84-1.73]
[0.55-2.01]
[0.84-2.66]
[0.66-1.92]
[0.72-1.68]
[0.84-1.91]
Model2
1.18
1.06
1.56
1.03
1.04
1.23
[0.82-1.71]
[0.55-2.05]
[0.87-2.80]
[0.59-1.80]
[0.67-1.62]
[0.81-1.87]
OFCs: orofacial clefts; CL: cleft lip only; CP: cleft palate only; CLP: cleft lip with cleft palate; CL/P: cleft lip with/without cleft
palate; CP/L: cleft palates with or without cleft lip
a
All diabetes refers to combination between pre-existing DM and GDM
Model1: Covariates in multiple logistic regression models included maternal age, maternal education levels, and depression.
Model2: Covariates in multiple logistic regression models included maternal age, maternal education levels, depression, and body
mass index.
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Table 3.8 Total, direct, and indirect effects with 95% CI of the association between
maternal obesity and risk of orofacial clefts mediated through maternal diabetes
Pre-existing
diabetes
OR [95% CIs]

GDM

All diabetesa

OR [95% CIs]
OR [95% CIs]
All OFCs
Direct effect
1.33 [1.12-1.58]
1.30 [1.09-1.54]
1.31 [1.11-1.55]
Indirect effect
1.02 [1.00-1.04]
1.00 [0.98-1.03]
1.00 [0.97-1.04]
Total effect
1.35 [1.14-1.61]
1.30 1.10-1.54]
1.32 [1.11-1.56]
Non-isolated OFCs
Direct effect
1.44 [1.08-1.92]
1.42 [1.07-1.89]
1.45 [1.09-1.92]
Indirect effect
1.06 [1.01-1.12]
1.00 [0.95-1.06]
1.01 [0.95-1.08]
Total effect
1.53 [1.15-2.04]
1.43 [1.08-1.89]
1.46 [1.11-1.93]
Isolated OFCs
Direct effect
1.28 [1.05-1.57]
1.25 [1.02-1.53]
1.25 [1.03-1.53]
Indirect effect
1.00 [0.98-1.02]
1.00 [0.98-1.03]
1.00 [0.97-1.03]
Total effect
1.28 [1.05-1.57]
1.25 [1.03-1.52]
1.25 [1.03-1.52]
a
All diabetes refers to combination between pre-existing DM and GDM
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Figure 3.1 Prevalence of OFCs during 1995-2011 (per 1000 live birth)
All: coefficient = -0.023; 95%confidence interval = -0.043, -0.004; p-value= 0.02
Non-isolated: coefficient = -0.002; 95%confidence interval = -0.013, 0.009; p-value=
0.73
Isolated: coefficient = -0.02; 95%confidence interval = -0.04, -0.003; p-value= 0.03
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Controls
OFC cases
Controls
OFC cases

p-value = 0.028

Figure 3.2 The regression line of maternal obesity (BMI ≥ 30 kg/m2) prevalence by year
divided by OFC cases and controls.
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CHAPTER 4
THE ASSOCIATION BETWEEN MATERNAL DIABETES AND BIOMARKERS
OF METABOLIC SYNDROME AND OROFACIAL CLEFTS

4.1 Abstract
Background: The evidence of the association between mothers having a
congenitally malformed offspring and risk of developing diabetes and metabolic
syndrome later in life is limited. This approach however may provide clues to the
presence of undetected metabolic abnormalities involved in teratogenesis early in
pregnancy.
Objective: to determine the association between the occurrence of maternal
diabetes and maternal biomarkers of metabolic syndrome and isolated orofacial clefts
(OFCs) using data from the Utah Cleft 2 study.
Methods: Cases and controls were selected from the participants in the Utah Cleft
1 study (1995-2005) and the National Birth Defects Prevention Study (NBDPS) in Utah
(2005-2011). Participants were interviewed by telephone, and physical examination and
blood collection was completed in clinical visits. Laboratory assays of metabolic
syndrome-related biomarkers were performed by Laboratory Corporation of America
(Labcorp), Utah and Quansys Bioscience, Logan, Utah. Independent t-test and chi-square
tests were used to assess the association between OFCs and continuous and categorical
variables. Two-way ANOVA was performed to assess the differences of adipokines and
cytokines. Multivariable logistic regression was used to estimate risk for OFCs while
adjusting for the potential confounding effects of maternal age and smoking.
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Results: Mothers having GDM in any pregnancy had an increased risk of OFCs
(OR: 3.05, 95% CI: 1.61-5.80) and this was consistent for each type of OFC. OFC casemothers tended to be more obese than controls (OR: 1.45, 95% CI 0.99-2.13). Mothers
of children with cleft palate, compared to controls, had higher mean levels of plasma
glucose, insulin, triglycerides, waist circumference and systolic blood pressure, and lower
HDL; these associations were not seen for mothers of children with cleft lip
only. Similarly, mean plasma IL-8 and leptin levels were associated with cleft palate but
not with cleft lip; risk analysis by tertile revealed a weaker association for IL-8 and cleft
palates with or without cleft lip (CP/L) (OR for highest vs lowest tertile: 1.36, 95% CI
0.81-2.30; p-trend 0.24) and a stronger association for leptin and CP/L (OR for highest
vs. lowest tertile: 2.21, 95% CI 1.28-3.81; p-trend 0.004) Metabolic syndrome indices
were associated with cleft palate (NCEP/ATP III score OR: 1.60, 95% CI 1.00-2.56; IDF
score OR: 1.64, 95% CI 1.04-2.59); these scores were not associated with cleft lip alone.
Conclusion: Gestational diabetes mellitus was associated with risk of OFCs and
this association may reflect a progression of metabolic syndrome abnormalities that are
teratogenic yet undetected in the periconceptional period. Individual metabolic syndrome
biomarkers and indices were associated with cleft palate, but were not associated with
cleft lip alone, this may reflect specific vulnerabilities of palate development which occur
later than lip development. IL-8 and leptin levels were also associated with cleft palate
and not cleft lip alone and suggest that further studies of novel metabolic syndromerelated biomarkers in the periconceptional period may be useful in understanding the
causes and prevention of OFCs.
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4.2 Introduction
OFCs occur in every 0.4 to 2 per 1000 births depending on geographic location,
racial and ethnic groups, maternal age, environmental exposures, and socioeconomic
status (1, 2). The U.S. National Birth Defects Prevention Network reported the
prevalence of OFCs during 2002-2006 of CL/P was 1.33 per 1000 live births, and 0.73
per 1000 live births for CP (3). The prevalence of OFCs in Utah is higher than the overall
prevalence in the United States (2.25 per 1000 births) (4)
Metabolic syndrome is the grouping of visceral obesity, insulin resistance,
hyperglycemia, dyslipidemia (hypertriglyceridemia and hypo-HDL cholesterolemia), and
hypertension (5). In addition, metabolic syndrome increases the risk of cardiovascular
diseases (CVD), type 2 diabetes mellitus, and stroke. Both type 2 diabetes mellitus and
gestational diabetes mellitus, risk factors of OFCs, have associations with metabolic
syndrome. Many studies have reported that metabolic syndrome increases the risk of type
2 diabetes mellitus (6-9). A meta-analysis study showed that the subsequent risk of
metabolic syndrome increased in women with a history of GDM (10). On the other hand,
metabolic syndrome in early pregnancy increases the incidence of GDM (11).
Biochemical markers are hormones, enzymes, antibodies, or other substances in
urine, blood, tissue, or other body fluids. These biomarkers have been used to detect
abnormality or disease. Besides HDL and triglyceride, liver function tests (ALT: alanine
aminotransferase and GGT: gamma-glutamyltransferase) (12-14), cytokines (CRP: Creactive protein, IL-6: interleukin-6, and TNF- α: tumor necrosis factor alpha) (15-18),
and adipokines (leptin and adiponectin) (16-18) also have association with metabolic
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syndrome. The biomarkers associated with metabolic syndrome have been correlated
with the risk of developing diabetes mellitus (13, 19-21).
A few studies have reported that mothers having a congenitally malformed child,
including OFCs increased risk of developing diabetes many years later (22, 23). Thus, we
hypothesize that Utah mothers giving birth to children with orofacial clefts have an
enhanced risk of diabetes and abnormal biomarkers associated with metabolic syndrome.
This study aims to analyze biomarkers related to metabolic syndrome in mothers after
giving birth to an OFC child compared to control-mothers of unaffected children.
4.3 Subjects and Methods
4.3.1 Study Design
The Utah Cleft 2 study is a case-control interview and clinical study of orofacial
clefts in Utah. The study protocol was reviewed and approved by the institutional review
boards of Utah State University (USU), the University of Utah, and the Utah Department
of Health (UDOH).
4.3.2 Study Participants
Cases and controls were selected from the participants in the Utah Cleft 1 casecontrol study (24) and the National Birth Defects Prevention Study (NBDPS) in Utah
(25). In the Utah Cleft 1 study, case‐mothers having a child with OFCs between January
1995 and June 2005 were recruited from UDOH, and control mothers were randomly
selected, frequency matched by birth month and year, and gender of case child at ratio
1:1 by using Utah birth certificate files. The NBDPS in Utah, also a state-wide
population-based case-control study, recruited case mothers having a child with OFCs
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between 2005-2011 from the UDOH database, and randomly selected control mothers
from birth certificates. The OFC cases were limited to isolated OFCs; cases with multiple
birth defects were excluded.
4.3.3 Data collection
Data from the Utah Cleft 2 case-control study were collected by trained
interviewers after participants were contacted by either mail or telephone during 20112015. Verbal consent was obtained by telephone before interviewing mothers about
medical history, nutritional supplements, and prescription medicines. In clinical visits,
mothers gave written informed consent and height, weight, waist circumference, and
blood pressure were measured and a blood sample was taken.
4.3.4 Laboratory analyses of biomarkers
Blood samples from non-fasting subjects were obtained using Purple top (EDTA)
and Blue-top (EDTA) tubes from mothers. Blood samples were centrifuged for 10 min at
3600 rpm and divided into aliquots of plasma, buffy coats, and red blood cells. Aliquots
for metabolic biomarkers were analyzed at the Laboratory Corporation of America
(Labcorp), Utah. Samples for analyzing cytokines and adipokines were kept at -80oC, and
shipped on dry ice to Quansys Bioscience, Logan, Utah. (Table 4.1)
a) Hematology, metabolic profiles, and lipid profiles b)
Labcorp (26) methods for metabolic biomarkers included Kinetic for liver
function tests, enzymatic for glucose, carbon dioxide, total cholesterol, triglyceride,
high-density lipoprotein (HDL), low-density lipoprotein (LDL), and very low-density
lipoprotein (VLDL), electrochemiluminescence immunoassay (ECLIA) for insulin,
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and Roche Tina Quant for hemoglobin A1c. Liver function tests included alanine
aminotransferase (ALT/SGPT), aspartate aminotransferase (AST/SGOT), and
alkaline phosphatase.
b) Cytokines and adipokines
Blood samples were collected from non-fasting participants and specimens were
placed on wet ice then centrifuged within 2 hours after collection and kept at -80oC
until analysis. Plasma was shipped on dry ice to Quansys Biosciences (27) (Logan,
Utah) in order to analyze CRP, cytokines (IL-1a, IL-6, IL-8, and TNFa), and
adipokines (adiponectin, leptin, and resistin). The serum specimens were analyzed by
the multiplex enzyme-linked, immuunosorbent assay (ELISAs) technology,
microscaled and multiplexed to simultaneously measure multiple proteins.
4.3.4 Statistical analyses
Descriptive analyses were conducted to determine the distribution of maternal
biomarkers by OFC status. Metabolic syndrome protocols of NCEP/ATP III (28) and IDF
(29) were used to classify metabolic syndrome status. Independent-sample t-tests and chisquare tests were used to assess the association between OFCs and continuous and
categorical variables respectively. Multivariable linear regression was used to adjust for
the potential confounding effects of maternal age and smoking status in the comparison
of continuous biomarkers of cases and controls. Multivariable logistic regression analysis
was used to estimate odds ratios (ORs) with 95% confident intervals (95% CI) for
evaluation of OFC risk. The linear trend test was analyzed to determine the trend of risk
across levels of each biomarker. All multivariate analyses were adjusted for maternal age
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and smoking. Due to wide range of undetected samples of cytokines and adipokines (039.7%), two-way ANOVA was performed to estimate the difference of mean between
OFC groups and the control group with models including covariates for detectedundetected status and the measured values for detected samples. All statistical analyses
were performed using the Statistical Package for Social Sciences (IBM SPSS) statistics
version 22 for Windows.
Table 4.1 Laboratory tests used in the Utah Cleft 2 case-control study
Items
Method
Lipid profiles (total cholesterol,
Enzymatic
triglyceride, lipoproteins)
Liver function test (alkaline
Kinetic
phosphatase, alanine aminotransferase,
and aspartate aminotransferase )
Glucose
Enzymatic
Insulin
ECLIA2
Hemoglobin A1c
Roche Tina Quant
C-reactive protein (CRP)
Multiplex ELISAs3
Cytokines and adipokines (interleukin-1
Multiplex ELISAs3
alpha, interleukin-6, interleukin-8,
leptin, resistin, tumor necrosis factor
alpha, and adiponectin)
1
Labcorp: Laboratory Corporation of America
2
ECLIA: Electrochemiluminescence immunoassay
3
ELISAs: Enzyme-Linked, Immuunosorbent Assay

Laboratory
Labcorp1
Labcorp1
Labcorp1
Labcorp1
Quansys Bioscience
Quansys Bioscience

4.4 Results
Efforts were made to recruit 1431 participants from the Utah Cleft 1 case-control
study and 456 participants from the NBDPS. A total of 794 participants (435 (30.4%)
from the Utah Cleft 1 case-control study and 359 (78.7%) from the NBDPS) were
enrolled in this study; 612 participants (77.1%) completed telephone interviews, clinic
visits and blood collection, and 157 (19.8%) completed the telephone interview only.

303
Refusals included 167 participants (116 (12.8%) controls and 51 (6.0%) cases) and 541
participants (189 (20.9%) controls and 352 (41.1%) cases) were unable to be contacted or
scheduled (table 4.2).
The mean maternal age at birth and age at clinical visit was not different between
cases and controls and the data collection for both groups was an average of 10 years
after the index birth. Among 360 isolated OFC cases, cleft palate only (CPO) accounted
for 25% (n=90), cleft lip only (CLO) accounted for 31.1% (n=112), and cleft lip with
cleft palate (CLP) accounted for 42.5% (n=153). The mean body mass index (BMI) of
cases and controls was not different. The rate of maternal smoking in three months before
interview was greater in all OFC groups compared to controls (Table 4.3). Alcohol
consumption in three months before interview was greater in OFC cases compared to
controls (Table 4.3). Type 2 diabetes was less common than GDM and was not associated
with OFC risk (Tables 4.3 and 4.4). Gestational diabetes (GDM) was associated with an
increased risk of OFCs (OR: 3.05, 95% CI: 1.61-5.80) and this was consistent for each
type of OFCs. OFC mothers tended to be more obese than controls (OR: 1.45, 95% CI:
0.99-2.13) (Tables 4.3 and 4.4).
When adjusted for maternal age and smoking, means of waist circumference,
insulin, glucose and triglyceride in the CP/L (cleft palate with or without cleft lip) group
were significant higher and mean HDL was lower than control mothers (Table 4.5); the
mean values for the CLO group were not significantly different from controls. The odds
ratios analyzed by tertiles generally showed similar finding, though the 95% CIs for most
comparisons included 1.0.
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OFC risk by level of the metabolic syndrome scores computed on the basis of
NCEP/ATPIII and IDF criteria, and risk by the individual component scores appear in
Table 4.8. Metabolic syndrome defined by NCEP/ATPIII criteria (≥ 3) was associated
with an increased risk of CP/L (OR: 1.60, 95% CI: 1.00-2.56) but no higher risk of CLO
(OR: 1.06, 95% CI: 0.54-2.05). Similarly, metabolic syndrome defined by IDF criteria
was associated with a greater risk of all CP (OR: 1.64, 95% CI: 1.04-2.59) but no greater
risk of CLO (OR: 1.16, 95% CI: 0.62-2.17). Elevated blood pressure, defined as systolic
blood pressure ≥ 130 mmHg or diastolic blood pressure ≥ 85 mmHg was associated with
CP/L (OR: 1.77, 95% CI: 1.02-3.09) but not CL only (OR: 1.03, 95% CI: 0.46-2.32). The
other individual metabolic syndrome component scores did not appear to be associated
with OFCs, underscoring the importance of combined metabolic syndrome indices rather
than individual components in association with OFC risk.
Mothers having CLO and cleft lip with/without cleft palate (CL/P) offspring had
AST levels higher than mothers in the control group when adjusted for maternal age and
smoking (adjusted p-value 0.05 and 0.05, respectively) (Table 4.7).
The mean and median cytokine IL-8 (p-value=0.003) and the adipokine leptin (pvalue = 0.006) levels were higher in CP/L cases compared to controls (Table 4.6). The
risk analysis by tertile revealed a weaker associated for IL-8 (OR for highest vs lowest:
1.36, 95% CI: 0.81-2.30, p-trend 0.24) and a stronger association for leptin (OR for
highest vs lowest: 2.21, 95% CI: 1.28-3.81, p-trend 0.004). IL-8 and leptin levels were
not associated with CLO. When analyses were stratified by BMI level (normal weight,
BMI 18.5 to 24.9 kg/m2; overweight, BMI 25 to 29.9 kg/m2; obese: BMI more than 30
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kg/m2), IL-8 and leptin levels generally increased with increasing BMI levels, and
significant differences emerged between CP/L vs controls. Based on BMI classification,
obese mothers having CPO offspring had higher leptin levels than obese mothers in the
control group when adjusted for maternal age and smoking (Figures 4.1).
4.5 Discussion
Mothers having GDM in any pregnancy had an increased risk of all types of
OFCs. Mothers having CLO and CL/P offspring were associated with obesity later in life.
Mothers having CP/L offspring had an increased risk of developing metabolic syndrome
based on both NCEP/ATP III and IDF definitions. Mothers having CP/L offspring had
higher IL-8 and leptin levels than control mothers.
The association between gestational diabetes mellitus and risk of non-isolated
OFCs is consistent with limited previous studies (30, 31). Correa et al. using the data
from the National Birth Defect Prevention Study (NBDPS) during 1997-2003 showed an
association between both pre-existing diabetes (type 1 or 2) and GDM and risk isolated
OFCs, while only pre-existing diabetes was associated with syndromic OFCs (31).
Correa et al. also reported higher estimates of odds ratios and wider confidence intervals
than our study (non-isolated CPO, OR: 10.73, 95% CI: 3.99-28.86 and non-isolated
CL/P, OR: 8.07, 95% CI: 3.05-21.39). Data from a large international consortium of
case-control studies from the U.S., Denmark, and Norway (30) found an association
between GDM and syndromic OFCs and CPO. A prospective study by Moore et al (32)
reported suggestive associations between pre-existing (type 1 or 2) and GDM and risk of
OFCs but also with very wide confidence intervals that included 1.0 (prevalence ratios
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(PR): 8.9, 95% CI: 0.85-46.5; and PR: 2.6, 95% CI: 0.82-8.5, respectively). The
mechanisms explaining the relationship between maternal diabetes and orofacial clefts
are unknown. Elevated blood glucose and insulin stimulates the production of many
adverse metabolic factors including ketone bodies, branched chain amino acids,
inflammatory markers, advanced glycation end products, altered expression levels of
specific genes, and increase the variation of gene expression levels (33-36). These factors
may disrupt normal embryonic development.
This study reported associations between CLO and CL/P and obesity, which is
consistent with the findings of the Utah birth certificate study of pre-pregnancy weight
reported in chapter 3. A large international consortium of U.S. and European populationbased studies by Kutbi et al (37) found that pre-pregnancy maternal obesity had an
increased risk of CPO, CLP, and CP/L but not CLO; this study suggested that obesity has
a specific effect on palate formation but not lip formation. A recent meta-analysis by
Blanco et al also presented that maternal obesity increased risk of CPO and CL/P (38).
Metabolic syndrome is a major public health issue because it increases the risk of
cardiovascular diseases (CVD), type 2 diabetes mellitus, stroke, etc. We found that
mothers of children with CP/L had an increased risk of developing metabolic syndrome
later in life. A case-control study in Mexico (23) found that the prevalence of diabetes in
mothers delivering a malformed child was higher than control group (controls: 4% and
cases: 16.7, 40.4 5, and 53.1% when follow-up 0, 12, and 25 years after the index
pregnancy, respectively). Another case-control study in the United Kingdom (22)
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reported mothers having CPO or CL/P offspring had a higher prevalence of increased
antagonism to insulin than control mothers (CPO: 75%, CL/P: 68.1%, and controls: 28%)
This study found that using the IDF definition identified a higher prevalence of
metabolic syndrome than using the NCEP/ATP III definition. Previous studies also
reported that using IDF criteria for screening metabolic syndrome provided a higher
prevalence than NCEP/ATP III criteria (39-42). The National Health and Nutrition
Examination Survey (NHANES) 1999-2002 (39) found that prevalence of metabolic
syndrome was 39.0±1.1 % based on IDF criteria, while 34.5±0.9 % based on NCEP/ATP
III. Both metabolic syndrome criteria had similar associations with OFCs in the present
study.
Previous studies found the association between NCEP/ATP III definition and risk
of carotid atherosclerosis (43, 44). However, recent studies suggested that metabolic
syndrome definition proposed by IDF was a better predictor for cardiovascular risk than
the definition by NCEP/ATP III. A cross sectional study in China presented that IDF
definition was more strongly associated with CHD than NCEP/ATP III definition (45). A
case-control study in Greece found that IDF definition for metabolic syndrome provided
a higher odd ratio for acute coronary syndrome than NCEP/ATP III (OR: 3.26, 95% CI:
2.12-5.00 vs OR: 2.32, 95% CI: 1.53-3.52) (46). A 13-year follow up study in Finns (42)
found that metabolic syndrome defined by IDF was associated with risk of coronary heart
disease (CHD) mortality (hazard ratio (HR): 1.42, 95% CI: 1.01-1.99), while the
association between metabolic syndrome defined by NCEP/ATP III definition and CHD
mortality was not significant (HR: 1.30, 95% CI: 0.94-1.81). However, this study also
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reported a 1.35 fold (95% CI: 1.05-1.74) risk of CVD mortality was associated with
metabolic syndrome according to NCEP/ATP III criteria, which was a bit higher than
metabolic syndrome diagnosed by IDF (HR: 1.33, 95% CI: 1.03-1.77). A cross sectional
analysis in a Greek population reported that NCEP/ATP III definition was more
predictive of cardiovascular disease (CVD) risk than IDF definition (47). A prospective
study in Austria (48) found metabolic syndrome defined by NCEP/ATP III definition was
strongly predictive of vascular events than the IDF definition (HR: 1.58, 95% CI: 1.102.26 vs HR: 1.06, 95% CI: 0.76-1.50).
Both definitions use the same five components, but there are a few differences.
The IDF definition requires the presence of central obesity plus two of the rest
components while NCEP/ATP III definition makes central obesity one of the five equally
weighted criteria. Moreover, the thresholds for waist circumference and fasting blood
glucose by the IDF definition are lower than those of the NCEP definition. The
thresholds of triglycerides and HDL cholesterol levels, and systolic and diastolic blood
pressure are the same. IDF definition emphasizes waist circumference, an index of
abdominal obesity which has an effect on metabolic processes by the intra-abdominal
visceral fat which has higher lipolysis rate than any other depots. Abdominal adipose
tissue elevates free fatty acids (FFA), cytokines (tumor necrosis factor alpha (TNF-𝛼) and
interleukin-6 (IL-6)), adipokines, and angiotensin II. Excess FFA circulation induces
insulin resistance, which results from reduced hepatic insulin clearance, decreased
skeletal muscle insulin sensitivity, increased hepatic cholesterol production with elevated
triglycerides and very low density lipoprotein (VLDL), and altered endothelial function.
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Elevated levels of cytokines also impair insulin sensitivity (5, 49). In addition, enlarged
fat cells causing fat overflow to muscles, the liver, and the pancreas lead to insulin
resistance (50), which plays an important role in the development of metabolic syndrome
(51). The IDF consensus group has mentioned other parameters that require further
research into metabolic syndrome including tomographic assessment of fat distribution
and liver fat, adipose tissue biomarkers (leptin and adiponectin), apolipoprotein B, small
LDL particles, insulin resistance parameters (fasting insulin, proinsulin levels,
homeostatic model assessment-insulin resistance (HOMA-IR), free fatty acid), oral
glucose tolerance test, measurement of endothelial dysfunction, microalbuminuria,
inflammatory markers (CRP, TNF-α, IL-6), thrombotic markers (plasminogen activator
type 1, fibrinogen), and pituitary-adrenal axis (29).
This study found that mothers having offspring with CP/L had higher insulin
levels than control mothers. Insulin resistance is defined as a condition in which normal
insulin levels are not adequate at maintaining a normal insulin response in peripheral
target tissues (adipose, muscle, and liver), which causes pancreatic beta cells to secrete
more insulin (hyperinsulinemia) to overcome the hyperglycemia condition (5). Elevated
levels of inflammatory markers also impair insulin sensitivity (5, 49). An in vitro study
by Hotanisligil et al found that TNF-α inhibits insulin receptor substrate 1 (IRS-1)
signaling pathway, which leads to insulin resistance (52). A human study by Bastard et al
reported that IL-6 level was associated with insulin resistance (53). This study
hypothesized that IL-6 overproduction from adipose tissue activates extracellular signal
regulated kinase (ERK) pathway and induces IRS-1, which inhibits insulin signaling. In
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addition, insulin resistance is a risk factor for developing GDM. Prospective studies
found that pregnant women having high fasting plasma insulin levels (FPI) in the first
trimester of gestation had an increased risk of GDM (54-56). The association between
insulin and OFCs requires further study.
We found that mothers of children having CPO and CP/L had higher IL-8 and
leptin levels than control mothers. IL-8 is a proinflammatory cytokine, which is produced
by macrophages and monocytes (57). A case-control study by Bruun et al (58) found that
plasma IL-8 levels were 38% higher in obese participants than in lean participants. In
addition, in the obesity group, IL-8 levels had a positive correlation with fasting insulin
levels and homeostasis model assessment for insulin resistance (HOMA-IR). A casecontrol study by Zozulinska et al (59) reported that serum IL-8 levels in participants with
type 1 and type 2 diabetes mellitus were higher than healthy participants (160.29 ± 34.81
and 138.7 ± 32.8 pg/ml VS 39.93 ± 4.96 pg/ml).
Serum leptin levels reflect the proportion of adipose tissue in the body, which is
highly correlated with fat mass. During pregnancy, leptin is also produced by placenta,
which has a pro-angiogenic effect in placental tissue (60) and an anti-apoptotic effect on
trophoblast cells (61). A study by Pérez-Pérez et al reported increased leptin and leptin
receptor gene expression in placentas from GDM pregnancies compared with normal
pregnancies (62). Many studies reported that leptin levels were significantly higher in
pregnancies with GDM compared with normal pregnancies (63-65). Studies focusing on
the association between either hyperleptinemia or leptin expression and birth defects are
limited. A study by Jones et al. (66) found that placental leptin RNA expression was
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significantly increased in hypoplastic left heart syndrome (HLHS) cases compared to
controls. However, a meta-analysis study reported that SGA (small for gestational age)
infants had lower cord blood leptin levels than AGA (appropriate for gestational age)
infants (67). An impact of increased leptin levels on placental nutrient transfer was
proposed by a cell study by Araujo et al (68). The study showed that there is no
significant change of the steady-state intracellular accumulation of folic acid, while
diabetic trophoblasts (DTB) cells from gestational diabetic pregnancies had higher rates
of inward and outward transport of intracellular folic acid. The higher turnover of
intracellular folic acid in DTB cells is required to maintain normal folic acid homeostasis.
Moreover, hyperleptinemic condition leads to decreased folic acid uptake. These findings
showed that leptin may act as a regulator of placental nutrient transport especially folic
acid, and a regulator of fetal growth. However, the study of that effect of leptin on folic
acid placental transport is limited.
The leptin gene is transcriptionally activated in response to hypoxia (69). A
mouse study by Webster et al. (70) showed that pregnant mice receiving phenytoin
during the period of early facial development had cleft lip offspring because phenytoin
causes bradycardia leading to a prolonged period of embryonic hypoxia. This study
proposed additional exposures increase the risk of cleft lip in humans including maternal
cigarette smoking, residence at high altitudes, and exposure to corticosteroids. High
leptin circulation decreases folic acid transportation (68), which may relate to not only
GDM pregnancies, but also pregnancies exposed to prolonged hypoxia. The association
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between increased leptin resulting from hypoxia and risk of birth defect requires further
study.
Our results suggest that gestational diabetes, maternal obesity, and metabolic
syndrome are associated with an increased risk of OFCs. When compared with control
mothers, mothers having cleft palate offspring had higher insulin, IL-8, and leptin levels.
Therefore, insulin, IL-8, and leptin levels may be links between GDM, metabolic
syndrome, and OFCs. Insulin, IL-8 and leptin might be performed as biomarkers for
predicting OFC occurrence. Mechanistic studies are needed to understand the causal
effects of maternal obesity, metabolic abnormalities, and gestational diabetes mellitus on
OFCs risk. The potential of using insulin, leptin, IL-8 and related biomarkers as
predictors of birth defect risk requires further study.
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Table 4.2 Tracking status of orofacial cleft (OFC) cases and controls in the Utah Cleft 2
Study.
Status
Completed interview, clinical visit, and
blood collection
Completed interview, clinical visit, and no
blood collection
Completed only interview, no clinical
visit, and no blood collection
Completed clinical visit and blood
collection, and no interview
Completed only blood collection
Refuse
Move out of state
Out of clinic area
Unable to contact or schedule
Non-isolated OFCs
Spanish speaking
Deceased
OFC: Orofacial cleft

Controls
n (%)
344 (38.0)

OFC cases
n (%)
268 (31.3)

4 (0.4)

2 (0.2)

74 (8.2)

83 (9.7)

5 (0.6)

3 (0.4)

8 (0.9)
116 (12.8)
135 (14.9)
25 (2.8)
189 (20.9)
0 (0)
5 (0.6)
0 (0)

3 (0.4)
51 (6.0)
70 (8.2)
15 (1.8)
352 (41.1)
1 (0.1)
8 (0.9)
1 (0.1)

Table 4.3 Demographic characteristics of isolated orofacial cleft case and controls: The Utah Cleft 2 Study
Characteristic

Maternal age at birth
of index child (SD)
p-value1
Maternal age at blood
collection (SD)
p-value1
Number of past
pregnancies (%)
p-value1
Number of live birth
(%)
p-value1
Current weight (lb)
p-value1
Current height (cm)
p-value1
Current BMI (kg/m2)
p-value1

Controls
n= 436
27.8(5.3)

All OFCs
n=358
27.5(5.3)

CLO
n=112
27.4(5.0)

Orofacial cleft cases
CL/P
CLP
n=268
n=156
27.5(5.2)
27.6(5.2)

n=360
37.7(7.0)

0.44
n=274
37.4(6.5)

0.40
n=90
36.9(6.3)

0.46
n=211
37.4(6.6)

n=423
4.5(2.21)

0.62
n=349
4.2(1.98)

0.33
n=109
4.2 (1.9)

n=423
4.1(6.7)

0.04
n=349
4.0(7.4)

0.27
n=109
3.5(1.5)

0.77
n=269
168.3(43.9)
0.18
n=268
164.4(7.6)
0.75
n = 267
28.37.5
0.26

0.36
n=89
170.4(44.6)
0.17
n=89
164.6(8.0)
0.98
n = 89
28.57.0
0.29

n=351
163.8(40.5)
n=351
164.6(8.5)
n=351
27.67.5

CPO
n=90
27.54(5.70)

CP/L
n=246
27.6(5.4)

0.24
n=121
37.7(6.9)

0.27
n=63
37.7(6.2)

0.56
n=184
37.7(6.6)

0.56
n=261
4.3(2.0)

0.98
n=152
4.3(2.1)

0.97
n=88
3.9(1.9)

0.97
n=240
4.2(2.0)

0.18
n=261
3.8(6.1)

0.34
n=152
4.1(7.9)

0.01
n=88
4.4(10.4)

0.05
n=240
4.2(8.9)

0.59
0.94
0.79
0.93
n=208
n=119
n=61
n=180
168.4(44.2) 166.9(44.1) 167.9(43.4) 167.2(43.7)
0.20
0.47
0.47
0.36
n=207
n=118
n=61
n=179
164.6(8.0) 164.6(8.0) 163.9(6.4) 164.3(7.50)
0.96
0.96
0.49
0.69
n = 207
n = 118
n = 60
n = 178
28.37.3
28.17.6
28.36.9
28.17.4
0.30
0.55
0.52
0.43
314

Table 4.3 Demographic characteristics of isolated orofacial cleft case and controls: The Utah Cleft 2 Study (Cont.)
Characteristic
Type 1 diabetes
mellitus
p-value2
Type 2 diabetes
mellitus
p-value2
Gestational diabetes
mellitus
p-value2
Maternal smoking in
past 3 months (%)
p-value2
Second hand smoking
(%)
p-value2
Maternal alcohol
consumption in past 3
months (%)
p-value2

Control

n=422
5 (1.2)

All OFCs
n=349
2 (0.6)
1.00
n=348
7 (2.0)

CLO
n=109
0 (0)
1.00
n=109
1 (0.9)

Orofacial cleft cases
CL/P
CLP
n=261
n=152
0 (0)
0 (0)
0.29
0.57
n=260
n=151
6 (2.3)
5 (3.3)

CPO
n=88
2 (2.3)
0.21
n=88
1 (1.1)

CP/L
n=240
2 (0.8)
1.00
n=239
6 (2.5)

n=422
14 (3.3)

0.39
n=348
33 (9.5)

1.00
n=109
10 (9.2)

0.35
n=260
24 (9.2)

0.14
n=151
14 (9.3)

1.00
n=88
9 (10.2)

0.22
n=239
23 (9.6)

n=423
19 (4.5)

<0.001
n=349
39 (11.2)

0.02
n=109
10 (9.2)

0.002
n=261
26 (10)

0.007
n=152
16 (10.5)

0.009
n=88
13 (14.9)

0.001
n=240
29 (12.1)

n=420
17 (4.0)

0.001
n=347
29 (8.4)

0.06
n=108
7 (6.5)

0.007
n=259
22 (8.5)

0.02
n=151
15 (9.9)

0.001
n=88
7 (8.0)

<0.001
n=239
22 (9.2)

n=422
86 (20.4)

0.01
n=349
93 (26.7)

0.30
n=109
28 (27.5)

0.02
n=261
66 (25.3)

0.01
n=152
38 (25.0)

0.16
n=88
27 (31.0)

0.009
n=240
65 (27.2)

0.04

0.24

0.13

0.25

0.05

0.05

n=422
3 (0.7)
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Table 4.3 Demographic characteristics of isolated orofacial cleft case and controls: The Utah Cleft 2 Study (Cont.)
Characteristic

Control
All OFCs

CLO

Orofacial cleft cases
CL/P
CLP

CPO

CP/L

Frequency of alcohol
consumption in past 3
months (%)
Never
337 (79.7)
256 (73.6)
61 (70.1)
195 (74.7)
114 (75.0)
81 (74.3)
175 (73.2)
< 1 time/month
30 (7.1)
31 (8.9)
11 (12.6)
20 (7.7)
10 (6.6)
10 (9.2)
21 (8.8)
1-3 times/month
27 (6.4)
36 (10.3)
7 (8.0)
29 (11.1)
20 (13.2)
9 (8.3)
27 (11.3)
1-2 times/week
21 (5.0)
18 (5.2)
5 (5.7)
13 (5.0)
6 (3.9)
7 (6.4)
11 (4.6)
3-4 times/week
8 (1.9)
7 (2.0)
3 (3.4)
4 (1.5)
2 (1.3)
2 (1.8)
5 (2.1)
p-trend
0.12
0.13
0.25
0.39
0.33
0.15
OFCs: orofacial clefts; CPO: cleft palate only; CLO: cleft lip only; CLP: cleft lip with cleft palate; CL/P: cleft lip with or without cleft
palate; CP/L: cleft palate with or without cleft lip.
1
p-value for independent t-test for OFC group compared to controls.
2
p-value for chi-square for OFC group compared to controls.
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Table 4.4 Odds ratio analysis of maternal diabetes history and risk of orofacial clefts
Diabetes history
All OFCs

CLO

Odds ratios (95 percent confidence intervals)
CL/P
CLP
CPO

CP/L

Type 2 diabetes
mellitus
No
1 [reference]
1 [reference]
1 [reference]
1 [reference]
1 [reference]
1 [reference]
Yes
1.71 [0.54-5.44] 0.77 [0.09-6.68] 1.97 [0.60-6.52] 2.86[0.82-10.01] 0.96 [0.11-8.31] 2.15 [0.65-7.11]
Gestational
diabetes mellitus
No
1 [reference]
1 [reference]
1 [reference]
1 [reference]
1 [reference]
1 [reference]
Yes
3.05 [1.61-5.80] 2.94 [1.27-6.82] 2.96 [1.50-5.84] 2.98 [1.39-6.40] 3.32 [1.39-7.94] 3.10 [1.57-6.15]
OFCs: orofacial clefts; CPO: cleft palate only; CLO: cleft lip only; CLP: cleft lip with cleft palate; CL/P: cleft lip with or without cleft
palate; CP/L: cleft palate with or without cleft lip.
History of GDM at any pregnancy
History of type 2 diabetes at any time.
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Table 4.5 Mean metabolic syndrome-related biomarkers by orofacial cleft case groups and controls: The Utah Cleft 2 Study
Biomarker

Systolic BP (mmHg)
Unadjusted p-value
Adjusted p-value
Diastolic BP (mmHg)
Unadjusted p-value
Adjusted p-value
Waist (cm)
Unadjusted p-value
Adjusted p-value
Glucose (mg/dL)
Unadjusted p-value
Adjusted p-value
Insulin (μlU/mL)
Unadjusted p-value
Adjusted p-value
HbA1c (%)
Unadjusted p-value
Adjusted p-value

Control
n = 353
109.412.2

n = 353
71.89.1

n = 352
92.317.2

329
91.020.4

n = 316
19.726.8

n = 324
5.420.30

All OFCs
n = 268
110.512.0
0.30
0.71
n = 268
72.510.4
0.43
0.88
n = 268
94.418.0
0.14
0.06
n = 248
93.425.7
0.22
0.07
n = 233
21.624.4
0.40
0..01
n = 246
5.440.53
0.66
0.58

CLO
n = 89
110.411. 7
0.53
0.58
n = 89
72.49.8
0.59
0.85
n = 89
94.317.3
0.32
0.75
n = 82
93.030.6
0.49
0.99
n = 78
15.715.2
0.21
0.14
n = 83
5.450.54
0.49
0.52

Orofacial cleft cases
CL/P
CLP
n = 208
n = 119
109.811.8
109.411.9
0.74
0.96
0.88
0.48
n = 208
n = 119
72.110.5
71.811.1
0.79
0.98
0.64
0.57
n = 208
n = 119
93.917.9
93.718.4
0.27
0.44
0.16
0.09
n = 189
n = 107
93.026.0
93.022.0
0.34
0.39
0.13
0.04
n = 182
n = 104
20.421.6
24.025.0
0.76
0.16
0.68
0.10
n = 187
n = 104
5.430.45
5.410.36
0.85
0.74
0.54
0.69

CPO
n = 60
112.812.5
0.05
0.23
n = 60
73.89.8
0.12
0.16
n = 60
95.818.6
0.14
0.07
n = 59
94.624.6
0.23
0.21
n = 51
25.832.3
0.21
0.14
n = 59
5.470.73
0.41
0.88

CP/L
n = 179
110.512.2
0.34
0.96
n = 179
72.510.7
0.49
0.81
n = 179
94.418.4
0.19
0.03
n = 166
93.622.9
0.21
0.02
n = 155
24.627.5
0.07
0.04
n = 163
5.430.52
0.81
0.71
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Table 4.5 Mean metabolic syndrome-related biomarkers by orofacial cleft case groups and controls: The Utah Cleft 2 Study (Cont.)
Biomarker

Cholesterol (mg/dL)
Unadjusted p-value
Adjusted p-value
Triglyceride (mg/dL)
Unadjusted p-value
Adjusted p-value
HDL (mg/dL)
Unadjusted p-value
Adjusted p-value
LDL (mg/dL)
Unadjusted p-value
Adjusted p-value
VLDL (mg/dL)
Unadjusted p-value
Adjusted p-value
LDL/HDL ratio
Unadjusted p-value
Adjusted p-value

Control
n = 328
177.533.6

n = 329
110.369.5

329
55.514.4

n = 328
99.928.0

n = 328
21.813.2

n = 328
1.920.75

All OFCs
n = 247
176.336.6
0.70
0.48
n = 247
118.281.3
0.21
0.03
n = 247
54.214.3
0.28
0.02
n = 244
98.631.3
0.59
0.64
n = 244
22.713.6
0.44
0.99
n = 244
1.950.86
0.60
0.88

CLO
n = 82
173.232.2
0.30
0.66
n = 82
107.854.6
0.76
0.57
n = 82
54.113.7
0.40
0.40
n = 82
97.627.9
0.50
0.99
n = 82
21.611.0
0.88
0.61
n = 82
1.920.72
0.99
0.81

Orofacial cleft cases
CL/P
CLP
n = 188
n = 106
173.834.6
174.236.6
0.23
0.40
0.27
0.22
n = 188
n = 106
113.472.5
117.783.7
0.63
0.37
0.19
0.19
n = 188
n = 106
54.113.9
54.114.0
0.27
0.38
0.06
0.05
n = 187
n = 105
97.030.6
96.632.7
0.27
0.31
0.45
0.28
n = 187
n = 105
22.313.3
22.815.0
0.70
0.50
0.93
0.79
n = 187
n = 105
1.930.84
1.930.93
0.91
0.88
0.84
0.91

CPO
n = 59
184.441.4
0.16
0.56
n = 59
133.4103.8
0.10
0.01
n = 59
54.615.9
0.66
0.08
n = 57
103.833.10
0.35
0.63
n = 57
24.014.4
0.26
0.91
n = 57
2.050.91
0.26
0.40

CP/L
n = 165
177.838.6
0.91
0.51
n = 165
123.391.4
0.11
0.02
n = 165
54.314.7
0.37
0.02
n = 162
99.132.9
0.78
0.53
n = 162
23.214.7
0.28
0.79
n = 162
1.970.92
0.52
0.78
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Table 4.5 Mean metabolic syndrome-related biomarkers by orofacial cleft case groups and controls: The Utah Cleft 2 Study (Cont.).
Biomarker

Alkaline
phosphatase (IU/L)
Unadjusted p-value
Adjusted p-value

Control
n = 328
64.318.7

All OFCs
n = 247
65.820.1

CLO
n = 81
64.418.9

Orofacial cleft cases
CL/P
CLP
n = 188
n = 107
65.920.2
67.121.1

CPO
n = 59
65.219.7

CP/L
n = 166
66.420.6

0.36
0.95
0.35
0.19
0.73
0.25
0.60
0.72
0.50
0.21
0.86
0.37
n = 328
n = 247
n = 81
n = 188
n = 107
n = 59
n = 166
ALT (SGPT) (IU/L)
18.18.9
19.210.4
19.510.4
19.611.2
19.611.8
18.17.1
19.110.4
Unadjusted p-value
0.15
0.20
0.09
0.15
1.00
0.26
Adjusted p-value
0.18
0.30
0.11
0.14
0.96
0.25
n = 328
n = 247
n = 81
n = 188
n = 107
n = 59
n = 166
AST (SGOT)(IU/L)
18.15.1
19.413.2
20.316.6
19.914.8
19.613.4
17.95.8
19.011.3
Unadjusted p-value
0.14
0.25
0.11
0.26
0.74
0.34
Adjusted p-value
0.08
0.05
0.05
0.08
0.94
0.15
OFCs: orofacial clefts; CPO: cleft palate only; CLO: cleft lip only; CLP: cleft lip with cleft palate; CL/P: cleft lip with or without cleft
palate; CP/L: cleft palate with or without cleft lip.
BP: blood pressure, WC: waist circumference, HbA1c: Hemoglobin A1c, HDL: high-density lipoprotein cholesterol, LDL: Lowdensity lipoprotein, VLDL: Very low-density lipoprotein ALT: Alanine Aminotransferase, AST: Aspartate Aminotransferase.
NCEP/ATP III: National Cholesterol Education Program, Adult Treatment Panel III
IDF: International Diabetes Federation
Unadjusted p-value for independent sample t-test
Adjusted p-value form analysis of covariance model including maternal age and smoking (Model)
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Table 4.6 Cytokine and adipokine levels of orofacial cleft cases and controls: The Utah Cleft 2 Study
Control
(n = 241)
Adiponectin
(ng/ml)
%Undetected
Median1IQR
Mean2SD
p-valuea
p-valueb
CRP (ng/ml)
%Undetected
Median1IQR
Mean2SD
p-valuea
p-valueb
IL-1a (pg/ml)
%Undetected
Median1IQR
Mean2SD
p-valuea
p-valueb

Orofacial cleft cases
CL/P
CLP
(n = 138)
(n = 78)

All OFCs
(n = 182)

CLO
(n = 60)

CPO
(n = 44)

CP/L
(n = 122)

0
89217379
10937560

0
76898220
10413644
0.54
0.70

0
736010204
107921185
0.91
0.82

0
78938412
10489749
0.63
0.79

0
85228223
10256971
0.54
0.61

0
72308120
101731327
0.60
0.81

0
82738083
10226767
0.45
0.57

1.2
23324
123764
159345
384310

0
33834
115461
152771
427596
0.59
0.67

0
26365
58834
79971.1
155579.0
0.47
0.41

0
30200
73054
147468
469983
0.88
0.84

0
35225
121045
199388
606773
0.70
0.72

0
50447
241589
169406
255936
0.11
0.15

0
38130
146133
188575
507720
0.25
0.29

21.2
3.514.50
3.692.80

17.6
3.704.34
3.852.63
0.99
0.94

15.0
4.194.14
4.252.79
0.32
0.52

17.4
3.724.40
3.932.70
0.71
0.88

19.2
3.464.50
3.692.63
0.74
0.73

18.2
3.283.25
3.582.38
0.47
0.54

18.9
3.354.27
3.652.53
0.52
0.58
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Table 4.6 Cytokine and adipokine levels of orofacial cleft cases and controls: The Utah Cleft 2 Study (Cont.)
Control
(n = 241)
IL-6 (pg/ml)
%Undetected
Median1IQR
Mean2SD
p-valuea
p-valueb
IL-8 (pg/ml)
%Undetected
Median1IQR
Mean2SD
p-valuea
p-valueb
Leptin (ng/ml)
%Undetected
Median1IQR
Mean2SD
p-valuea
p-valueb
Resistin (ng/ml)
%Undetected
Median1IQR
Mean2SD
p-valuea
p-valueb

All OFCs
(n = 182)

CLO
(n = 60)

Orofacial cleft cases
CL/P
CLP
(n = 138)
(n = 78)

CPO
(n = 44)

CP/L
(n = 122)

11.6
3.823.15
3.873.22

12.6
4.023.55
3.892.55
0.93
0.91

11.7
4.384.00
4.272.94
0.53
0.54

13.0
4.363.56
4.042.61
0.35
0.34

14.1
4.253.20
3.862.32
0.40
0.38

11.4
3.103.49
3.422.32
0.10
0.11

13.1
3.583.38
3.702.32
0.76
0.83

34.9
2.851.59
3.181.21

33.5
3.051.78
3.451.88
0.03
0.02

35.0
2.691.53
3.191.33
0.88
0.47

37.7
2.711.61
3.221.35
0.40
0.60

39.7
2.831.72
3.241.38
0.16
0.16

20.5
3.322.21
4.162.89
<0.001
0.001

32.8
3.121.93
3.572.09
0.003
0.003

0.8
8.7915.36
18.4023.16

0
10.1433.50
26.8739.83
0.04
0.06

0
8.9923.68
20.1426.67
0.83
0.71

0
9.6331.21
26.4742.91
0.13
0.26

0
10.7834.68
31.3451.73
0.03
0.05

0
11.0637.48
28.1328.44
0.01
0.01

0
10.8735.14
30.1844.64
0.004
0.006

1.7
29243284
22351602

1.1
26863283
21931740
0.74
0.92

3.3
26863298
23691947
0.46
0.45

1.4
26713239
21321771
0.54
0.61

0
25163150
19491611
0.12
0.16

0
28173368
23861643
0.66
0.47

0
26893274
21071630
0.35
0.50
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Table 4.6 Cytokine and adipokine levels of orofacial cleft cases and controls: The Utah Cleft 2 Study (Cont.)
Control
(n = 241)

All OFCs
(n = 182)

CLO
(n = 60)

Orofacial cleft cases
CL/P
CLP
(n = 138)
(n = 78)

CPO
(n = 44)

CP/L
(n = 122)

TNF-α (pg/ml)
%Undetected
7.1
7.1
5.0
5.8
6.4
11.4
8.2
1
Median IQR
12.077.61
12.528.36
13.086.06
12.687.99
12.326.36
12.079.38
12.327.81
Mean2SD
12.7611.09
13.097.43
14.128.05
13.417.55
12.877.14
12.077.04
12.587.09
a
p-value
0.50
0.27
0.43
0.83
0.98
0.86
p-valueb
0.46
0.31
0.41
0.75
0.96
0.74
OFCs: orofacial clefts; CPO: cleft palate only; CLO: cleft lip only; CLP: cleft lip with cleft palate; CL/P: cleft lip with or without cleft
palate; CP/L: cleft palate with or without cleft lip.
CRP: C-reactive protein, IL-1a: Interleukin-1 alpha, IL-6: Interleukin-6, IL-8: Interleukin-8, TNF-α: Tumor necrosis factor alpha
1
median and interquartile range (IQR) from all samples
2
mean and standard deviation (SD)
a
Unadjusted p-value for test difference to control among detected group (two-way ANOVA)
b
Adjusted p-value for test difference to control among detected group with analysis of covariance model including maternal age and
smoking (two-way ANOVA).
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Table 4.7 Odds ratio analysis of body mass index and biomarkers related to metabolic syndrome and risk of orofacial clefts: The Utah
Cleft 2 Study
Odds ratios (95 percent confidence intervals)
CL/P
CLP
CPO

All OFCs

CLO

CP/L

0.77 [0.22-2.61]
Reference
1.09 [0.72-1.63]
1.45 [0.99-2.13]
p-trend 0.06

0.63 [0.08-5.18]
Reference
0.86 [0.45-1.66]
2.01 [1.17-3.45]
p-trend 0.012

1.03 [0.30-3.52]
Reference
1.13 [0.73-1.75]
1.53 [1.01-2.31]
p-trend 0.048

1.31 [0.33-5.15]
Reference
1.31 [0.78-2.20]
1.19 [0.71-2.00]
p-trend 0.47

N/A
Reference
0.97 [0.49-1.93]
1.24 [0.65-2.35]
p-trend 0.54

0.83 [0.21-3.22]
Reference
1.19 [0.76-1.86]
1.21 [0.78-1.87]
p-trend 0.39

1 (reference)
1.13 (0.76-1.69)
1.16 (0.78-1.75)
p-trend 0.46

1 (reference)
0.92 (0.52-1.64)
0.85 (0.47-1.54)
p-trend 0.59

1 (reference)
1.18 (0.77-1.82)
1.20 (0.77-1.86)
p-trend 0.42

1 (reference)
1.47 (0.85-2.54)
1.58 (0.92-2.74)
p-trend 0.10

1 (reference)
0.99 (0.50-1.94)
1.07 (0.54-2.09)
p-trend 0.86

1 (reference)
1.27 (0.80-2.00)
1.37 (0.86-2.17)
p-trend 0.19

1 (reference)
0.73 (0.49-1.08)
0.87 (0.58-1.32)
p-trend 0.41

1 (reference)
0.86 (0.49-1.52)
0.96 (0.53-1.76)
p-trend 0.85

1 (reference)
0.73 (0.47-1.12)
1.04 (0.67-1.61)
p-trend 0.98

1 (reference)
0.63 (0.36-1.08)
1.09 (0.64-1.85)
p-trend 0.90

1 (reference)
0.73 (0.39-1.35)
0.45 (0.20-0.99)
p-trend 0.04

1 (reference)
0.67 (0.43-1.04)
0.83 (0.52-1.33)
p-trend 0.33

1 (reference)
1.07 (0.70-1.61)
1.25 (0.83-1.90)
p-trend 0.29

1 (reference)
0.91 (0.50-1.64)
0.87 (0.47-1.61)
p-trend 0.66

1 (reference)
1.06 (0.68-1.67)
1.26 (0.80-1.97)
p-trend 0.32

1 (reference)
1.23 (0.70-2.16)
1.65 (0.95-2.86)
p-trend 0.07

1 (reference)
1.07 (0.52-2.23)
1.24 (0.60-2.56)
p-trend 0.56

1 (reference)
1.17 (0.72-1.90)
1.50 (0.93-2.41)
p-trend 0.09

2

BMI (kg/m )
Underweight
Normal
Overweight
Obese
Glucose (mg/dl)
≤ 84
85-93
≥ 94
HbA1c (%)
≤ 5.30
> 5.30 - 5.50
> 5.50
Insulin
(μlU/mL)
≤ 7.80
>7.80 -18.10
> 18.10
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Table 4.7 Table 4.7 Odds ratio analysis of body mass index and biomarkers related to metabolic syndrome and risk of orofacial clefts:
The Utah Cleft 2 Study (Cont.)

All OFCs
Cholesterol
(mg/dL)
≤ 161
162-188
≥189
Triglyceride
(mg/dL)
≤ 70
71-120
≥ 121
HDL (mg/dL)
≤ 48
49-61
≥ 62
LDL (mg/dL)
≤ 86
87-109
≥ 110

Odds ratios (95 percent confidence intervals)
CLO
CL/P
CLP

CPO

CP/L

1 (reference)
1.04 (0.70-1.56)
1.09 (0.73-1.63)
p-trend 0.67

1 (reference)
1.06 (0.59-1.88)
0.88 (0.48-1.61)
p-trend 0.69

1 (reference)
0.99 (0.64-1.53)
0.92 (0.59-1.43)
p-trend 0.72

1 (reference)
0.94 (0.56-1.61)
0.95 (0.56-1.62)
p-trend 0.86

1 (reference)
1.27 (0.61-2.64)
1.85 (0.93-3.68)
p-trend 0.07

1 (reference)
1.04 (0.65-1.65)
1.21 (0.77-1.90)
p-trend 0.42

1 (reference)
1.07 (0.71-1.60)
1.20 (0.80-1.79)
p-trend 0.38

1 (reference)
1.13 (0.63-2.05)
1.11 (0.62-2.02)
p-trend 0.72

1 (reference)
0.95 (0.61-1.47)
1.05 (0.68-1.62)
p-trend 0.84

1 (reference)
0.82 (0.48-1.41)
1.00 (0.60-1.69)
p-trend 0.99

1 (reference)
1.64 (0.79-3.39)
1.91 (0.94-3.89)
p-trend 0.08

1 (reference)
1.03 (0.65-1.64)
1.24 (0.79-1.95)
p-trend 0.36

1 (reference)
0.79 (0.53-1.18)
0.72 (0.48-1.08)
p-trend 0.11

1 (reference)
0.71 (0.36-1.41)
0.80 (0.41-1.55)
p-trend 0.49

1 (reference)
0.82 (0.53-1.26)
0.70 (0.45-1.09)
p-trend 0.11

1 (reference)
0.72 (0.42-1.22)
0.70 (0.41-1.18)
p-trend 0.17

1 (reference)
0.96 (0.54-1.71)
0.71 (0.38-1.30)
p-trend 0.27

1 (reference)
0.72 (0.45-1.13)
0.73 (0.46-1.15)
p-trend 0.16

1 (reference)
0.88 (0.59-1.32)
0.84 (0.56-1.27)
p-trend 0.41

1 (reference)
1.05 (0.59-1.86)
0.79 (0.43-1.46)
p-trend 0.46

1 (reference)
0.84 (0.55-1.29)
0.72 (0.46-1.12)
p-trend 0.15

1 (reference)
0.70 (0.42-1.20)
0.67 (0.39-1.15)
p-trend 0.14

1 (reference)
1.07 (0.52-2.20)
1.39 (0.69-2.77)
p-trend 0.34

1 (reference)
0.80 (0.51-1.27)
0.87 (0.55-1.37)
p-trend 0.53
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Table 4.7 Odds ratio analysis of body mass index and biomarkers related to metabolic syndrome and risk of orofacial clefts: The Utah
Cleft 2 Study (Cont.)

VLDL (mg/dL)
≤ 14
15-24
≥ 25

Odds ratios (95 percent confidence intervals)
CL/P
CLP

All OFCs

CLO

1 (reference)
1.10 (0.74-1.65)
1.19 (0.79-1.78)
p-trend 0.41

1 (reference)
1.22 (0.67-2.19)
1.23 (0.68-2.23)
p-trend 0.49

1 (reference)
0.94 (0.61-1.45)
1.07 (0.70-1.65)
p-trend 0.77

1 (reference)
0.76 (0.44-1.31)
0.97 (0.58-1.64)
p-trend 0.87

CPO

CP/L

1 (reference)
1.92 (0.94-3.93)
1.76 (0.85-3.65)
p-trend 0.14

1 (reference)
1.05 (0.66-1.66)
1.17 (0.74-1.84)
p-trend 0.52

LDL/HDL ratio
≤ 1.50
> 1.50-2.13
> 2.13

1 (reference)
1 (reference)
1 (reference)
1 (reference)
1 (reference)
1 (reference)
0.78 (0.52-1.18) 0.97 (0.53-1.77) 0.75 (0.48-1.17) 0.62 (0.36-1.07) 0.90 (0.44-1.82) 0.70 (0.44-1.12)
0.99 (0.66-1.48) 1.19 (0.66-2.16) 0.95 (0.61-1.46) 0.80 (0.47-1.36) 1.16 (0.58-2.29) 0.91 (0.58-1.43)
p-trend 0.97
p-trend 0.56
p-trend 0.80
p-trend 0.39
p-trend 0.67
p-trend 0.67
OFCs: orofacial clefts; CPO: cleft palate only; CLO: cleft lip only; CLP: cleft lip with cleft palate; CL/P: cleft lip with or without cleft
palate; CP/L: cleft palate with or without cleft lip.
BMI: body mass index, HbA1c: Hemoglobin A1c, HDL: high-density lipoprotein cholesterol, LDL: Low-density lipoprotein, VLDL:
Very low-density lipoprotein, ALT: Alanine Aminotransferase, AST: Aspartate Aminotransferase.
BMI: underweight, ≤ 18.5 kg/m2; normal, 18.5-24.9 kg/m2; overweight, 25.-29.9 kg/m2; obese, ≥ 30 kg/m2.

326

Table 4.8 Risk of orofacial clefts associated with NCEP/ATP III and IDF metabolic syndrome criteria and components.
All OFCs

CLO

Odds ratios (95 percent confidence intervals)
CL/P
CLP
CPO

CP/L

MET score
(NCEP/ATP
III)
<3
1 [reference]
1 [reference]
1 [reference]
1 [reference]
1 [reference]
1 [reference]
≥3
1.42 [0.92-2.17] 1.06 [0.54-2.05] 1.31 [0.82-2.09] 1.51[0.88-2.60] 1.78 [0.91-3.49] 1.60 [1.00-2.56]
MET score (IDF)
WC < 80 cm
1 [reference]
1 [reference]
1 [reference]
1 [reference]
1 [reference]
1 [reference]
WC > 80 cm + 2
1.48 [0.98-2.24] 1.16 [0.62-2.17] 1.38 [0.89-2.18] 1.58 [0.93-2.67] 1.78 [0.92-3.42] 1.64 [1.04-2.59]
more
Systolic BP ≥ 130 or 1.51 [0.91-2.53] 1.03 [0.46-2.32] 1.30 [0.73-2.29] 1.50 [0.78-2.89] 2.34 [1.10-4.96] 1.77 [1.02-3.09]
diastolic BP ≥ 85
mmHg
WC > 88 cma
1.09 [0.79-1.50] 1.18 [0.74-1.89] 1.11 [0.79-1.57] 1.06 [0.70-1.61] 1.04 [0.58-1.75] 1.04 [0.73-1.50]
WC > 80 cmb
1.13 [0.78-1.64] 1.03 [0.60-1.77] 1.16 [0.77-1.74] 1.27 [0.77-2.10] 1.04 [0.55-1.95] 1.18 [0.77-1.81]
TG ≥ 150 mg/dL
1.05 [0.70-1.58] 0.77 [0.40-1.47] 1.00 [0.64-1.55] 1.18 [0.70-1.97] 1.24 [0.65-2.39] 1.20 [0.77-1.87]
HDL < 50 mg/dL
1.22 [0.87-1.69] 1.16 [0.71-1.90] 1.21 [0.84-1.73] 1.25 [0.81-1.93] 1.23 [0.71-2.15] 1.24 [0.86-1.80]
a
FPG > 110 mg/dL
1.41 [0.70-2.84] 1.01 [0.33-3.10] 1.30 [0.60-2.81] 1.52 [0.63-3.67] 1.75 [0.62-4.98] 1.61 [0.75-3.42]
b
FPG > 100 mg/dL
1.20 [0.65-2.23] 0.87 [0.32-2.35] 1.13 [0.57-2.21] 1.32 [0.61-2.87] 1.46 [0.57-3.74] 1.37 [0.70-2.67]
OFCs: orofacial clefts; CPO: cleft palate only; CLO: cleft lip only; CLP: cleft lip with cleft palate; CL/P: cleft lip with or without cleft
palate; CP/L: cleft palate with or without cleft lip.
BP: blood pressure, WC: waist circumference, TG: triglyceride, HDL: high-density lipoprotein cholesterol, FPG: fasting plasma
glucose
a National Cholesterol Education Program, Adult Treatment Panel III
b
International Diabetes Federation
MET: metabolic syndrome
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NCEP/ATP III: National Cholesterol Education Program, Adult Treatment Panel III [raised waist circumference (≥ 102 cm in males,
≥ 88 cm in females), raised blood pressure (systolic blood pressure ≥ 130 mmHg or diastolic blood pressure ≥ 85 mmHg), raised
triglyceride (≥ 150 mg/dL), reduced HDL cholesterol (<40 mg/dL in males, <50 mg/dL in females), raised fasting plasma glucose
(fasting plasma glucose ≥ 110 mg/dL or previous diagnosed type 2 diabetes)]
IDF: International Diabetes Federation [raised waist circumference (≥ 94 cm in males, ≥ 80 cm in females), raised blood pressure
(systolic blood pressure ≥ 130 mmHg or diastolic blood pressure ≥ 85 mmHg), raised triglyceride (≥ 150 mg/dL), reduced HDL
cholesterol (<40 mg/dL in males, <50 mg/dL in females), raised fasting plasma glucose (fasting plasma glucose ≥ 100 mg/dL or
previous diagnosed type 2 diabetes)]
WC: Waist circumference
N/A: Not applicable
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Table 4.9 Risk of orofacial clefts associated with cytokine and adipokine levels.
Tertile
Adiponectin (mg/L)
≤ 6199.51
> 6199.5210907.73
≥ 10907.73
CRP (mg/L)
≤ 14061.55
> 14061.5571263.16
> 71263.16
IL-1a (pg/ml)
≤ 2.08
> 2.08-4.96
> 4.96
IL-6 (pg/ml)
≤ 2.78
> 2.78-5.01
> 5.01

Odds ratios (95 percent confidence intervals)
CL/P
CLP
CPO

All OFCs

CLO

CP/L

1 (reference)
0.73 (0.45-1.17)

1 (reference)
0.79 (0.40-1.56)

1 (reference)
0.73 (0.44-1.22)

1 (reference)
0.68 (0.36-1.30)

1 (reference)
0.72 (0.33-1.55)

1 (reference)
0.70 (0.41-1.19)

0.80 (0.50-1.27)
p-trend 0.34

0.74 (0.37-1.48)
p-trend 0.39

0.83 (0.50-1.38)
p-trend 0.48

0.90 (0.49-1.66)
p-trend 0.76

0.69 (0.31-1.52)
p-trend 0.35

0.82 (0.49-1.39)
p-trend 0.47

1 (reference)
1.28 (0.80-2.05)

1 (reference)
1.31 (0.68-2.54)

1 (reference)
1.28 (0.77-2.11)

1 (reference)
1.24 (0.66-2.33)

1 (reference)
1.31 (0.55-3.08)

1 (reference)
1.26 (0.73-2.18)

1.17 (0.73-1.88)
p-trend 0.51

0.72 (0.34-1.51)
p-trend 0.43

0.98 (0.58-1.65)
p-trend 0.96

1.21 (0.65-2.27)
p-trend 0.55

1.96 (0.88-4.34)
p-trend 0.09

1.45 (0.85-2.47)
p-trend 0.18

1 (reference)
1.12 (0.70-1.79)
1.17 (0.73-1.87)
p-trend 0.52

1 (reference)
1.26 (0.61-2.63)
1.68 (0.84-3.39)
p-trend 0.14

1 (reference)
1.02 (0.60-1.71)
1.27 (0.77-2.11)
p-trend 0.35

1 (reference)
0.87 (0.47-1.64)
1.04 (0.56-1.92)
p-trend 0.91

1 (reference)
1.44 (0.68-3.07)
0.85 (0.36-1.98)
P-trend 0.75

1 (reference)
1.06 (0.63-1.80)
0.97 (0.57-1.67)
p-trend 0.93

1 (reference)
0.72 (0.45-1.16)
1.00 (0.63-1.60)
p-trend 1.00

1 (reference)
0.77 (0.38-1.56)
1.10 (0.56-2.18)
p-trend 0.77

1 (reference)
0.74 (0.44-1.25)
1.13 (0.68-1.88)
p-trend 0.62

1 (reference)
0.72 (0.38-1.38)
1.15 (0.62-2.13)
p-trend 0.63

1 (reference)
0.66 (0.31-1.42)
0.67 (0.30-1.48)
p-trend 0.30

1 (reference)
0.70 (0.41-1.20)
0.96 (0.56-1.62)
p-trend 0.86
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Table 4.9 Risk of orofacial clefts associated with cytokine and adipokine levels (Cont.).
Tertile
IL-8 (pg/ml)
≤ 2.20
> 2.20-3.53
> 3.53
Leptin (ng/ml)
≤ 5.95
> 5.95-15.44
> 15.44
Resistin (ng/ml)
≤ 481.22
>481.22- 3328.74
> 3328.74

Odds ratios (95 percent confidence intervals)
CL/P
CLP
CPO

All OFCs

CLO

CP/L

1 (reference)
0.93 (0.58-1.49)
1.21 (0.76-1.93)
p-trend 0.43

1 (reference)
1.06 (0.54-2.07)
0.92 (0.45-1.87)
p-trend 0.83

1 (reference)
0.82 (0.49-1.36)
0.96 (0.58-1.60)
p-trend 0.85

1 (reference)
0.65 (0.35-1.24)
0.99 (0.54-1.81)
p-trend 0.93

1 (reference)
1.57 (0.65-3.84)
2.65 (1.14-6.14)
p-trend 0.018

1 (reference)
0.86 (0.50-1.49)
1.36 (0.81-2.30)
p-trend 0.24

1 (reference)
1.07 (0.67-1.73)
1.73 (1.07-2.77)
p-trend 0.02

1 (reference)
0.81 (0.41-1.61)
1.07 (0.54-2.12)
p-trend 0.89

1 (reference)
0.97 (0.57-1.62)
1.56 (0.94-2.60)
p-trend 0.09

1 (reference)
1.13 (0.59-2.20)
2.10 (1.12-3.93)
p-trend 0.02

1 (reference)
1.55 (0.66-3.65)
2.46 (1.07-5.63)
p-trend 0.03

1 (reference)
1.27 (0.73-2.22)
2.21 (1.28-3.81)
p-trend 0.004

1 (reference)
1.20 (0.75-1.92)
1.00 (0.62-1.60)
p-trend 1.00

1 (reference)
1.43 (0.71-2.90)
1.24 (0.61-2.51)
p-trend 0.58

1 (reference)
1.06 (0.64-1.77)
0.92 (0.55-1.53)
p-trend 0.74

1 (reference)
0.86 (0.46-1.59)
0.74 (0.40-1.38)
p-trend 0.34

1 (reference)
1.81 (0.80-4.08)
1.36 (0.59-3.14)
p-trend 0.50

1 (reference)
1.11 (0.65-1.88)
0.91 (0.53-1.54)
p-trend 0.72

TNF-α (pg/ml)
≤ 9.54
> 9.54-14.48
> 14.48

1 (reference)
1 (reference)
1 (reference)
1 (reference)
1 (reference)
1 (reference)
0.82 (0.51-1.31) 0.92 (0.45-1.89) 0.92 (0.55-1.54) 0.92 (0.50-1.70) 0.54 (0.23-1.25) 0.77 (0.45-1.32)
1.09 (0.68-1.74) 1.39 (0.70-2.76) 1.11 (0.66-1.85) 0.92 (0.49-1.74) 1.04 (0.50-2.18) 0.97 (0.57-1.64)
p-trend 0.72
p-trend 0.34
p-trend 0.69
p-trend 0.80
p-trend 0.93
p-trend 0.89
OFCs: orofacial clefts; CPO: cleft palate only; CLO: cleft lip only; CLP: cleft lip with cleft palate; CL/P: cleft lip with or without cleft
palate; CP/L: cleft palate with or without cleft lip.

330

60

p-value =0.04
50

40

30

20

10

0
Normal

Overweight
Control

CLO

Obese
CPO

Figure 4.2 Medians of leptin levels divided by maternal body mass index
OFCs: orofacial clefts; CPO: cleft palate only; CLO: cleft lip only; CP/L: cleft palate with or without cleft lip.
p-value for test difference to control among detected group with analysis of covariance model including maternal age and
smoking (two-way ANOVA)
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CHAPTER 5
THE ASSOCIATION BETWEEN GENES RELATED TO GESTATIONAL
DIABETES MELLITUS AND THE RISK OF OROFACIAL CLEFTS

5.1 Abstract
Background: Gestational diabetes mellitus (GDM) has been associated with an
increased risk of orofacial clefts (OFCs) and there is some evidence that GDM may be
specifically related to palate development rather than lip. Genetic studies have identified
many genes associated with non-syndromic OFCs, but none are clearly associated with
GDM.
Objective: to determine the association between genes related to GDM and the
risk of OFCs.
Methods: Genetic data from the GENEVA study of OFCs consisted of 892 cleft
lip with or without cleft palate (CL/P) and 910 cleft palate with or without cleft lip
(CP/L) trios of Asian ancestry and 665 CL/P and 644 CP/L trios of European ancestry.
Twenty GDM-related genes were selected for analysis of association with OFCs.
Genotypic transmission disequilibrium tests (gTDT) were used to analyze genetic effects
and gene-environment (GxE) interactions with periconceptional maternal multivitamin
use (PCMV), smoking, and environmental tobacco smoke (ETS).
Results: SLC30A8 was associated with CL/P and HNF1B was associated with
CP/L in Asian trios. In Europeans, ADRB3 and TNF-α were associated with both CL/P
and CP/L; ABCC8 was associated with CL/P only and ADIPOQ and HNF1 were
associated with CP/L only. Considering interactions with PCMV, associations were
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found for ABCC8 and CDKAL1 in Europeans. Considering interactions with maternal
smoking, associations were found for CDKN2A/2B in Asian and for LEP in Europeans.
In Asians, FTO, HHEX, and PPARG had associations with OFCs when considering
interaction with ETS.
Conclusion: Several genes related to GDM were associated with risk of isolated
CL/P and CP/L through genotypic effects alone and gene-environment interactions with
PCMV, maternal smoking, and ETS. These associations do not point to a single major
GDM gene associated with OFCs, but support the hypothesis that GDM may be causally
related to OFCs via multiple GDM susceptibility genes and interactions with
environmental factors.
5.2 Introduction
Orofacial clefts (OFCs) are among the most common congenital birth defects.
Globally, approximately 1.43 in 1000 newborns suffer from OFCs (1). The prevalence of
OFCs is different among varying ethnic and racial groups (2). National Birth Defects
Prevention Network reported the prevalence of OFCs during 2002-2006 of CL/P was
1.33 per 1000 live births, and 0.73 per 1000 live births for CP (3). The prevalence of
OFCs in Utah is higher than the overall prevalence of the United States (2.25 per 1000
births) (4).
The etiology of orofacial clefts is not fully understood. The updated evidence
suggests that there are the multiple factors for this defect including both genetic and
environmental factors (5). Maternal diabetes mellitus, obesity, and underweight have
been found as risk factors for OFCs (6-13). Pre-diabetes mellitus and GDM increased risk
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of OFCs (6-8). Many case-control studies and a meta-analysis found that maternal
obesity increased risk of OFCs. The previous study by Kutbi (11) reported the association
between maternal obesity and risk of CL/P and CP/L. In addition, we found that GDM
increased risk of cleft palate only (CPO) and CP/L in the previous chapter.
OFCs are classified as either syndromic or non-syndromic. Syndromic OFCs are
those occurring with other birth defects, while non-syndromic clefts have no other
structural or functional anomalies. The prevalence of syndromic OFCs is around 25
percent of all OFCs; around seventy-five percent of syndromic OFCs can be described by
known genetic conditions including Van der Woude syndrome, Bamforth–Lazarus
syndrome, Kabuki syndrome, Pierre Robin syndrome, and Treacher Collins syndrome
(14). Genetic studies have identified genes related to syndromic OFCs and have provided
clear associations between cleft phenotypes and the mutations of genes (15). Genetic
studies have also found associations between non-syndromic orofacial clefts and genes
related to growth factors, transcription factors, xenobiotic metabolism, immune response,
and one-carbon metabolism (16). Genome-wide association studies (GWAS) have
identified additional genes associated with non-syndromic orofacial clefts, but none to
date are clearly associated with GDM (17-20).
Several environmental factors, including PCMV, smoking, and ETS have been
associated with OFCs. These same exposures have been associated with diabetes,
therefore it is of interest to explore possible interaction between GDM-related genes and
these environmental factors.
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There has been no genetic association study focusing on GDM-related genes and
OFC risk. Therefore, this study aims to determine the association between genes known
to be related to GDM and risk of OFCs through genetic effects and gene-environment
interactions.
5.3 Subjects and Methods
5.3.1 Study Design
The study design is based on trios of children with an isolated orofacial cleft and
their mothers and fathers using genome wide association (GWA) data available from the
International Genetic Epidemiology study of Oral Clefts, a part of the Gene-Environment
Association Studies Initiative (GENEVA) of the National Institutes of Health (NIH) (20).
This study is a multi-center, international study of trios from Europe, the U.S., including
Utah, China, Taiwan, Singapore, Korea, and the Philippines, which aims to investigate
genes associated with oral clefts. Families were recruited from treatment centers or
population-based registries. Research protocols for human study were reviewed and
approved by institutional review boards of each participating institutions and parents
provided informed consent.
Principal Components Analysis (PCA) was used to document ancestral population
affiliation. OFC cases were examined by either a clinical geneticist or an experienced
clinician to minimize misclassification of the OFCs. All cases with cleft palate with or
without cleft lip (CP/L) were analyzed together based on evidence that maternal obesity
and diabetes have a specific effect on palate development (11). Trios having CL/P and
CP/L were analyzed in this study separately.
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5.3.2 Maternal exposure assessment
Parents were asked about family history of oral clefts and other birth defects and
maternal exposures during the periconceptional period (three months before conception
through the first trimester) including smoking, alcohol consumption, environmental
tobacco smoke exposure (ETS), and multivitamin use (PCMV).
5.3.3 Gene selection and genotyping
Gene selection was based on publications focusing on genes associated with
GDM through March 2015. Eighty-three genes were found to have significant
associations with GDM. In order to narrow the gene list, GDM candidate genes (Table
5.1) were limited to those with statistically significant associations with GDM and either
type 2 diabetes or obesity in at least three candidate gene studies or at least two GWA
studies or at least one meta-analysis study. Genomic coordinates of selected genes were
obtained from the major human genome assembly released by the Genome Reference
Consortium, NCBI36/hg18, via the website of the National Center for Biotechnology
Information (NCBI) (21). Case and parent samples were collected as whole blood in
EDTA tube for analyzing DNA. DNA samples were previously genotyped using the
Illumina Human610 Quad v.1 B BeadChip at the Center for Inherited Disease Research
(CIDR) and 99.1% passed quality control standards (20). Genotypes were not called if
the quality score was more than 1 HapMap replicate error, more than 1 percent difference
in call rate between genders, or more than 4% difference in heterozygote frequency.
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5.3.4 Statistical analysis
Statistical analyses were performed in the R program 3.1.2 TRIO package (22).
Isolated CL/P and CP/L were analyzed separately. Individuals with more than 10 percent
missing genotypes were excluded from the study. Four quality control (QC) criteria were
used to flag and remove SNPs: 1) high rates of missing genotype calls (>10%), 2) low
minor allele frequency (MAF <0.01), 3) high rates of Mendelian errors (> 5%) and 4)
significant deviation from Hardy-Weinberg equilibrium (p >10-5). MAFs were calculated
using parents only. SNPs within 100kb upstream and downstream of the selected genes
were selected and used in this analysis in order include the promoter region (23, 24).
Because this study included hypotheses for targeted GDM genes, based on strong
evidence from previous studies, a gene-level approach to analysis was employed with
Bonferroni adjustment of p-values based on the number of SNPs used in each individual
gene region as employed in previous studies (25-28).
The associations between genes related to GDM and risk of OFCs was examined
by the genotypic transmission disequilibrium (gTDT) test developed by Schwender et al
(29). Europeans and Asians were analyzed separately because of different allelic
frequencies. All each SNP, one of the four possible pairs of parental alleles is known to
be inherited by the case-child, and the other three untransmitted genotypes are used as
pseudo-controls. The gTDT approach can be formulated as a conditional logistic
regression model which can be written as:

ln {P(ith case) / [(1-P(ith case))]}{ = β0i + βGXi,
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where Xi represents the corresponding risk genotypes under an additive,
dominant, or recessive model. P(ith case) is the probability of being the observed case in
the case and pseudo-controls set in the ith trio. The association between SNPs and OFCs
was estimated with odds ratios as OR (OFCs) = exp (βG) with 95 percent confidence
intervals (CIs) calculated from estimated standard errors of βG.
The effects of gene-environment (GxE) interactions were examined using the
conditional logistic regression model assuming an additive model of inheritance by the
following model:

ln {P(ith case) / [(1-P(ith case))]} = β0i + βGXi, + βEEi + βEG (XiEi)

where Ei is environmental factor (exposed or unexposed). βEG represents the
coefficient of GxE interaction. Both the gene and GxE interaction terms included in
conditional logistic regression model provided an estimate of odds ratio (OR) under the
additive model. The estimated OR of being a case with one copy of the risk allele in the
unexposed mother was given by OR(OFCs|G no E) = exp (βG) and among the exposed
mothers was OR(OFCs|G and E) = exp (βG+ βEG) for the odds ratio of being a case with
one copy of the risk allele in the presence of maternal exposure. A one-degree of freedom
(df) likelihood ratio test (LRT) was performed for studying the effect of GxE interaction
alone (30) and 2 df LRT examined the inherited effect of genotype while accounting for
effects of GxE interaction within the same model (31).
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5.4 Results
For Asians, 892 CL/P and 910 CP trios, and for Europeans, 665 CL/P and 644
CP/L trios were analyzed (Table 5.2). European mothers had a higher rate of PCMV use
than Asians (Tables 5.3 and 5.4) (CL/P: 54.0% vs 14.7%; CP/L: 54.5% vs 16.5).
European trios with CL/P and CP/L had high missing rates of ETS (31.4 and 31.7%,
respectively). Therefore, GxE interaction with ETS was analyzed only in Asian trios.
Test of association considering genotypic effect alone in Asians and Europeans
In Asian trios, SLC30A8 (rs924388) was associated with CL/P under the
dominant model (OR: 1.42, 95% CIs: 1.16-1.74) (Table 5.5). The estimated OR of having
a CP/L child carrying the minor allele at rs2158254 in HNF1B gene under the recessive
model in Asians was 0.53 (95%CI: 0.37-0.75).
In Europeans, ADRB3 (rs7812866) and TNF-α (rs28470596) were both
associated with CL/P and CP/L (Table 5.6). Moreover, both rs2237991 and rs2074315 in
ABCC8 showed significant association with CL/P under the dominant model (OR: 0.64,
95%CI: 0.52-0.79; OR: 0.64, 95%CI: 0.52-0.79; respectively). The estimated odds ratios
for Europeans for CP/L carrying the minor allele at rs17373877 in ADIPOQ and
rs6607292 in HNF1B were 0.55 (95%CI: 0.39-0.78; additive model) and 0.50 (95%CI:
0.35-0.73; recessive model), respectively. There were no significant associations between
genes related to GDM and risk of CL/P and CP/L in analyses that combined Asians and
Europeans.

352
Tests of association jointly considering genotypic effects and GxE interactions in
Asians and Europeans: periconceptional maternal multivitamin (PCMV) as exposure.
ABCC8 (rs4148622) and CDKAL1 (rs12201217) showed evidence of GxPCMV
interaction in the 1 df LRT in European CL/P and CP/L, respectively (ABCC8: OR
(CL/P│G no PCMV): 0.58, 95% CI: 0.42-0.81 and OR (CL/P│G and PCMV): 1.26, 95%
CI: 1.01-1.58; CDKAL1: OR (CP/L│G no PCMV): 2.10, 95%CI: 1.45-3.03 and OR
(CP/L│G and PCMV): 1.30, 95%CI: 1.04-1.61). After considering GxE interaction
effects in the 2 df LRT, genotypic effects for FTO (rs836994) in Asian CL/P, ADIPOQ
(rs7645316) in European CP/L, and TNF-α (rs28470596) in European CL/P and CP/L
became significant (OR (CL/P│G and PCMV): 1.23, 95%CI: 0.88-1.70; (OR (CP/L│G
and PCMV): 0.71, 95%CI: 0.57-0.89; OR (CL/P│G and PCMV): 0.49, 95% CI: 0.290.82; OR (CP/L│G and PCMV): 0.28, 95%CI: 0.15-0.52; respectively). There was no
gene that showed evidence of GxPCMV in Asian CP trios (Table 5.7).
Test of association jointly considering genotypic effect and GxE interaction in Asians
and Europeans: periconceptional maternal smoking (smoke) as exposure.
CDKN2A/2B (rs1063192) and LEP (rs12538332) showed evidence of geneenvironment interactions with maternal smoking in the 1 df LRT in Asian CL/P and
European CL/P, respectively (CDKN2A/2B: OR (CL/P│G no smoking): 1.16, 95%CI:
0.98-1.37 and OR (CL/P│G and smoking): 0.15, 95%CI: 0.03-0.68; LEP: OR (CL/P│G
no smoking): 0.83, 95%CI: 0.68-1.02 and OR (CL/P│G and smoking): 1.52, 95% CI:
1.11-2.13). After considering GxE interaction effects in the 2 df LRT, genotypic effects
for ABCC8 in European CL/P (rs2237991) and CP/L (rs4148617), and TNF-α
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(rs28470596) in European CL/P and CP/L became significant (OR (CL/P│G and
Smoke): 0.56, 95%CI: 0.40-0.79, OR (CP/L│G and Smoke): 0.52, 95%CI: 0.38-0.73,
OR (CL/P│G and smoke): 0.25, 95%CI: 0.12-0.52, and OR (CP/L│G and smoke): 0.29,
95%CI: 0.15-0.60, respectively). There was no gene that showed evidence of GxPCMV
in Asian CP/L trios (Table 5.8).
Test of association jointly considering genotypic effect and GxE interaction in
Asians: periconceptional maternal environmental tobacco smoke (ETS) as exposure.
Four SNPs in FTO (rs3751812, rs8050136, rs9930333, and rs9941349) had
protective minor allele associations with CL/P, but only in mothers not exposed to ETS
(OR range: 0.59-0.60; Table 5.9). Similar protective associations were found for CP/L for
FTO (rs3751812 and rs8050136). Increased risk for CL/P was found for ETS exposed
only for five SNPs of HHEX (OR range 1.45-6.00) and found these were also associated
with CP/L (OR range 8.50-16.0) though the 95% CI, while not including 1.0, were large.
Three SNPs of PPARG were associated with increased risk of CL/P among ETS-exposed
mothers (OR range 1.25-1.45).
5.5 Discussion
This study found several novel associations between GDM-related genes and
OFCs and interaction with maternal environmental factors previously associated with
OFCs. The study reported that HNF1B was associated with CP/L in both Asians and
Europeans. SLC30A8 had an association with CL/P in Asian trios only. In Europeans,
ADRB3 and TNF-α had associations with both CL/P and CP/L. Moreover, ABCC8 and
ADIPOQ were associated with CL/P and CP/L, respectively, in Europeans. Five genes
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were associated with OFCs when interaction with PCMV was considered -- FTO in
Asians and ABCC8, ADIPOQ, CDKAL1, and TNF-α in Europeans. Interactions between
genotype and maternal smoking were found for CDKN2A/2B in Asian CL/P, and in
Europeans, ABCC8, LEP, and TNF-α were associated with CL/P. In Asian mothers
exposed to environmental smoking, FTO and HHEX were associated with an increased
risk of CL/P and CP/L, and PPARG was associated with an increased risk of CL/P.
Linkage and association studies have reported over two dozen genes significantly
associated with OFCs, but these differ across populations (32). While these studies have
revealed the novel genes, it has been difficult to identify the etiologic mechanisms. A
family-based study by Meeks et al.(33) focused on genes associated with one-carbon
metabolism (OCM), and found that FUT6 (fucosyltransferase 6) and TCN2
(transcobalamin 2) had an association with OFCs in Asian population.
GxE interaction in OFCs have been conducted by many studies but not to date
have focused on GDM-related genes. A case-parent trio study by Beaty et al (34)
reported genes associated with cleft palate only (CPO) when maternal environmental
exposures were considered including BAALC (brain and acute leukemia gene
cytoplasmic) with maternal multivitamin use, ZNF236 (Zinc Finger Protein 236) and
TBK1(tank-binding kinase 1) with maternal smoking, and MLLT3 (brain and acute
leukemia gene cytoplasmic) and SMC2 (structural maintenance of chromosomes 2) with
maternal alcohol exposure. Another study by Beaty et al. (25) reported GRID2 (glutamate
Ionotropic Receptor Delta Type Subunit 2) and ELAVL2 (ELAV like RNA binding
protein 2) had an association with CL/P when interaction with maternal smoking was
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considered. A family-based study focusing on a Chinese population by Wu et al (35)
showed interactions between IRF6 and both maternal multivitamin use and
environmental tobacco smoke in CL/P risk. Another study by Wu et al (36) reported that
SLC2A9 (solute carrier family 2 member 9) and WDR1 (WD repeat domain 1) gene
increased risk of CP/L if mothers were exposed to environmental tobacco smoke. A
family-based study by Wang et al (37) reported a novel gene (FGFR2: fibroblast growth
factor receptor 2) was associated with CL/P when maternal multivitamin use and
smoking were considered. A study by Meeks (33) found that six genes related to onecarbon metabolism had an association with OFCs if mothers used PCMV (DHFR
(dihydrofolate reductase), MMAA (methylmalonic aciduria (cobalamin deficiency) cblA
type), MTR (5-methyltetrahydrofolate-homocysteine methyltransferase), and TCN2 in
European populations and CBS (cystathionine-beta-synthase) and MTHFD2L
(methylenetetrahydrofolate dehydrogenase (NADP+ dependent) 2-like) gene in Asian
populations).
The association between maternal environmental exposures and risk of orofacial
is inconsistent. Maternal use of multivitamin supplements in early pregnancy has been
linked to decreased risk of OFCs; in a meta-analysis on overall 25% reduction in birth
prevalence of OFCs with multivitamin use was reported (38). However, later data from
the National Birth Defects Prevention Study (NBDPS) found no association between
maternal use of supplement containing folic acid and risk of CL/P and CPO (39).
Maternal smoking has been reported to increase the risk of both CL/P and cleft palate. An
international population-based study, including Norway and the United States, reported
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that mothers with active smoking increased risk of all types of isolated clefts (OR: 1.27,
95% confidence interval (95% CI): 1.11-1.46 for all OFCs; OR: 1.28, 95% CI: 1.09-1.51
for CL/P, OR: 1.25, 95% CI: 1.01-1.55 for CPO) (40). A study from Brazil by Leite et al.
(41), however, presented no association between maternal smoking during the first
trimester of gestation and OFCs. In addition, the effect of environmental tobacco smoke
from passive exposure on the risk of OFCs still appears to be inconsistent. Case-control
studies in China reported that passive smoke exposure of mothers increased the risk of
OFCs (42, 43). However, a cohort study in the United States reported that environmental
tobacco smoke exposure was not associated with CL/P and CPO (44). Inconsistent
association between ETS and risk of OFCs might result from GxE interaction, which
requires further study. The statistically significant gene-environment interactions may or
may not correspond to biological interaction. Therefore, biological interaction requires
further study to confirm the mechanisms involved.
This study found that the presence of the minor allele at rs924388 in SLC30A80
increased risk of CL/P in Asians by 42% under the dominant model. SLC30A8, a
member of zinc transporter (ZNT) family, encodes the zinc transporter ZnT8. ZnT
proteins transport zinc out of cells when zinc is excess, and sequester cytoplasmic zinc
into cell when zinc is replete. Zinc facilitates the formation of dense core granules for
insulin crystallization in pancreatic β-cell and has a positive influence on insulin gene
transcription (45). Reduced zinc concentration in the secretory granules leads to increased
proinsulin to insulin ratio in blood circulation and decreased glucose-induced insulin
secretion (45). A cross-sectional study in the Chinese Han population found a strong
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interaction between SLC30A8 (rs13266634) variant and plasma zinc concentrations in
association with type 2 diabetes (46). Moreover, a cross sectional meta-analysis study
also reported the interaction effect between SLC30A8 (rs11558471) variant and total zinc
intake on fasting plasma glucose concentration (47). The association between plasma zinc
concentration and risk of non-syndromic OFCs was reported in a Philippine population
with poor zinc status, but the association was not found in Utah, U.S. population with
adequate zinc status (48, 49). However, due to limited data in this study, the interaction
between SLC30A8 and plasma zinc levels in association with OFCs cannot be
determined. The mechanism explaining the association between SLC30A8 variant and
risk of OFCs requires further studies in zinc-poor and zinc-replete populations.
In European trios, the presence of the minor allele of ADRB3 at rs7812866
increased the risk of CL/P and CP/L (44% and 53%, respectively) under the dominant
model. ADRB3 is a member of beta-adrenergic receptor family, which regulates energy
balance through lipolysis in adipocytes, free fatty acid mobilization from adipose cells
and thermogenesis in skeletal muscle (50, 51). The mutation of ADRB3 is associated
with decreased resting metabolic rate, obesity, obesity-related diseases (diabetes and
hypertension), calorigenic dysfunction, early onset of diabetes mellitus, and increased
body weight with aging (51, 52). Therefore, gene related to obesity (Table 5.11) might be
associated with CP/L. This hypothesis is supported by a study by Kutbi et al reporting the
association between maternal obesity and risk of CP/L and suggesting that obesity has a
specific effect on palate formation but not lip formation (11). However, the association
between obese genes and risk of CP/L requires further study to confirm the hypothesis.
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While ADRB3 has been strongly linked to obesity and diabetes, the mechanisms
explaining the association between ADRB3 gene and risk of OFCs require further study.
HNF1B (rs2158254) had an association with CP/L in both European and Asian trios.
HNF1B (HNF1 homeobox B), a member of the homeodomain-containing superfamily of
transcription factors, is expressed in liver, pancreas, bile ducts, thymus, genital tract,
lung, and gut (53). Functions of HNF1B include epithelial differentiation during human
organogenesis (54), renal tubulogenesis regulation (55), hepatic insulin sensitivity control
(56), and pancreatic endocrine cell generation (57). Moreover, HNF1B gene is also
associated with pancreatic β cell dysfunction and insulin resistance (56). Polymorphisms
in HNF1B have been strongly associated with diabetes, but the mechanisms explaining
the association between HNF1B and risk of OFCs require further study.
ADIPOQ (rs17373877) was associated CP/L in Europeans, and ADIPOQ
(rs7645316) was associated with CP in European trios when GxE interaction (PCMV)
was considered. ADIPOQ has an influence on adiponectin concentration, which is
involved in increased glucose uptake via glucose transporter-4, and increased fatty acid
uptake and oxidation (58). Yamauchi reported that adiponectin stimulated
phosphorylation of acetyl coenzyme A carboxylase, glucose uptake, lactate production,
and fatty acid oxidation through activated 5-prime-AMP-activated protein kinase (59).
While ADIPOQ has been strongly linked to obesity and diabetes, the mechanism of
ADIPOQ or adiponectin level and risk of OFCs requires further study.
TNF-α (rs28470596) was associated with both CL/P and CP/L in European trios
in the gTDT and in the 2 df that controlling for gene-environment interactions with
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PCMV and smoking. Rs28470596 is located approximately 85 kb upstream of TNF-α, a
region with several genes related to immune function in MICB, MHC (major
histocompatibility complex) Class I Polypeptide-Related Sequence B, which is expressed
in monocytes and normal tissues (60). Polymorphisms of MICB cause autoreactive T-cell
stimulation, which relates to relevant differences in immune response against infections,
autoimmune diseases, and tumor transformation (61). TNF-α encodes a cell signaling
protein produced at inflammatory sites. TNF-α interferes with insulin signaling in
adipose, muscle, and liver cells. TNF-α inhibit glucose-induced insulin secretion (62). A
cell study by Tsiotra et al. (63) found that TNF-α suppressed both basal and glucoseinduced insulin secretion and proinsulin mRNA transcription. TNF-α reduces GLUT4
mRNA levels in adipocytes and myocytes and inhibits insulin-stimulated glucose
transport, which induces insulin resistance (64). It is uncertain whether polymorphisms
in the TNF-α region are related to the regulation of TNF-α or to effects on other genes in
the MHC regions. For example, a study by Rahimov et al of the IRF6-OFC association
(65) found that rs642961 (10 kb downstream of IRF6, an IRF6 enhancer), disrupted the
binding site of transcription factor AP-2α, which appeared to be the causal variant
associated with cleft lip. The mechanism of rs28470596 on TNF-α and OFCs requires
further study
ABCC8 (rs2237991 and rs2074315) showed significant association with CL/P in
the dominant model in Europeans. When GxE interactions were considered, ABCC8 was
associated with CL/P (rs4148622 for PCMV and rs2237991 for maternal smoking).
ABCC8 influences the K-ATP channel function, which causes increased insulin secretion
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by pancreatic β-cells. Elbein et al. reported ABCC8 polymorphism that decreased
pancreatic β-cell compensation leading to reduce insulin sensitivity (66).
Interactions with ETS reveal that FTO (rs9930333, rs9941349, rs3751812 and
rs8050136), HHEX (rs7078243, rs2497351, rs12784232, rs11187173 and rs1418388) and
PPARG (rs7618046, rs3856806 and rs12629751) were associated with CL/P and CP in
Asians. FTO shares sequence with iron- and 2-oxoglutarate-dependent oxygenases, and
FTO mRNA levels found in the hypothalamus are regulated by feeding and fasting (67).
A mouse study by Gao et al (68) found that mice with FTO mutations had postnatal
growth retardation (lower body weight, shorter body length, and lower bone mineral
density) and decreased insulin-like growth factor 1 (IGF-1) levels. A case-control study
in Romanian by Duicu et al found that rs9939609 in FTO was associated with
adiponectin and leptin levels. HHEX encodes a transcription factor related to Wnt
signaling for cell growth and development. A mouse study found that HHEX knockout
mice had impaired forebrain, cardiovascular, thyroid, and liver development (69, 70).
PPARG is associated with insulin action, adipocyte differentiation, lipid storage, and fatspecific gene expression (71). PPARG (72) also activates glucose transporter 2 and
glucokinase in liver and pancreatic β-cells, which improves glucose homeostasis.
LEP was associated with European CL/P when interaction with maternal smoking
was considered. LEP encodes leptin hormone which regulates body weight through leptin
receptors. Leptin is involved in food intake inhibition, energy expenditure regulatory,
energy and glucose homeostasis, bone formation, immune and inflammatory response,
angiogenesis, hematopoiesis, and would healing (73). Elevated leptin level during
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pregnancy result from the production in placenta rather than adipose tissue. Maternal
leptin increases the mobilization of maternal fat stores, and regulates placental growth,
angiogenesis, and nutrient transfer. (74). A vitro study by Araujo et al (75) reported that
increased leptin levels in GDM mothers inhibit placental folic acid transport. The
previous chapter (chapter 4) analyzing the association between biomarkers and risk of
OFCs reported that mothers having CL/P, CPO, and CP/L offspring had higher leptin
levels than control mothers. Many studies have found that leptin concentrations were
lower in smokers than in nonsmokers (76-80). The study by Nagayasu et al. (80) also
presented that nicotine suppressed leptin gene expression. The study by Larsson and
Ahren (81) and Donahue et al. (82) reported that leptin levels were not different between
smoker and nonsmoker. However, the study Pertkins and Fonte (83) reported that
smoking cessation increased leptin concentrations, and suggested that nicotine in tobacco
caused leptinemia by inducing corticosteroid release from adrenal glands. The
inconsistent associations between smoking and leptin levels may result from the study
designs disregarding the different ethnicities, age, health status, and genetic variation
(84). Thus there are many possible mechanism where by leptin may influence OFC risk.
The interaction effect between leptin and smoking on risk of OFCs and effect of smoking
on LEP gene expression require further study to explore.
Major genes having associations with CL/P and CP/L when considering genotypic
effect alone are related to beta-cell dysfunction and insulin resistance (Table 5.11). Five
of seven genes showing gene-environment interaction with maternal smoking and ETS
are related to beta-cell dysfunction (Table 5.12). A study by Beaty et al (20) reported
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MAFB was associated with CL/P based on GWAS data, and had a role in palate
formation based on expression study in mice. A mouse study by Banerjee et al (85) found
that decreased MAFB expression in maternal beta-cell caused GDM. The hypothesis
about the association between genes related to beta-cell dysfunction and insulin
resistance and OFCs through genetic effects alone and gene-environment interactions
requires further study to confirm. Moreover, the mechanism of gene-environment
interaction with maternal smoking and ETS in OFCs, which focuses on genes related to
beta-cell function, requires further study.
This study is a multi-center, international family-based study. Family-based
designs can control confounding bias from the population stratification which is a critical
issue in international multi-center designs. For rare diseases, family-based designs
provide better statistical power than case-control designs. Moreover, GxE interaction
analysis provided additional genes associated when considering GxE interaction (Table
5.13). However, this study cannot identify the etiological mechanism of significant genes
on OFC risk. Biological interaction studies are needed to identify the mechanisms of
interaction effects between genes and maternal exposures on lip and palate development.
This study reported the association between novel genes related to GDM and risk
of CL/P and CP/L in term of genetic effects or GxE interactions with PCMV, maternal
smoking, and ETS. Strong association between GDM and risk of OFCs has been reported
in previous studies. Therefore, this study supports the hypothesis that genes related to
GDM are associated with OFCs through genotypic effects alone and gene-environment
interactions with PCMV, maternal smoking, and ETS. The study does not point to a
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single major GDM gene associated with OFCs, but supports the hypothesis that GDM
may be causally related to OFCs via multiple GDM susceptibility genes and interactions
with environmental factors. Further studies are needed to understand the mechanism
through which genes related to diabetes and obesity influence the risk of OFCs.

Table 5.1 Summary of genes associated with gestational diabetes (GDM), diabetes mellitus, and obesity selected for analysis.
Gene ID
ABCC8
(11p15.1)
ADIPOQ
(3q27)

Gene name
ATP-binding cassette, subfamily C (CFTR/MRP),
member 8
Adiponectin, C1Q and
collagen domain
containing

ADRB3
(8p12)

Adrenoceptor beta 3

CDKAL1
(6p22.3)

CDK5 regulatory subunit
associated protein 1-like 1

BC
X

Mechanism1
IR IN OB

X

X

X

X

X

AT

SNP2
rs4148643
rs1799854
rs1799859
rs266729
rs822396
rs1063537
rs1501299
rs2241766
rs2241767
rs12637534
rs16861194
rs16861209
rs17366568
rs17846866
rs4994
rs72655364
rs72655365
rs2206734
rs2237892
rs4712524
rs7754840
rs7756992
rs9295475

T2DM3
(86)
(86-88)
(86, 87)
(93, 94)
(95, 96)
(95, 96)
(100)
(93, 94)
(100)
(100)
(101)
(95, 102)
(106)
(106)
(107)
(108)
(109)
(110-115)
(110-114)
(109)

References
GDM4
(86)
(86)
(89, 90)
(97-99)
(103)
(116, 117)
(116, 118)
-

Obesity
(91)
(92)
(91, 92)
(92)
(104, 105)
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Table 5.1 Summary of genes associated with gestational diabetes (GDM), diabetes mellitus, and obesity selected for analysis (Cont.).
Gene ID

Gene name

CDKAL1
(Cont.)
CDKN2A/2B
(9p21)

Cyclin-dependent kinase
inhibitor 2A/B

FTO
(16q12.2)

Fat mass and obesity
associated

BC

Mechanism1
IR IN OB

AT

SNP2
rs9460546
rs10946398
rs564398
rs1412829
rs2383208
rs10811661

X

X

T2DM3

rs965670
rs9926289
rs9930506
rs9939609

(109)
(119-122)
(120-122)
(123)
(113-115,
120-122,
125-128)
(130)
(132)
(132)
(121, 122,
133)
(134, 135)

rs17817449

(133)

rs965670
rs1121980
rs1421085
rs3751812
rs6499640
rs6602024
rs7193144
rs7907949
rs8050136

References
GDM4
(124)
(116)

Obesity
-

-

(129)
(129)
(130, 131)
(129)
(129)
(129)
(129)

(136)

(129)
(129)
(129)
(129, 130,
137-139)
-

-
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Table 5.1 Summary of genes associated with gestational diabetes (GDM), diabetes mellitus, and obesity selected for analysis (Cont.).
Gene ID

Gene name

GCK
(7p15.3p15.1)

Glucokinase

HHEX
(10q23.33)

Haematopoietically
expressed
homeobox

BC
X

Mechanism1
IR IN OB

AT

SNP2
rs1799884
rs2244164
rs2268573
rs2284779
rs12534623
rs4604517
rs7923837

X

rs5015480
rs1111875

HNF1A
(12q24.2)

HNF1 homeobox A

X

HNF1B
(17q12)

Hepatocyte nuclear factor
1-beta

X

X

rs1169288
rs2701175
rs7305618
rs7957197
rs21573907
rs10962
rs2688
rs1008284

T2DM3
(143)
(143)
(144)
(143)
(145)
(110, 113,
115, 119,
122, 128,
146)
(113, 119,
121)
(110, 113115, 119,
122, 127,
128, 146)
(147, 148)
(149)
(150)
(151)
(150)
(144)
(88)
(143)

References
GDM4
(140-142)
-

Obesity
-

(116)

-

(116)

-

(116)

-

(140)
-

366

Table 5.1 Summary of genes associated with gestational diabetes (GDM), diabetes mellitus, and obesity selected for analysis (Cont.)
Gene ID

Gene name

BC

Mechanism1
IR IN OB

HNF1B
(Cont.)

IGF2BP2
(3q27.2)

IRS1
(2q36)
KCNJ11
(11p15.1)

KCNQ1
(11p15.5p15.4)

AT

SNP2
rs1016991
rs2285741
rs3110641
rs4430796
rs6422978
rs11263755
rs12450628
rs1470579

Insulin-like growth factor
2mRNA binding protein 2

Insulin receptor substrate1
Potassium channel,
inwardly
rectifying subfamily J,
member 11
Potassium channel,
voltage gated KQT-like
subfamily Q, member 1

X

rs4376068
rs4402960

X
X

X

rs6769511
rs7651090
rs1801278
rs2943641
rs5215
rs5219

rs2074196
rs2237892
rs2237895

T2DM3
(88)
(144)
(144)
(151)
(144)
(144)
(143)
(110, 113115, 128, 153)
(109)
(108, 110,
113-115, 128,
153)
(109)
(125)
(155, 156)
(162)
(119, 122)
(115, 125,
128, 153)
(164)
(150, 164)
-

References
GDM4
(152)
(117)

Obesity
-

(124, 154)

-

(157-160)
(163)

(161)
-

(165)
(165-167)
(166, 168)
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Table 5.1 Summary of genes associated with gestational diabetes (GDM), diabetes mellitus, and obesity selected for analysis (Cont.)
Gene ID
KCNQ1
(Cont.)
LEP
(7q31.3)

MTNR1B
(11q21-q22)

Gene name

BC

Leptin

X

Melatonin receptor 1B

X

PPARG
(3p25)

Peroxisome proliferatoractivated receptor gamma

SLC30A8
(8q24.11)

Solute carrier family 30
(zinc transporter), member
8

Mechanism1
IR IN OB

X

X

X

AT

SNP2

T2DM3

rs2237896
rs231362
rs2167270
rs6966536
rs7799039
rs10954173
rs10954174
rs11761556
rs1387153
rs10830962

(151)
(173)
(173)
-

rs10830963

(175-177)

rs1801282

(115, 121,
122, 125, 153,
179)
rs3856806
rs3802177
(110, 119,
123, 133)
rs11558471
(119)
rs13266634
(110, 115,
119, 121, 123,
125, 133, 146,
153)

References
GDM4
(168)

Obesity
-

(90)
(172)
(157, 174)
(117)
(157, 174,
178)
(180)

(169, 170)
(171)
(171)
-

(180)
-

-

(116)

-

(181)
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Table 5.1 Summary of genes associated with gestational diabetes (GDM), diabetes mellitus, and obesity selected for analysis (Cont.)
Mechanism1
IR IN OB

References
BC
AT
GDM4
Obesity
TCF7L2
Transcription factor 7-like X
rs4506565
(136)
(10q25.3)
2
rs6585205
(119)
rs7901695
(108)
(182)
rs7903146
(113, 115,
(116, 118,
119, 121-123, 182, 185)
126, 146, 153,
183, 184)
rs10885409
(127)
rs114748339
(186)
rs12255372
(187)
TNF-α
Tumor necrosis factor
X
X
rs361525
(188)
(6p21.3)
alpha
rs1800610
(149)
rs1800629
(189, 190)
(191, 192) (193, 194)
1
Mechanism related to diabetes and metabolic syndrome, BC: beta-cell dysfunction; IR: insulin resistance; IN: inflammation markers
(cytokines and adipokines); OB: Obesity; AT: Atherosclerotic processes
2
SNP, single-nucleotide polymorphism
3
T2DM, type 2 diabetes mellitus
4
GDM, gestational diabetes mellitus
Gene ID

Gene name

SNP2

T2DM3
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Table 5.2 Number of complete trios by recruitment site; GENEVA Orofacial Cleft Consortium
Recruitment Site

Asian Trios
CL/P

Denmark
Norway
Iowa, US
Maryland, US
Pittsburgh, Pennsylvania, US
Utah, US
Philippines
Singapore
Taiwan
Weifang, People Republic of China
Wuhan, People Republic of China
Chengdu, People Republic of China
Korea
Total

3 (0.3%)
1 (0.1%)
94 (10.5%)
56 (6.3%)
218 (24.4%)
183 (20.5%)
176 (19.7%)
106 (11.9%)
55 (6.2%)
892

European
CP/L
-

3 (0.3%)
2 (0.2%)
1 (0.1%)
94 (10.3%)
84 (9.2%)
250 (27.5%)
159 (17.5%)
178 (19.6%)
101 (11.1%)
38 (4.2%)
910
CL/P: cleft lip with or without cleft palate; CP/L: cleft palate with or without cleft lip

CL/P
21 (3.2%)
275 (41.4%)
44 (6.6%)
83 (12.5%)
87 (13.1%)
152 (22.9%)
3 (0.4%)
-

665

CP/L
20 (3.1%)
270 (41.9%)
52 (8.1%)
88 (13.7%)
73 (11.3%)
135 (21.0%)
6 (0.9%)
644
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Table 5.3: Environmental maternal exposures in Asian trios by site.
Environmental
risk factor
exposure by
Site
Norway
No
Yes
Missing
Maryland, US
No
Yes
Missing
Utah, US
No
Yes
Missing
Philippines
No
Yes
Missing
Singapore
No
Yes
Missing

Cleft lip with or without cleft palate (N=892)
Smoking
PCMV
Drinking
ETS

Cleft palate with or without cleft lip (N=910)
Smoking
PCMV
Drinking
ETS

3 (100%)
-

1 (33.3%)
1 (33.3%)
1 (33.3%)

2 (66.7%)
1 (33.3%)
-

2 (66.7%)
1 (33.3%)
-

3 (100%)
-

1 (33.3%)
1 (33.3%)
1 (33.3%)

2 (66.7%)
1 (33.3%)
-

2 (66.7%)
1 (33.3%)
-

1 (100%)
-

1 (100%)
-

1 (100%)
-

1 (100%)

2 (100%)
-

2 (100%)
-

2 (100%)
-

1 (50.0%)
1 (50.0%)

-

-

-

-

1 (100%)
-

1 (100%)
-

1 (100%)
-

1 (100%)
-

90 (95.7%)
4 (4.3%)
-

65 (69.1%)
29 (30.9%)
-

89 (94.7%)
5 (5.3%)
-

94 (100%)

90 (95.7%)
4 (4.3%)
-

65 (69.1%)
29 (30.9%)
-

89 (94.7%)
5 (5.3%)
-

94 (100%)

51 (91.1%)
5 (8.9%)
-

29 (51.8%)
27 (48.2%)
-

54 (96.4%)
2 (3.6%)
-

42 (75.0%)
14 (25.0%)
-

78 (92.9%)
6 (7.1%)
-

44 (52.4%)
40 (47.6%)
-

78 (92.9%)
6 (7.1%)
-

67 (79.8%)
17 (20.2%)
-

371

Table 5.3: Environmental maternal exposures in Asian trios by site (Cont.).
Environmental
risk factor
exposure by
Site

Cleft lip with or without cleft palate (N=892)
Smoking
PCMV
Drinking
ETS

Cleft palate with or without cleft lip (N=910)
Smoking
PCMV
Drinking
ETS

Taiwan
No
Yes
Missing

203(93.1%)
15 (6.9%)
-

173(79.4%)
44 (20.2%)
1 (0.5%)

210(96.3%)
8 (3.7%)
-

103(47.2%)
113(51.8%)
2 (0.9%)

233(93.2%)
17 (6.8%)
-

199(79.6%)
51 (20.4%)
-

239(95.6%)
11 (4.4%)
-

120(48.0%)
128(51.2%)
2 (0.8%)

Weifang, PRC
No
Yes
Missing

182(99.5%)
1 (0.5%)
-

162(88.5%)
11 (6.0%)
10 (5.5%)

182(99.5%)
1 (0.5%)

116(63.4%)
65 (35.5%)
2 (1.1%)

158(99.4%)
1 (0.6%)
-

143(89.9%)
7 (4.4%)
9 (5.7%)

157(98.7%)
2 (1.3%)
-

99 (62.3%)
59 (37.1%)
1 (0.6%)

Wuhan, PRC
No
Yes
Missing

176 (100%)
-

37 (21.0%)
14 (8.0%)
125(71.0%)

173(98.3%)
3 (1.7%)

171(97.2%)
3 (1.7%)
2 (1.1%)

178(100%)
-

38 (21.3%)
16 (9.0%)
124(69.7%)

175(98.3%)
3 (1.7%)

172(96.6%)
2 (1.1%)
4 (2.2%)

Chengdu, PRC
No
Yes
Missing

105(99.1%)
1 (0.9%)
-

101(95.3%)
2 (1.9%)
3 (2.8%)

103(97.2%)
3 (2.8%)
-

12 (11.3%)
92 (86.8%)
2 (1.1%)

100(99.0%)
1 (1.0%)
-

97 (96.0%)
2 (2.0%)
2 (2.0%)

98 (97.0%)
3 (3.0%)
-

14 (13.9%)
86 (85.1%)
1 (1.0%)

Korea
No
Yes
Missing
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55 (100%)
53 (96.4%) 48 (87.3%) 37 (67.3%)
38 (100%)
37 (97.4%) 33 (86.8%) 27 (71.1%)
2 (3.6%)
12 (21.8%)
1 (2.6%)
7 (18.4%)
7 (12.7%)
6 (10.9%)
5 (13.2%)
4 (10.5%)
Smoking: mother smokes in the periconceptional period (3 months prior through 3rd month of pregnancy)
PCMV: mother takes multivitamins or prenatal vitamins in the periconceptional period (3 months prior through 3 rd month of
pregnancy)
Drinking: mother has alcohol consumption in the perinatal period (3 months prior through 3rd month of pregnancy)
ETS: mother exposed to environmental tobacco smoke during pregnancy or three months before pregnancy

Table 5.4 Environmental maternal exposures in European trios by site.
Site

Cleft lip with or without cleft palate (N=665)
Smoking
PCMV
Drinking
ETS

Cleft palate with or without cleft lip (N=644)
Smoking
PCMV
Drinking
ETS

Denmark
No
Yes
Missing

14 (66.7%)
7 (33.3%)
-

9 (42.9%)
12 (57.1%)
-

15 (71.4%)
6 (28.6%)
-

21 (100%)

14 (70%)
6 (30%)
-

8 (40.0%)
12 (60.0%)
-

14 (70%)
6 (30%)
-

20 (100%)

Norway
No
Yes
Missing

150(54.5%)
125(45.5%)
-

104(37.8%)
87 (31.6%)
84 (30.5%)

130(47.3%)
145(52.7%)
-

232(84.4%)
43 (15.6%)
-

158(58.5%)
112(41.5%)
-

108(40.0%)
88 (32.6%)
74 (27.4%)

123(45.6%)
147(54.4%)
-

229(84.8%)
41 (15.2%)
-

Iowa, US
No
Yes
Missing

31 (70.5%)
13 (29.5%)
-

11 (25.0%)
32 (72.7%)
1 (2.3%)

13 (29.5%)
31 (70.5%)
-

44 (100%)

37 (71.2%)
15 (28.8%)
-

12 (23.1%)
39 (75.0%)
1 (1.9%)

17 (32.7%)
35 (67.3%)
-

52 (100%)

Maryland, US
No
Yes
Missing

58 (69.9%)
23 (27.7%)
2 (2.4%)

12 (14.5%)
66 (79.5%)
5 (6.0%)

56 (67.5%)
25 (30.1%)
2 (2.4%)

21 (25.3%)
6 (7.2%)
56 (67.5%)

59 (67.0%)
27 (30.7%)
2 (2.3%)

11 (12.5%)
73 (83.0%)
4 (4.5%)

60 (68.2%)
25 (28.4%)
3 (3.4%)

23 (26.1%)
7 (8.0%)
58 (65.9%)

66 (75.9%)
21 (24.1%)
-

16 (18.4%)
70 (80.5%)
1 (1.1%)

49 (56.3%)
37 (42.5%)
1 (1.1%)

87 (100%)

53 (72.6%)
20 (27.4%)
-

14 (19.2%)
58 (79.5%)
1 (1.4%)

41 (56.2%)
31 (42.5%)
1 (1.4%)

73 (100%)

Pittsburgh,
Pennsylvania, US
No
Yes
Missing
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Table 5.4 Environmental maternal exposures in European trios by site (Cont.)
Site
Utah, US
No
Yes
Missing

Cleft lip with or without cleft palate (N=665)
Smoking
PCMV
Drinking
ETS
140(92.1%)
12 (7.9%)
-

63 (41.4%)
89 (58.6%)
-

132(86.8%)
20 (13.2%)
-

137(90.1%)
14 (9.2%)
1 (0.7%)

Cleft palate with or without cleft lip (N=644)
Smoking
PCMV
Drinking
ETS
120(88.9%)
15 (11.1%)
-

57 (42.2%)
78 (57.8%)
-

119(88.1%)
16 (11.9%)
-

119(88.1%)
15 (11.1%)
1 (0.7%)

Singapore
No
Yes
Missing

2 (66.7%)
2 (66.7%)
2 (66.7%)
5 (83.3%)
3 (50.0%)
5 (83.3%)
4 (66.7%)
1 (33.3%)
3 (100%)
1 (33.3%)
1 (33.3%)
1 (16.7%)
3 (50.0%)
1 (16.7%)
2 (33.3%)
rd
Smoking: mother smokes in the periconceptional period (3 months prior through 3 month of pregnancy)
PCMV: mother takes multivitamins or prenatal vitamins in the periconceptional period (3 months prior through 3 rd month of
pregnancy)
Drinking: mother has alcohol consumption in the perinatal period (3 months prior through 3rd month of pregnancy)
ETS: mother exposed to environmental tobacco smoke during pregnancy or three months before pregnancy
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Table 5.5 Conditional logistic regression results from genotypic Transmission Disequilibrium Test (gTDT): risk of orofacial clefts
among Asian trios from GENEVA Orofacial Cleft Consortium.
phenotype

Gene ID

CL/P

SLC30A8

Significant
SNPs
rs924388

Allele
A/G

MAF
(%)
17.3

Model fitted

Odds ratios
(95%CIs)
1.31 [1.10-1.57]
1.42 [1.74-1.16]
1.21 [0.77-1.90]
0.88 [0.76-1.02]
0.92 [0.77-1.10]
0.53 [0.37-0.75]

Raw
p-value1
2.7x10-3
7.2x10-4
0.41
8.9x10-2
0.38
4.5x10-4

Threshold
P-value2
7.7x10-4

Additive
Dominant*
Recessive
CP/L
HNF1B
rs2158254
A/G
27.4
Additive
8.3x10-4
Dominant
Recessive*
CL/P: cleft lip with/without cleft palate; CP/L: cleft palate with or without cleft lip
Allele: minor allele/major allele; MAF: minor allele frequency
Threshold p-value was adjusted for the number of SNPs in each gene as reported in Table 5.10
* Model achieves significance after Bonferroni correction
1
p-value significance of the gTDT without multiple testing correction.
2
p-value significance of the gTDT after gene-level Bonferroni correction, calculated as 0.05 divided by the number of SNPs in each
gene.
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Table 5.6 Conditional logistic regression results from genotypic Transmission Disequilibrium Test (gTDT): risk of orofacial clefts
among European trios from GENEVA Orofacial Cleft Consortium.
phenotype

Gene ID

CL/P

ABCC8

Significant
SNPs
rs2237991

Allele
C/T

MAF
(%)
27.9

rs2074315

G/T

27.2

CL/P

ADRB3

rs7812866

C/A

47.3

CL/P

TNF-α

rs28470596

T/C

5.0

CP/L

ADIPOQ

rs17373877

A/G

6.1

CP/L

ADRB3

rs7812866

C/A

46.8

CP/L

HNF1B

rs6607292

A/G

35.5

Model fitted
Additive*
Dominant*
Recessive
Additive
Dominant*
Recessive
Additive
Dominant*
Recessive
Additive*
Dominant*
Recessive
Additive*
Dominant
Recessive
Additive
Dominant*
Recessive
Additive
Dominant
Recessive*

Odds ratios
(95%CIs)
0.72 [0.60-0.86]
0.64 [0.52-0.79]
0.90 [0.62-1.30]
0.73 [0.61-0.87]
0.64 [0.52-0.79]
0.93 [0.65-1.35]
1.07 [0.92-1.24]
1.44 [1.13-1.83]
0.81 [0.64-1.03]
0.36 [0.24-0.55]
0.36 [0.24-0.55]
N/A
0.55 [0.39-0.78]
0.56 [0.40-0.80]
N/A
1.11 [0.94-1.30]
1.53 [1.19-1.97]
0.83 [0.65-1.06]
0.82 [0.69-0.98]
0.96 [0.76-1.20]
0.50 [0.35-0.73]

Raw
p-value1
2.5x10-4
3.6x10-5
0.58
4.1x10-4
4.3x10-5
0.71
0.41
3.5x10-3
8.4 x10-2
9.6x10-7
1.3x10-6
N/A
6.7x10-4
1.4x10-3
N/A
0.21
9.2x10-4
0.14
2.6x10-2
0.71
3.6x10-4

Threshold
P-value2
3.1x10-4

5.6x10-3

2.4x10-4

8.5x10-4

5.6x10-3

7.1x10-4
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Table 5.6 Conditional logistic regression results from genotypic Transmission Disequilibrium Test (gTDT): risk of orofacial clefts
among European trios from GENEVA Orofacial Cleft Consortium (Cont.).
phenotype

Gene ID

CP/L

TNF-α

Significant
SNPs
rs28470596

Allele
T/C

MAF
(%)
4.7

Model fitted
Additive*
Dominant*
Recessive

Odds ratios
(95%CIs)
0.27 [0.17-0.42]
0.27 [0.17-0.42]
N/A

Raw
p-value1
8.75x10-9
1.1x10-8
N/A

Threshold
P-value2
2.4x10-4

CL/P: cleft lip with/without cleft palate; CP/L: cleft palate with or without cleft lip
Allele: minor allele/major allele; MAF: minor allele frequency
Threshold p-value was adjusted for the number of SNPs in each gene as reported in Table 5.10
* Model achieves significance after Bonferroni correction
1
p-value significance of the gTDT without multiple testing correction.
2
p-value significance of the gTDT after gene-level Bonferroni correction, calculated as 0.05 divided by the number of SNPs in each
gene.
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Table 5.7 Estimated odds ratio (OR) (caseG no E) and OR (caseG and E) from conditional logistic regression using cases and 3
pseudo-controls in both Asian and European trios from GENEVA Orofacial Cleft Consortium for 21 genes related to gestational
diabetes mellitus considering G-E interaction between each SNP and mother taking multivitamins or prenatal vitamins in the perinatal
period (PCMV)
Ancestry

phenotype

Gene ID

Significant
SNPs

Allele

MAF
(%)

OR (caseG no
PCMV)

OR (caseG and
PCMV)

LRT 1
df Pvalue
0.58
1.0x10-4
0.09
0.90
6.5x10-5
0.81

LRT 2
df Pvalue
3.0x10-4
5.0x10-4
3.6x10-6
6.8x10-4
3.5x10-4
2.53x10-8

CL/P
FTO**
rs836994
A/G
50.1
1.36 [1.16-1.60] 1.23 [0.88-1.70]
CL/P
ABCC8*
rs4148622
T/C
26.8
0.58 [0.42-0.81] 1.26 [1.01-1.58]
**
CL/P
TNF-α
rs28470596
T/C
5.0
0.22 [0.10-0.50] 0.49 [0.29-0.82]
**
CP/L
ADIPOQ
rs7645316
C/T
33.5
0.70 [0.52-0.93] 0.71 [0.57-0.89]
CP/L
CDKAL1* rs12201217
T/C
37.8
2.10 [1.45-3.03] 1.30 [1.04-1.61]
**
CP/L
TNF-α
rs28470596
T/C
4.7
0.25 [0.12-0.54] 0.28 [0.15-0.52]
CL/P: cleft lip with/without cleft palate; CP/L: cleft palate with or without cleft lip
Allele: minor allele/major allele; MAF: minor allele frequency
1
Raw p-value for 1 degree of freedom likelihood ratio test examining the exclusive effect of gene-environment interaction.
2
Raw p-value for 2 degree of freedom likelihood ratio test examining the effect of genotype after considering effect of geneenvironment interaction.
*
only 1 degree of freedom likelihood ratio test achieved significance after Bonferroni correction (Table 5.10)
**
only 2 degree of freedom likelihood ratio test achieved significance after Bonferroni correction (Table 5.10)
Asian
European
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Table 5.8 Estimated odds ratio (OR) (caseG no E) and OR (caseG and E) from conditional logistic regression using cases and 3
pseudo-controls in both Asian and European trios from GENEVA Oralfacial Cleft Consortium for 21 genes related to gestational
diabetes mellitus considering G-E interaction between each SNP and maternal smoking in the perinatal period.
Ancestry

phenotype

Gene ID

Significant
SNPs

Allele

MAF
(%)

OR (caseG no
smoke)

OR (caseG
and smoke)

LRT 1
df Pvalue1
1.2x10-3
0.09
1.3x10-4
0.18
9.2x10-3
0.76

LRT 2
df Pvalue2
2.4x10-3
2.7x10-4
5.6x10-3
7.5x10-7
2.6x10-4
2.2x10-9

CL/P
CDKN2A/2B* rs1063192
C/T
19.5 1.16 [0.98-1.37] 0.15 [0.03-0.68]
**
CL/P
ABCC8
rs2237991
C/T
27.9 0.79 [0.64-0.98] 0.56 [0.40-0.79]
CL/P
LEP*
rs12538332 C/A
29.7 0.83 [0.68-1.02] 1.52 [1.11-2.13]
**
CL/P
TNF-α
rs28470596
T/C
5.0
0.45 [0.28-0.74] 0.25 [0.12-0.52]
CP/L
ABCC8**
rs4148617
T/C
24.5 0.89 [0.71-1.12] 0.52 [0.38-0.73]
CP/L
TNF-α **
rs28470596
T/C
4.7
0.25 [0.14-0.46] 0.29 [0.15-0.60]
CL/P: cleft lip with/without cleft palate; CP/L: cleft palate with or without cleft lip
Allele: minor allele/major allele; MAF: minor allele frequency
1
Raw p-value for 1 degree of freedom likelihood ratio test examining the exclusive effect of gene-environment interaction.
2
Raw p-value for 2 degree of freedom likelihood ratio test examining the effect of genotype after considering effect of geneenvironment interaction.
*
only 1 degree of freedom likelihood ratio test achieved significance after Bonferroni correction (Table 5.10)
**
only 2 degree of freedom likelihood ratio test achieved significance after Bonferroni correction (Table 5.10)
Asian
European
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Table 5.9 Estimated odds ratio (OR) (caseG no E) and OR (caseG and E) from conditional logistic regression using cases and 3
pseudo-controls in both Asian and European trios from GENEVA Oral Cleft Consortium for 21 genes related to gestational diabetes
mellitus considering G-E interaction between each SNP and maternal exposure to environmental tobacco smoke in the perinatal period
(ETS).
Ancestry phenotype

Gene ID

Significant
SNPs

Alelle

MAF
(%)

OR (caseG no
ETS)

LRT 1
df Pvalue1
1.17 [0.86-1.59] 1.2x10-3
1.16 [0.85-1.59] 1.6x10-3
1.35 [0.94-1.93] 3.5x10-3
1.37 [0.95-1.96] 3.0x10-3
1.45 [1.08-1.94] 3.1x10-4
6.00 [1.77-20.37] 7.1x10-4
6.00 [1.77-20.37] 9.3x10-4
6.00 [1.77-20.37] 9.3x10-4
6.00 [1.77-20.37] 9.3x10-4
1.50 [1.18-1.90] 3.5x10-4
1.60 [1.21-2.12] 5.6x10-4
1.45 [1.12-1.88] 6.0x10-4
1.25 [0.87-1.81] 9.2x10-4
1.27 [0.88-1.84] 9.4x10-4
16.0 [2.12-120.65] 1.5x10-3
16.0 [2.12-120.65] 1.1x10-3
16.0 [2.12-120.65] 1.1x10-3
8.50 [1.96-36.79] 4.9x10-3
OR (caseG and
ETS)

CL/P

FTO
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rs9930333***
G/T
4.4
0.62 [0.49-0.78]
***
rs9941349
T/C
16.9 0.62 [0.49-0.79]
***
rs3751812
T/G
12.4 0.59 [0.45-0.78]
rs8050136***
A/C
12.4 0.60 [0.45-0.79]
*
CL/P
HHEX
rs7078243
A/C
17.5 0.72 [0.56-0.92]
rs2497351*
A/G
3.1
0.78 [0.44-1.38]
*
rs12784232
A/G
2.9
0.81 [0.46-1.43]
rs11187173*
A/G
2.9
0.81 [0.46-1.43]
*
rs1418388
A/G
2.9
0.81 [0.46-1.43]
*
CL/P
PPARG
rs7618046
C/T
45.8 0.87 [0.73-1.04]
rs3856806*
T/C
22.6 0.86 [0.69-1.07]
*
rs12629751
T/C
28.8 0.82 [0.67-1.00]
CP/L
FTO
rs3751812***
T/G
12.3 0.58 [0.44-0.76]
***
rs8050136
A/C
12.3 0.59 [0.45-0.78]
CP/L
HHEX
rs12784232***
A/G
2.5
1.21 [0.66-2.22]
***
rs11187173
A/G
2.5
1.15 [0.63-2.09]
***
rs1418388
A/G
2.8
1.15 [0.63-2.09]
rs2497351**
A/G
2.7
1.21 [0.66-2.22]
CL/P: cleft lip with/without cleft palate; CP/L: cleft palate with or without cleft lip
Allele: minor allele/major allele; MAF: minor allele frequency
1
Raw p-value for 1 degree of freedom likelihood ratio test examining the exclusive effect of gene-environment interaction.
Asian

LRT 2
df Pvalue2
2.5x10-4
2.8x10-4
3.0x10-4
3.3x10-4
1.3x10-3
1.1x10-2
1.3x10-2
1.3x10-2
1.3x10-2
1.2x10-3
1.5x10-3
2.7x10-3
1.9x10-4
3.0x10-4
2.8x10-4
3.1x10-4
3.1x10-4
7.4x10-4

2

Raw p-value for 2 degree of freedom likelihood ratio test examining the effect of genotype after considering effect of geneenvironment interaction.
*
only 1 degree of freedom likelihood ratio test achieved significance after Bonferroni correction (Table 5.10)
**
only 2 degree of freedom likelihood ratio test achieved significance after Bonferroni correction (Table 5.10)
***
both 1 and 2 degree of freedom likelihood ratio test achieved significance after Bonferroni correction (Table 5.10)
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Table 5.10 Threshold p-value was adjusted for the number of SNPs in each gene as
reported.
Asian trios
Gene
ABCC8
ADIPOQ
ADRB3
CDKAL1
CDKN2A/2B
GCK
FTO
HHEX
HNF1A
HNF1B
IGF2BP2
IRS1
KCNJ11
KCNQ1
LEP
MTNR1B
PPARG
SLC30A8
TCF7L2
TNF-α

No.
SNP
152
56
10
252
43
45
124
34
38
60
43
38
105
179
33
44
52
65
59
188

Threshold P-value
3.3x10-4
8.9x10-4
5.0x10-3
2.0x10-4
1.2x10-3
1.1x10-3
4.0x10-4
1.5x10-3
1.3x10-3
8.3x10-4
1.2x10-3
1.3x10-3
4.8x10-4
2.8x10-4
1.5x10-3
1.1x10-3
9.6x10-4
7.7x10-4
8.5x10-4
2.7x10-4

European trios
No.
SNP
159
59
9
280
44
45
128
38
43
70
47
44
108
184
38
47
59
66
70
210

Threshold P-value
3.1x10-4
8.5x10-4
5.6x10-3
1.8x10-4
1.1x10-3
1.1x10-3
3.9x10-4
1.3x10-3
1.2x10-3
7.1x10-4
1.1x10-3
1.1x10-3
4.6x10-4
2.7x10-4
1.3x10-3
1.1x10-3
8.5x10-4
7.6x10-4
7.1x10-4
2.4x10-4

Table 5.11 Summary genes showing significant association with orofacial clefts with the genotypic Transmission Disequilibrium
(gTDT) test.
Mechanism1

Gene
BC
ABCC8

IR

IN

SNP

OB AT

X

rs2237991

Asian

European

MAF

MAF

26.1

27.9

Asians
CL/P

Europeans
CP/L

CL/P

CP/L

Additive
Dominant

ADIPOQ

X

X

ADRB3
HNF1B

SLC30A8
TNF-α

X
X

X

X

X
X

X

rs2074315

25.3

27.2

rs17373877

9.9

6.1

rs7812866

29.1

46.8

rs2158254

27.4

45.4

rs6607292

46.7

35.5

rs924388

17.3

9.6

rs28470596

12.9

4.7

Dominant
Additive
Dominant

Dominant

Recessive
Recessive
Additive
Additive

Additive

Dominant

Dominant

CL/P: cleft lip with/without cleft palate; CP/L: cleft palate with or without cleft lip
1
Mechanism based on gene function; BC: Beta-cells dysfunction; IR: Insulin resistance; IN: Inflammatory markers (cytokines and
adipokines); OB: Obesity; AT: Atherosclerotic process
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Table 5.12 Summary genes showing significant gene-environment interaction (GxE) at 1df LRT
Mechanism1

Gene

Asians
PCMV

BC
ABCC8*

X

CDKAL1

X

CDKN2A/2B

X

IR

OB

X

LEP

X

ETS

PCMV

Smoke

CL/P CP/L CL/P CP/L CL/P CP/L CL/P CP/L CL/P CP/L

X
X
X

HHEX

AT

Smoke

X

FTO

PPARG

IN

Europeans

X

X

X

X

X

X
X

X
X

CL/P: cleft lip with/without cleft palate; CP/L: cleft palate with or without cleft lip
1
Mechanism related to diabetes and metabolic syndrome, BC: Beta-cells dysfunction; IR: Insulin resistance; IN: Inflammatory
markers (cytokines and adipokines); OB: Obesity; AT: Atherosclerotic process
*
significant genetic association (genotypic transmission disequilibrium; gTDT) among European trios
GxE, PCMV: Periconceptional multivitamin, Smoke: maternal smoking, ETS: Environment Tobacco Smoke.
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Table 5.13 Summary genes showing significant when considering gene-environment interaction (GxE) at 2 df LRT.
Mechanism1

Gene

Asians
PCMV

BC
ABCC8*

X

ADIPOQ*

X

IR

IN

AT

Smoke

ETS

PCMV

Smoke

CL/P CP/L CL/P CP/L CL/P CP/L CL/P CP/L CL/P CP/L
X

X

X

X

X

FTO
HHEX

OB

Europeans

X
X

PPARG

X

TNF-α *

X

X

X

X

X

X

X
X

X

X

CL/P: cleft lip with/without cleft palate; CP/L: cleft palate with or without cleft lip
1
Mechanism related to diabetes and metabolic syndrome, BC: Beta-cells dysfunction; IR: Insulin resistance; IN: Inflammatory
markers (cytokines and adipokines); OB: Obesity; AT: Atherosclerotic process
*
significant genetic association (genotypic transmission disequilibrium; gTDT) among European trios
GxE, PCMV: Periconceptional multivitamin, Smoke: maternal smoking, ETS: Environment Tobacco Smoke.
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CHAPTER 6
CONCLUSION
6.1 Summary
Epidemiological research on orofacial clefts (OFCs) has determined the etiology
of OFCs to be multifactorial including genetic factors, environmental factors, and
combination of these factors. Environmental factors including maternal smoking,
maternal alcohol consumption, maternal nutritional status, certain medicines and
supplement intakes, eating behavior during pregnancy and prior to pregnancy, and
maternal medical conditions (diabetes and obesity) have been reported to be associated
with the incidence of OFCs (1-5). Insulin resistance and obesity are considered as risk
factors of metabolic diseases. Several biomarkers including HDL, triglyceride, liver
function tests (ALT: alanine aminotransferase and GGT: gamma-glutamyltransferase) (68), cytokine (CRP: C-reactive protein, IL-6: interleukin-6, TNF- α: tumor necrosis factor
alpha, and leptin) (9-12), and adipokines (adiponectin) (10-12) are associated with
metabolic syndrome. Genetic studies have identified several genes associated with OFCs
most of which have unknown etiologic mechanism. Genome-wide association studies
have reported the significant genetic effects alone and with gene-environment interaction
effect on the risk of OFCs but these effects differ across populations (13).
The results from this dissertation support the association between maternal
obesity and diabetes and risk cleft palate. Moreover, underweight mothers had a
decreased risk of cleft lip only (CLO) and an increased risk of cleft palate only (CPO).
The protective effect of underweight mothers on CLO risk is inconsistent with previous
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studies (14). Maternal body mass index (BMI) and maternal diabetes might have effects
on facial formation in a variety of pathways. It is difficult to identify the independent
effects of maternal obesity and diabetes on OFCs because the relationship between
obesity and diabetes is complex. Obesity increases the risk of inadequate folate status
(15-18); BMI may have an adverse effect on cellular uptake and tissue distribution of
folate. Obesity leads to insulin resistance because of the impairment of insulin sensitivity
in sites of glucose disposal, which can develop to type 2 diabetes mellitus and GDM (19).
Elevated blood glucose and insulin stimulates the production of ketone bodies, branched
chain amino acid, inflammatory markers, and advanced glycation end products. These
products alter expression levels of specific genes and increase the variation of gene
expression levels (20-23). Inadequate folate status and adverse metabolic production may
disrupt normal embryonic development.
The results suggest that gestational diabetes, maternal obesity, and metabolic
syndrome are associated with increased risk of cleft palate. Mothers having cleft palate
with or without cleft lip (CP/L) offspring had an increased risk of developing metabolic
syndrome based on both NCEP/ATP III and IDF definitions. When compared with
control mothers, mothers having cleft palate offspring had a higher insulin, IL-8, and
leptin levels. Insulin resistance associated with insulin and IL-8 levels is a risk factors of
developing GDM (24). Leptin levels are significant higher in pregnancies with GDM
compared with normal pregnancies (25-27). Therefore, insulin, IL-8, and leptin levels
may be links among GDM, metabolic syndrome, and OFCs. Having OFCs offspring
might be a risk factor of developing metabolic syndrome among mothers later in life.
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Insulin, IL-8 and leptin might be performed as biomarkers for predicting OFC
occurrence.
The strong association between maternal diabetes and risk of OFCs leads to the
genetic association study related to these metabolic conditions. The study of genetic
effects alone found that two genes (SLC30A8 and HNF1B) were associated with Asian
OFCs and five genes (ABCC8, ADIPOQ, ADRB3, HNF1 and TNF-α) were associated
with European OFCs. Two genes were associated with OFCs when interaction with
perinatal period (PCMV) was considered-- ABCC8 and CDKAL1 in Europeans.
Interactions between genotype and maternal smoking were found for CDKN2A/2B in
Asians, and for LEP in Europeans. When considering gene-environment interaction with
environmental tobacco smoke (ETS), FTO, HHEX, and PPARG increased risk of OFCs
in Asians. Our result suggests that genes related to GDM have an effect on risk of nonsyndromic OFCs through either genetic effect alone or gene-environment interaction
effects with maternal periconceptional multivitamin use, smoking, and environment
tobacco smoke. Therefore, the etiology of non-syndromic OFCs is multifactorial between
genes and environment.
6.2 Future Direction
This dissertation examines role of maternal diabetes mellitus in orofacial clefts
through studies of medical histories, biomarkers, and genes. Further study is required to
confirm the result and transcend the limitations of this project.
The completeness of the data from registries is a limitation in this dissertation. We
found under-reporting of maternal medical conditions and a large amount of missing data
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of potential confounders (smoking and alcohol consumption). Training programs might
help registry recorders give priority to complete data. Moreover, the small number of
participants with diabetes results in wide confidence intervals and small mediation effects
of maternal diabetes on the association between maternal overweight and obesity and risk
of OFCs. Therefore, further studies require larger sample sizes in order to confirm the
association and mediation effect.
This dissertation found associations between maternal biomarkers of metabolic
syndrome and orofacial clefts. We found that insulin, IL-8, and leptin levels were higher
in mother having cleft palate offspring than control mother. Therefore, a prospective
study that regularly monitors insulin, IL-8 and leptin levels before the conception period
until the next pregnancy may be in order to determine predictability for OFC occurrence.
Moreover, the association between cytokines and adipokines and risk of OFCs requires
further study with larger sample sizes and different ethnic groups in order to confirm and
compare the associations.
Genetic association have found that many SNPs in same gene were associated
with OFCs; therefore, haplotype analysis and gene-gene interactions may find more
regions or genes which have small effects individually but show strong statistical
evidence of linkage and association when combined. This dissertation analyzed geneenvironment interaction associations between genes related to diabetes and obesity and
maternal environmental factors (maternal multivitamin use, smoking, and environmental
tobacco smoke). Additional environmental data for gene-environment interaction analysis
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is required in further studies such as maternal BMI and biomarkers related to metabolic
syndrome and diabetes mellitus.
Observational studies provide evidence of association between exposures and
diseases, but often cannot identify the etiological mechanisms of disease from exposure.
Therefore, strong associations between maternal diabetes and obesity on risk of OFCs
found through maternal medical conditions, maternal biomarkers and genetic associations
require further research to explore the etiological mechanisms. Further studies will be
required to understand how maternal diabetes and obesity has an effect on OFCs
occurrence. Moreover, biological interaction studies needs to identify the mechanisms of
interaction effects between genes and maternal exposures on fetal development.
6.3 Public Health Significance
The association between maternal diabetes and obesity and risk of OFCs may lead
to increased awareness among people and health care providers. Effective interventions
are needed for promoting healthy body weight and metabolic status in reproductive age
women in order to reduce the risk of OFCs. Moreover, early screening for GDM risk is
needed for the periconceptional period and in the first month of gestation in order to
allow early interventions for controlling hyperglycemia, hyperinsulinemia and other
associated metabolic abnormalities to prevent OFCs and other congenital malformations.
Mothers having an OFC child developed metabolic syndrome and had abnormal
biomarkers later in life may and it may be proposed that having OFC child is a risk
indicator for subsequent maternal metabolic syndrome. These mothers may receive
regularly metabolic syndrome monitoring and intervention to prevent developing
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metabolic syndrome and related diseases. On the contrary, metabolic syndrome score,
insulin, IL-8, and leptin levels may be focus as indicator for OFC prediction. Moreover,
the association of biomarkers before or during periconceptional period and risk of OFCs
requires further study.
The association between genetic effects alone and gene-environment interaction
effects and risk of OFCs might be difficult to apply in public health because the
biological function of detected variants is still difficult to interpret and people may carry
the effects of one or more variants in several genes. Strategies for dealing with multiple
causal genes and applying the strategy effectively are required in genetic studies of
OFCs. These associations do not point to a single major GDM gene associated with
OFCs, but support the hypothesis that GDM may be causally related to OFCs via
multiple GDM susceptibility genes and interactions with environmental factors.
However, the finding in this dissertation confirms that etiology of OFCs is multifactorial
including genetics and environment.
Individuals with OFCs face both physical and mental health problems, which
require multi-specialty team care. OFC prevention and prediction are important to public
health. This dissertation reported that maternal diabetes mellitus, maternal pre-pregnancy
weight and genes related to GDM had associations with the risk of OFCs. Mothers
having an OFC child had an increased risk of developing metabolic abnormalities later in
life. Potential risk factors were reported in this dissertation that can be applied for OFC
prevention. This dissertation also reported potential biomarkers for predicting OFCs.
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Moreover, mothers having an OFC child require regular monitoring for metabolic
abnormalities later in life.
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